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Abstract 
 
INTRODUCTION: The mechanism behind obesity-related cardiomyopathies is at present 
not completely known, however, cardiac insulin resistance has been implicated as one of 
the main arbitrators of obesity-related cardiovascular disease. A few studies have 
associated perturbations in the insulin-mediated PI3K/PKB/Akt pathway in mediating this 
insulin resistance. Moreover, this pathway has been shown to regulate myocardial 
apoptosis, which in turn has been implicated in a number of cardiovascular diseases. 
Currently, few studies have compared the early onset and advanced effects of obesity on 
the heart. 
 
AIMS: To compare the early and advanced stages of obesity in terms of myocardial (i) 
PI3K/PKB/Akt signalling, (ii) apoptotic signalling and (iii) mitochondrial integrity. 
Furthermore, we aim to assess the cardiac mitochondrial (i) PI3K/PKB/Akt signalling, (ii) 
apoptotic signalling and (iii) integrity during the advanced stages of obesity. 
 
METHODS: Male Wistar rats were randomly assigned to either a control or diet-induced 
obesity (DIO) group. Controls were fed a standard rat chow diet and the DIO group fed a 
high caloric diet (standard rat chow supplemented with sucrose and condensed milk). The 
diets were implemented for either 8 or 20 weeks and thereafter, the body weight, intra-
peritoneal fat mass, and fasting blood glucose and insulin levels (including intra-peritoneal 
glucose tolerance tests (IPGTTs)) were determined. Freeze-clamped hearts from both 
groups were subjected to cytosolic western blot analysis for PI3K p85 subunit, PKB/Akt, 
GSK-3α/β, Bad, Bax and Bcl-2. A fraction of each heart was also subjected to WB analysis 
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of the mitochondrial electron transport chain (ETC) complexes (I-V). Thereafter, the above 
mentioned proteins were also probed for in mitochondria isolated from the 20 weeks group 
after administering insulin and exposing the hearts to ischemia. Oxidative phosphorylation 
(OXPHOS) capacity analysis was then conducted on mitochondria isolated from 20 weeks 
DIO and control groups and thereafter a citrate synthase (CS) activity assay was 
performed on these mitochondria. 
 
RESULTS: After the 8 and 20 weeks diet, the DIOs had significantly increased intra-
peritoneal fat mass, fasting plasma glucose and insulin levels, compared to their controls. 
Cytosolic WB analysis: The tp85, pp85 and pPKB/Akt levels were significantly higher in the 
DIOs in comparison to the controls after 8 weeks of diet. Furthermore, pBad and Bax 
expression were significantly elevated in these animals. After 20 weeks of diet, the DIOs 
had significantly decreased pp85, tPKB/Akt and pPKB/Akt levels. The tBad was 
significantly elevated, while the Bad phosphorylated over total expression (P/T) ratio was 
significantly decreased, in these animals. CS activity assay: CS activity was significantly 
decreased in the DIOs, versus the controls, at 20 weeks. Mitochondrial ETC WB analysis: 
The subunit expression in complexes I-III and V did not differ significantly after 8 weeks 
however, the expression was significantly lower in complexes I and II after 20 weeks. 
Interestingly, the complexes III and V expression was significantly elevated. Mitochondrial 
OXPHOS analysis: The ADP/O ratio with (1) glutamate or (2) palmitoyl-L- carnitine as 
substrate, showed a significant decrease in the DIOs at 20 weeks. Mitochondrial WB 
analysis: The pp85 subunit was significantly elevated in the control and DIO groups, 
exposed to insulin and ischemia, in comparison to the untreated controls. The Bcl-2 levels 
were significantly decreased in the insulin and ischemia DIOs, when matched against the 
untreated DIOs. The tBad expression did not differ significantly between the insulin and 
Stellenbosch University http://scholar.sun.ac.za
 v 
 
untreated controls, while the tBad was significantly augmented in the ischemia controls 
versus untreated controls. All significant differences were taken as p<0.05. 
CONCLUSION: The results indicate that the initial stage of diet-induced obesity is 
associated with cardioprotection as there is augmented PI3K/PKB/Akt pathway signalling 
and a decrease in apoptotic markers. In contrast, during the advanced stages of obesity a 
decreased activity in PI3K/PKB/Akt pathway is associated with myocardial apoptosis and 
decreased mitochondrial function and integrity. 
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Abstrak 
 
INLEIDING: Die meganisme verantwoordelik vir vetsug-verwante kardiomiopatieë is 
huidiglik nie bekend nie maar kardiale insulienweerstandigheid word geïmpliseer as een 
van die hoof bemiddelaars van vetsug-verwante hartsiektes.  Verskeie studies het 
versteurings in die insulien-gemediëerde PI3K/PKB/Akt pad geassosieer met die 
bevordering van hierdie insulienweerstandigheid. Daarbenewens is dit getoon dat hierdie 
pad betrokke is in die regulering van miokardiale apoptose, wat op sy beurt geïmpliseer is 
in 'n aantal kardiovaskulêre siektes. Daar is tans min studies beskikbaar wat die vroeë en 
laat gevolge van obesiteit op die hart vergelyk. 
DOELWITTE: Om die vroeë en gevorderde stadiums van vetsug te vergelyk in terme van 
miokardiale (i) PI3K/PKB/Akt seintransduksie, (ii) apoptotiese seintransduksie en (iii) 
mitokondriale integriteit. Verder, het die studie ten doel om die kardiale mitokondriale (i) 
PI3K/PKB/Akt en (ii) apoptotiese seintransduksie en (iii) integriteit in die gevorderde 
stadiums van vetsug te bepaal. 
METODES: Manlike Wistar rotte is ewekansig toegewys aan óf 'n kontrole of dieet-
geïnduseerde vetsug (DIO) groep. Kontroles is met 'n normale rotkos dieet en die DIO 
groep met 'n hoë kalorie dieet (normale rotkos aangevul met sukrose en kondensmelk) 
gevoed. Die dieet is vir 8 of 20 weke volgehou en daarna was die liggaamsgewig, intra-
peritoneale vet massa, en vastende bloed glukose en insulien vlakke (insluitende intra-
peritoneale glukose toleransie toets (IPGTT`s)) bepaal. Gevriesklampte harte van beide 
groepe is onderwerp aan sitosoliese WB-analise vir die PI3K p85 subeenheid, PKB / Akt, 
GSK-3α/β, Bad, Bax en Bcl-2. `n Fraksie van hierdie harte is ook onderwerp aan westerse 
klad analise (WK-analise) van die mitokondriale elektron vervoer ketting (EVK) komplekse 
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(I-V). Daarna is bogenoemde proteïene ondersoek in mitokondrieë geïsoleer uit die 20 
weke groep ná die toediening van insulien en die blootstelling van die harte aan iskemie. 
Die oksigraaf mitokondriale oksidatiewe fosforilering (OXPHOS) kapasiteit analise is dan 
op mitokondrieë van 20 weke DIO en kontrole groepe uitgevoer en daarna is 'n 
sitraatsintase (SS) aktiwiteitstoets  gedoen. 
RESULTATE: Na die 8 en 20 weke dieet, het die intra-peritoneale vet massa, vastende 
plasma glukose en insulien vlakke in die DIOs aansienlik toegeneem, in vergelyking met 
hul kontroles. Sitosoliese WK-analise: Die tp85, pp85 en pPKB/Akt vlakke was beduidend 
hoër in die DIOs in vergelyking met die kontroles, na 8 weke van die dieet. Verder is die 
pBad en Bax vlakke beduidend verhoog in hierdie diere. Na 20 weke van die dieet, het die 
pp85, tPKB/Akt en pPKB/Akt vlakke beduidend afgeneem in die DIOs, in vergelyking met 
die kontroles. Die tBad was beduidend verhoog, terwyl die Bad verhouding van 
gefosforileerde oor die totale proteïen uitdrukking (P/T)-verhouding) beduidend verminder 
het in hierdie diere. SS aktiwiteitstoets: SS aktiwiteit is beduidend verminder in die DIOs, 
teenoor die kontroles, op 20 weke. Mitokondriale EVK WK-analise: Die subeenheid 
uitdrukking in komplekse I-III en V was nie beduidend verskillend na 8 weke nie. Na 20 
weke egter, was die uitdrukking aansienlik laer in komplekse I en II. Interessant genoeg, is 
die uitdrukking aansienlik verhoog in komplekse III en V. Mitokondriale OXPHOS analise: 
Die ADP/O verhouding met (1) glutamaat of (2) palmitiel-L-karnitien as substraat, het 
beduidend afgeneem in die DIOs teen 20 weke. Mitokondriale WK-analise: Die pp85 
subeenheid was beduidend verhoog in die kontrole en DIO groepe, blootgestel aan 
insulien en iskemie, in vergelyking met die onbehandelde kontroles. Die Bcl-2 vlakke was 
beduidend verminder in die insulien en isgemie DIOs, in vergelyking met onbehandelde 
DIOs. Die tBad uitdrukking het nie beduidend verskil tussen die insulien en onbehandelde 
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kontroles nie, terwyl die tBad beduidend verhoog was in die isgemie kontroles versus 
onbehandelde kontroles. Alle beduidende verskille is geneem as p<0.05. 
GEVOLGTREKKING: Die resultate dui daarop dat die eerste fase van dieet-geïnduseerde 
obesiteit geassosieer is met kardiale beskerming want `n toename in PI3K/PKB/Akt 
seintransduksie en 'n afname in apoptotiese merkers is waargeneem. In teenstelling, in die 
gevorderde stadium van vetsug is daar 'n afname in aktiwiteit in die PI3K/PKB/Akt pad wat 
verband hou met verhoogde miokardiale apoptose en verminderde mitokondriale funksie 
en integriteit. 
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Chapter 1: Introduction 
 
1.1 The Obesity Pandemic 
1.1.1 Global Statistics for Obesity 
Obesity is termed as a surplus amount of body fat in relation to lean mass (body mass 
index (BMI) >30 kg/m2), such that the obese individual’s health is compromised, whereas 
overweight (BMI between 25 and 30 kg/m2) is defined as an elevation in body weight in 
relation to height [Lopaschuk et al. 2007, Nguyen et al. 2010]. 
Historically thought of as being restricted to wealthy individuals of developed nations, the 
incidence of obesity has currently reached epidemic proportions right across the world, for 
both adults and children alike. With the present global economic crises and the increasing 
urbanization of developing countries, the number of obese individuals’ are only expected 
to surge. In 2005, around 1.6 billion people were overweight and at least 400 million 
people were obese across the globe, as indicated by World Health Organization (WHO) 
estimates. This organization predicts that by the year 2015, 2.3 billion individuals will be 
overweight and 700 million will be obese worldwide. [Nguyen et al. 2010] 
 
1.1.2 Repercussions of Obesity 
The effects of obesity are far reaching as it not only affects the individual but also have 
implications for the rest of society.  
1.1.2.1 The Economic Impacts of Obesity 
In terms of the societal impact, an immense financial burden is placed on the global 
economy on an annual basis as billions are spent on the treatment of obesity-related 
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physical disabilities and secondary diseases, the so called direct costs of obesity. The 
indirect economic cost to the global community is estimated to perhaps be more costly 
than the obesity-related conditions themselves. These indirect costs can be manifested in 
various ways, for example, additional financial strain is placed on the welfare system as a 
result of early retirement and unemployment due to obesity-related morbidities. [Yach et al. 
2006] 
 
1.1.2.2 The Health Impacts of Obesity 
From an individualistic point of view, obesity can severely affect an individual’s quality of 
life as this disease can give rise to an array of other chronic diseases such as cancer, type 
2 diabetes mellitus (T2DM) and cardiovascular disease.  
In fact, cardiovascular disease is viewed as one of the leading co morbidities of obesity, 
owing to the large variety of cardiovascular dysfunctions excess weight gain can induce. 
Obese individuals are at significantly higher risk of developing cardiomyopathies such as 
congestive heart failure, ischemic heart disease, myocardial infarction and sudden cardiac 
death, than their leaner counterparts. These disorders are initiated by obesity, and are 
independent of cardiovascular risk factors or syndromes such as hypertension, 
dyslipidemia, atherosclerosis and type 2 diabetes mellitus. [Hall et al. 2002, Van Gaal et al. 
2006] 
 
Cardiovascular disease-related deaths, a leading mode of death in obese and T2DM 
individuals across the globe [Coort et al. 2007], has increased from less than 10%, at the 
start of the 20th century, to 50% at the end of the 20th century [Trivedi et al. 2008]. The 
existence of a strong correlation between obesity, insulin resistance and myocardial 
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disease has been duly noted. However, the precise relationship between these three 
diseases has not been completely elucidated [Bergman et al. 2007]. Thus, the ensuing 
chapter serves to review this association between obesity, insulin resistance and 
cardiovascular disease in order to improve our understanding of their complex 
relationships.  
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Chapter 2: Literature Review 
 
2.1 Insulin Signalling and the Heart 
2.1.1 Overview of the polypeptide hormone insulin 
The beta cells of the pancreas are responsible for insulin production, which plays a pivotal 
role in regulating carbohydrate and fat metabolism by mediating the translocation of 
transporter proteins to the myocardial sarcolemma. In doing so it facilitates the uptake of 
glucose and free fatty acids from the blood, which are subsequently stored as energy 
reserves [Waselle et al. 2005, Bertrand et al. 2008]. The liver, skeletal muscle, adipocytes 
and the heart are all target organs of insulin action; and in the adipose tissue glucose is 
metabolized to and stored as triglycerides. On the other hand, glycogen is metabolized 
from the pre-cursor glucose and stored in the liver and skeletal muscle [Luiken et al. 2004].  
The release of insulin from the pancreas is dependent on the concentration of glucose, 
amino acids as well as fatty acids in the blood [Waselle et al. 2005]. Furthermore, the 
measure of insulin released by the beta cells will differ depending on the type and intensity 
of the stimulus, as well as its means of administration [Kahn et al. 2006]. 
In addition to its role in carbohydrate and fat metabolism, insulin also plays a significant 
part in ribosomal biogenesis and protein synthesis [Kemi et al. 2008], nuclear factor 
translation and cardiomyocyte growth [Walsh 2006, O’Neill et al. 2005] as well as the 
regulation of cell death or survival [Duronio 2008]. 
The sections to follow, first review substrate utilization and metabolism in the heart during 
normal physiological conditions and the changes that occur in these during obesity. 
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Thereafter, the transport proteins involved in the myocardial uptake of these substrates, as 
well as the role that insulin plays in this process, are discussed. 
 
2.1.2 Myocardial substrate utilization under normal physiological conditions and the 
transport proteins involved in substrate uptake 
The myocardium is one of the biggest consumers of adenosine triphosphate (ATP) in the 
body and just like any other metabolic tissue it is dependent on various metabolic 
processes to provide this energy. In order to satisfy this large energy demand, for optimal 
myocardial functioning, the heart mainly utilizes long-chain fatty acids (LCFA) (60–70%) as 
it yields the largest amount of ATP of all the metabolic substrates [Bertrand et al. 2008]. 
Glucose, lactate and ketone bodies further contribute to the heart`s energy requirements 
[Coort et al. 2007, Bertrand et al. 2008]. However, in order for these metabolic substrates 
to be metabolised, they have to first gain entry into the cardiomyocyte and this is achieved 
by the use of various transport proteins. 
 
2.1.2.1 Glucose transporters 
There are two forms of glucose transporter (GLUT) proteins present in the myocardium 
namely GLUT1, which can be found in all tissues, and GLUT4, which is mainly restricted to 
insulin sensitive tissues [Coort et al. 2007, Bertrand et al. 2008]. Despite the heart 
expressing a relatively large amount of GLUT1, in comparison to other tissues, GLUT4 
expression is still predominant. In terms of cellular location for basal conditions, GLUT1 is 
mainly located in the sarcolemma and believed to be more involved in mediating basal 
glucose uptake. GLUT4, on the other hand, is predominantly found in endosomes in the 
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intracellular compartment of cardiac myocytes. However, there are indications that 
myocardial intracellular stores of GLUT1 exist which can be recruited to the sarcolemma 
by insulin, just like GLUT4, as well as by myocyte contraction [Luiken et al. 2004]. 
 
2.1.2.2 Fatty acid transporters 
Previously, it was thought that LCFAs only entered cells by means of simple diffusion, 
however in recent years, a number of LCFA membrane associated transport proteins have 
been identified that are believed to mediate the uptake of LCFA`s. 
The latter mechanism is believed to be predominant [Luiken et al. 2004] and despite not 
being wholly understood, it is known that their translocation to the sarcolemma is arbitrated 
by insulin. Like GLUT, LCFA transport proteins are located in intracellular endosomes and 
are thought to work together to facilitate the transport of LCFA`s into the heart [Coort et al. 
2007, Luiken et al. 2002]. 
The first of these transport proteins is a fatty acid translocase (FAT), the rodent homologue 
of the human homologue cluster determinant 36 (CD36), which is an 88kDa fatty acid 
translocase protein found at both the sarcolemma as well as in intracellular storage 
compartments [Coort et al. 2007, Luiken et al. 2002]. 
 
2.1.2.2.1 FAT/CD36 
This translocase is thought to resemble GLUT1, more so than GLUT4, since its 
translocation to the sarcolemma increases 1.5 fold when stimulated by insulin, as opposed 
to GLUT4 which more than doubles at the sarcolemma. Additionally, FAT/CD36 is less 
concentrated in cytoplasmic endosomes and more prevalent at the sarcolemma under 
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basal, non-stimulated conditions; much like GLUT1 and in contrast to GLUT4, which is 
mainly localized in cytoplasmic endosomes under these conditions [Luiken et al. 2002]. 
Cardiac myocyte contraction serves as another stimulus for the translocation of FAT/CD36 
to the sarcolemma and is mediated by the adenosine monophosphate (AMP) kinase 
signalling pathway (AMPK signalling pathway), which will not be discussed in further detail 
in this literature review [Coort et al. 2004]. 
 
2.1.2.2.2 FABPpm 
The 43kDa fatty acid binding protein (FABPpm) is a second type of LCFA transport 
protein, which is present on the outermost surface of the sarcolemma and which is 
believed to act together with FAT/CD36 in the LCFA uptake process.  
This is supported by data which showed that inhibition of FABPpm, with an anti-FABPpm 
antibody, decreases LCFA transport across the sarcolemmal membrane. Additionally, 
when both FAT/CD36 and FABPpm were inhibited the effects were non-additive, 
suggesting that they act in a similar fashion [Glatz et al. 2001, Luiken et al. 2002, Coort et 
al. 2004]. 
 
2.1.2.2.3 FATP 
In cardiac myocytes two isoforms of the fatty acid transport protein (FATP) family, the third 
type of LCFA transport protein, is found namely, FATP1 and FATP6. FATP6 expression is 
not only restricted to the heart but is also more abundant than FATP1. These two FATP`s 
are believed to act together, as well as in conjunction with FAT/CD36, during the LCFA 
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transport process as they are not only associated with the sarcolemma but also co-
localizes with FAT/CD36 [Coort et al. 2007, Luiken et al. 2002]. 
It is evident from the above that there are quite a number of different transport proteins 
involved in transporting various substrates into the myocyte, ensuring that that the energy 
demands of the heart are met.  
 
2.1.3 The role of insulin-mediated PI3K/PKB/Akt signalling in GLUT and FAT/CD36 
translocation to the myocardial sarcolemma under normal physiological conditions 
Insulin governs myocardial substrate usage and substrate transport protein localization 
and therefore is involved in the maintenance of normal plasma glucose and lipid 
concentrations. Insulin is known to activate the PI3K/PKB/Akt pathway, which in turn, 
mediates the uptake of glucose as well as LCFAs into the myocardium, when standard 
physiological conditions prevail [Bertrand et al. 2008, Van Gaal et al. 2006, Coort et al. 
2004]. The precise insulin-mediated PI3K/PKB/Akt signalling mechanism, which promotes 
GLUT and FAT/CD36 translocation to the sarcolemma, has not been completely 
elucidated thus far. However, several studies have been able to shed some light on the 
signalling mechanism [Luiken et al. 2002, Chabowski et al. 2005]. 
The insulin-mediated PI3K/PKB/Akt signalling pathway (see figure 2.1) commences when 
(1) insulin molecules bind to the extracellular segment of the sarcolemmal bound insulin 
receptor (IR), activating the intrinsic intracellular tyrosine kinase activity of the β-subunits 
within the receptor. The receptor then undergoes autophosphorylation and activation. (2) 
Once the IR is activated, it induces the cytoplasmic binding of the adaptor insulin receptor 
substrate-1 (IRS-1) protein to these receptors, catalyzing the phosphorylation of multiple 
tyrosine residues within IRS-1. IRS-1 is not the only insulin receptor substrate protein 
Stellenbosch University http://scholar.sun.ac.za
 9 
 
involved in the insulin receptor cascade, insulin receptor substrate-2 (IRS-2) has also been 
identified to play an important role in insulin-mediated glucose transport. IRS-1 is the 
dominant isoform involved in the metabolic effects of insulin in skeletal muscle, adipose 
tissue and the heart; whereas IRS-2 complements these effects in the liver. Insulin 
receptor substrate-3 (IRS-3) has been identified in rodent adipocytes but is thought most 
likely not to be expressed in humans [Sciacchitano et al. 1997]. On the other hand, insulin 
receptor substrate-4 (IRS-4) is expressed in human embryonic kidney cell lines but has 
been reported not to be involved in insulin signalling and glucose homeostasis [Fantin et 
al. 2000].  
 
(3) Once activated, IRS-1 proceeds to recruit the p85 regulatory subunit of 
phosphatidylinositol 3 kinase (PI3K) and in doing so allows binding of this subunit to the 
p110 catalytic subunit of the kinase, resulting in activation. This is mediated by the binding 
of the sarc homology -2 (SH2) domain, which is located in PI3K`s regulatory subunit p85, 
to the phosphotyrosine residues of IRS-1. Insulin-mediated PI3K activation has been said 
to mediate GLUT and FAT/CD36 sarcolemmal translocation [Koonen et al. 2005, Schwenk 
et al. 2010]. (4) PI3K is then able to generate phosphatidylinositol (3,4,5)-triphosphate 
(PIP3) molecules, by phosphorylating the phosphatidylinositol (PI) phosphates at the third 
carbon. PIP3 acts like a second messenger to (5) recruit the downstream serine/threonine 
kinases 3-phosphoinositide-dependent protein kinase-1 (PDK-1) and protein kinase B 
(PKB/Akt) to the plasma membrane, mainly from the cytosol [Hajduch et al. 2001]. These 
kinases bind to PIP3 by means of their pleckstrin homology (PH) domains. Subsequently, 
PDK-1 phosphorylates the T-loop of PKB/Akt at its Thr308 residue, while integrin-linked 
kinase (ILK) is thought to phosphorylate the protein at its Ser473 residue, thereby fully 
activating it [Mora et al. 2004, Bertrand et al. 2008, Coort et al. 2007, Kalra et al. 2010]. 
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PI3K/PKB/Akt signalling has been shown to be involved in GLUT translocation, and it is 
speculated that this signalling is also involved in the translocation of FAT/CD36 to the 
membrane [Schwenk et al. 2010]. It has been speculated that the PI3K/PKB/Akt signalling 
pathway for GLUT and FAT/CD36 insulin-mediated sarcolemmal translocation might 
disperse at some point as they have different intracellular locations [Holloway et al. 2008]. 
In support of this speculation, Jain et al. (2012) found that GLUT translocation to skeletal 
muscle sarcolemma, as well as glucose uptake, was blighted in Munc18c (-/+) mice, upon 
insulin stimulation. On the other hand, when insulin served as stimulus the elevation in 
fatty acid transporter translocation to the sarcolemma and fatty acid transport, was 
unaffected in these mice. Munc18c plays an essential role in the fusion of GLUT4 and 
other insulin-mediated amino peptidase storage vesicles to the plasma membrane 
[Thurmond et al. 2000]. (6) Nevertheless, it would seem once PKB/Akt is activated, it 
stimulates the translocation of (i) GLUT receptors as well as (ii) LCFA transport proteins to 
the myocardial sarcolemma.  
 
Thus, we see that insulin plays a pivotal role in the translocation of glucose and fatty acid 
transporters to the myocardial membrane, via the PI3K/PKB/Akt pathway, thereby 
mediating substrate uptake and metabolism in the heart. 
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Figure 2.1. Insulin mediated activation of the PI3K/PKB/Akt pathway and its role in 
translocation of GLUT receptors and FAT/CD36 transport proteins to the myocardial 
sarcolemma, when normal physiological conditions prevail. Taken and adapted from Coort 
et al. 2007. 
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2.1.4 Glucose uptake and metabolism under normal physiological conditions  
Once GLUT receptors have translocated to the myocardial sarcolemma, it allows for 
glucose uptake to ensue. Upon reaching the cytoplasm, glucose is rapidly phosphorylated 
by the enzyme hexokinase to form glucose-6-phosphate (G-6-P) [Coort et al. 2007, 
Petersen et al. 2002]. 
A portion of the G-6-P is metabolised further, in a number of steps as shown in figure 2.2, 
to provide the heart with ATP for its immediate energy requirements. The first step is the 
entry of glucose-6-phosphate into the aerobic glycolytic pathway, where one molecule is 
eventually converted to two molecules of pyruvate with the breakdown of two molecules of 
ATP to ADP and the release of one molecule of reduced nicotinamide adenine 
dinucleotide (NADH).  
The next major step is the oxidative decarboxylation of pyruvate to acetyl coenzyme-A 
(acetyl-CoA) by the multienzyme complex pyruvate dehydrogenase (PDH), with the 
release of more NADH and some carbon dioxide. PDH is situated on the inner 
mitochondrial membrane. 
Acetyl-CoA is therefore formed in the mitochondria where it enters the tricarboxylic acid 
(TCA) cycle, the third key step, and is converted to oxaloacetate in a series of steps (see 
figure 2.2). This four carbon molecule proceeds to react with the next incoming acetyl-
CoA, forming citrate and thus allowing the TCA cycle to continue. During the oxidation of 
one molecule acetyl-CoA to one molecule of oxaloacetate, the TCA cycle additionally 
yields one guanosine 5'-triphosphate (GTP), three NADH and one 5,10-
methylenetetrahydrofolate reductase (FADH2) molecules. 
The final step of glucose metabolism encompasses oxidative phosphorylation (OXPHOS) 
whereby the energy rich molecules (GTP, NADH and FADH2) generated during glycolysis, 
pyruvate decarboxylation and the TCA cycle, donate their electrons to electron carriers. 
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This donation eventually drives ATP synthesis by the electron transport chain (ETC), 
located within the mitochondrial membrane. Please refer to figure 2.2. The OXPHOS 
process will be discussed in greater detail in section 2.1.5.1. 
 
As mentioned, only a portion of myocardial G-6-P is metabolized to produce ATP, the 
other subset is converted to glycogen for glucose storage [Tirone et al. 2001]. Initially, G-6-
P undergoes isomerization to glucose-1-phosphate (G-1-P) and is subsequently converted 
to uridine 5’-diphosphate glucose (UDP-glucose), which is ultimately polymerized into 
glycogen by the enzyme glycogen synthase (GS) [Petersen et al. 2002]. 
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Figure 2.2. Summary of the events during glycolysis and the Kreb`s cycle. (1) Illustrate the 
oxidation of glucose to pyruvate (2) which is subsequently converted to Acetyl CoA, with 
the release of energy intermediates. (3) Acetyl Co-A thereafter enters the TCA cycle to 
release even more energy intermediates, (4) which is eventually reduced by the 
mitochondrial ETC chain to produce ATP.  
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Obtained and edited from: 
(1) [http://rosswiki2009.pbworks.com/w/page/11977900/Glycolysis]  
(2) [http://www.coenzyme-a.com/tca.htm]  
(3) [http://thealchemistkitten.files.wordpress.com/2009/11/blaze_tca_cycle.jpg] 
 
2.1.5 Long chain fatty acid uptake and metabolism under normal physiological 
conditions 
LCFAs can be found in the circulation either in complex with albumin or esterified in the 
lipid core of very-low density lipoproteins (VLDLs) and chylomicrons [Spector 1984, Van 
der Vusse et al. 2000]. 
LCFAs which are bound to albumin are able to detach themselves rather easily from this 
plasma protein whereas esterified LCFAs are only released after being hydrolyzed at the 
luminal surface of the myocardial endothelium by lipoprotein lipase (LPL). Via an indistinct 
mechanism, the free LCFAs are transported across the endothelium and are once again 
bound to albumin, thus serving as the LCFAs “transport vehicle”, when in the extracellular 
fluid surrounding the cardiac myocytes. Once the LCFAs arrive at the sarcolemma, they 
once again separate from albumin and are transported across the sarcolemma by means 
of the various LCFA transport proteins discussed previously [Coort et al. 2007]. 
 
Upon entering the cytoplasm of the cardiomyocyte, the LCFAs bind to fatty acid binding 
proteins, namely heart-type cytoplasmic fatty acid-binding protein (H-FABPc), which act as 
vehicles for transporting the fatty acids through the aqueous cytoplasm [Coort et al. 2007]. 
Consequently, these fatty acids are activated by conversion to fatty acyl coenzyme-A 
molecules (fatty acyl-CoAs), by the enzyme fatty acyl-CoA synthetase (FACS) [Gargiulo et 
al. 1999], which subsequently binds to the cytoplasmic acyl-CoA binding protein (ACBP) 
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[Knudsen et al. 2000, Faergeman 2002]. This binding protein serves as another molecular 
vehicle, which is responsible for transporting the fatty acyl-CoAs to their site of metabolic 
conversion or breakdown [Schaap et al. 1999, Glatz et al. 2001].  
When fatty acyl-CoAs are bound to ACBP they can be transported to: (1) the mitochondria 
for β-oxidation, (2) a site in the cytoplasm where it will undergo esterification into 
triacylglycerol (TAG) and phospholipids, and (3) the cytoplasm for entry into signal 
transduction pathways. The destiny of the fatty acyl-CoAs is determined by the needs of 
the myocytes at a given point in time. If the plasma content of LCFAs are elevated then 
insulin will predominantly direct it to TAG and phospholipid esterification, consequently 
sequestering it as part of the intracellular “lipid pool”. However, if the myocardial ATP 
demand is high then myocyte contractions will shunt the LCFAs to mitochondrial β-
oxidation for energy production [Coort et al. 2007, Coort et al. 2004]. 
Fatty acyl-CoAs destined for mitochondrial β-oxidation reaches the mitochondria with the 
assistance of three specific carnitine-dependent enzymes. The first key regulatory enzyme 
is carnitine palmitoyl transferase I (CPT-I), which acts at the outer mitochondrial 
membrane to catalyze the formation of acyl-carnitine. Thereafter, acyl-carnitine gets 
transported into the mitochondria by the second enzyme carnitine/acyl-carnitine 
transferase (CACT). The third enzyme, carnitine palmitoyl transferase II (CPT-II), 
generates fatty acyl-CoA at the inner mitochondrial membrane by transferring an acyl 
group to CoA molecule from the mitochondrial pool [Coort et al. 2007]. 
Fatty acyl-CoAs are eventually converted to acetyl-CoA, via the process of β-oxidation, 
once it enters the mitochondria and the latter is subsequently metabolized in the citric acid 
cycle to yield high energy molecules such as GTP, FADH2 and NADH [Schulz 1994, 
Ghisla 2004]. These molecules are eventually converted to ATP by means of oxidative 
phosphorylation in the mitochondrial electron transport chain. An overview of (a) 
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cytoplasmic fatty acid uptake, activation as well as (b) mitochondrial β-oxidation is given in 
figure 2.3 [Coort et al. 2007, Lopuschuk et al. 2010]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Overview of long-chain fatty acid (LCFA) utilization in cardiac myocytes under 
normal physiological conditions. (a) Initially the LCFAs undergo cytoplasmic uptake and 
activation in cardiac myocytes. (b) Thereafter, these LCFAs are transported into the 
mitochondria and undergo β-oxidation. Taken and adapted from Coort et al. 2007. 
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2.1.5.1 A closer look at the oxidative phosphorylation (OXPHOS) process and the 
mitochondrial electron transport chain (ETC) 
Oxidative phosphorylation encompasses two major steps that is, the production of an 
electrochemical gradient via electron transfer and the synthesis of ATP. An overview of 
mitochondrial electron transport and ATP synthesis is given in figure 2.4. 
 
2.1.5.1.1 Electron transfer 
The most significant function of the mitochondria is to furnish the cell with energy in the 
form of ATP, which is derived from sources such as fats, proteins and carbohydrates 
[Leonard et al. 2000]. As mentioned in sections 2.1.4 and 2.1.5, the reducing equivalents 
i.e. energy rich molecules (GTP, NADH and FADH2) released during the metabolism of 
these substrates, are what drives ATP synthesis via the process of oxidative 
phosphorylation in the mitochondrial ETC [Leonard et al. 2000].  The electron transport 
chain consists of five complexes, namely NADH dehydrogenase, succinate 
dehydrogenase, cytochrome bc1 complex, cytochrome c oxidase and ATP synthase, 
otherwise referred to as complexes I to V. There are two components of the ETC which do 
not form part of the five complexes, but are nonetheless essential for electron (e-) transfer. 
These would be cytochrome c which interacts with complex IV, and “floats” on the outside 
of the inner mitochondrial membrane, and ubiquinone (coenzyme Q) which is able to 
diffuse within the mitochondrial membrane [Pedersen et al. 1999, DiMauro et al. 2009]. 
Complex I structure has been said to vary according to tissue type, whereas the 
configuration of complexes II and IV remain more consistent [Rustin et al. 1994].  
The oxidative phosphorylation process commences when complex I oxidises NADH to 
nicotinamide adenine dinucleotide (NAD+) and transfers two electrons to ubiquinone 
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(coenzyme Q). During this process four protons (H+) are pumped across the mitochondrial 
inner membrane to the intermembrane space, initiating the ETC proton gradient [Pedersen 
et al. 1999, Garrett et al. 1999]. Ubiquinone passes the electrons from complexes I and II 
through complex III, cytochrome c, and complex IV, while it pumps protons from the matrix 
to the intermembrane space in parallel. In complex IV, cytochrome c is reduced and its 
electrons donated to oxygen (O2), which generates two water (H2O) molecules. The 
protons in the intermembrane space all contribute to the 150mV electrochemical proton 
gradient that will drive ATP synthesis [Pedersen et al. 1999, Leonard et al. 2000]. The 
reducing equivalents generated during the metabolism of glutamate, pyruvate, and 3-
hydroxybutyrate gain entry into the ETC via complex I. Whereas the electron transfer 
protein which is attached to coenzyme Q as well as complex I, are points of entry for the 
reducing equivalents produced from fatty acid β-oxidation. Succinate on the other hand 
undergoes reduction at complex II [Leonard et al. 2000].  
 
2.1.5.1.2 ATP synthesis 
The electrochemical gradient results in the proton concentration in the intermembrane 
space being much higher than that it the mitochondrial matrix. This unequal distribution of 
protons causes complex V (ATP synthase) to transfer some of these protons back into the 
mitochondrial matrix, thus commencing the ATP synthesis step. 
 
ATP synthase contains two key components F0 and F1, where F0 is found in the inner 
mitochondrial membrane (IMM) and has a rotational capacity, while F1 extends into the 
matrix and is unable to rotate. Furthermore, F0 is responsible for translocating the protons 
while F1 synthesizes the ATP.  
Stellenbosch University http://scholar.sun.ac.za
 20 
 
The F0 unit seizes a proton and attaches it to the protein rotor, which binds F0 and F1 
together, causing it to rotate and unload the proton on the inside of the membrane. During 
this process the rotor spins inside the stationary F1 subunit changing the chemical energy 
of the electrochemical gradient to mechanical energy, which in turn brings adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) into correct alignment for phosphorylation 
and ATP production. One molecule of ATP is produced from 2 or 3 protons while one 
molecule of glucose yields about 31.5 molecules of ATP, whereas the saturated fatty acid 
palmitate yields 106 molecules of ATP [Vo et al. 2004]. 
 
2.1.5.1.3 Mitochondrial respiration coupling and uncoupling 
As mentioned in the previous section, during the transfer of electrons between the ETC 
complexes protons are pumped across the inner mitochondrial membrane to the 
intermembrane space, which creates an electrochemical gradient. This gradient exists 
because the protons are unable to diffuse back into the matrix, to reach equilibrium, across 
the IMM. The protons are only able to gain access to the matrix via ATP synthase because 
the F0 subunitof this synthase  grabs hold of the proton, while the F1 subunit  uses the free 
energy involved to phosphorylate ADP and produce ATP (as explained in section 
2.1.5.1.2). Thus, it is easy to see that the oxidation-reduction reactions and ATP 
production in the mitochondria are coupled; coining the entire process coupled oxidative 
phosphorylation [Pendersen et al. 1999, Nicholls et al. 2001, Ricquier 2005]. 
Uncoupled oxidative phosphorylation occurs when there is a “leak” in the IMM, thus 
allowing protons to diffuse across it into the matrix that is, without having passed though 
ATP synthase and without producing ATP. The free energy involved is given off as heat 
instead [Nicholls et al. 2001, Ricquier 2005]. 
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Figure 2.4: Overview of the electron transport process by complexes I to IV and 
electrochemical proton gradient production in the ETC, and its role in ATP synthesis via 
ATP synthase (complex V).  Taken and edited from Lücker et al. 2010. 
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2.1.5.1.4 ETC complexes and their subunits 
There is mounting evidence that the complexes of the electron transport chain are actually 
supercomplexes as they consist of multiple dimmers [Schägger et al. 2001]. The 
mitochondrial ETC complexes of bovine heart, bacteria and other eukaryotes have been 
characterized more extensively to date, as obtaining sufficient mitochondria from human 
tissue has proven difficult [Murray et al. 2003]. Therefore, the complex composition of 
these animals will be discussed in further detail. 
Complexes I to V have been reported to contain 42, 4, 11, 13 and 14 polypeptide subunits, 
respectively [Pedersen et al. 1999, Leonard et al. 2000]; each of which contribute to 
complex assembly and integrity in their own way. 
 
2.1.5.1.4.1 Complex I 
This complex consists of multiple subunits, for example 46 in bovine heart mitochondria 
with a total molecular weight of 980kDa, whereas human myocardial tissue has 42 
subunits with a molecular mass of about 1000kDa. It has been shown, in bovine heart 
mitochondria, that 7 of the subunits are encoded by mitochondrial DNA, whereas the 
genes for the other 35 subunits are encoded in the nucleus [Carrol et al. 2003, Murray et 
al. 2003]. 
Studies on bovine heart mitochondria have resolved complex I and discovered that it is L-
shaped, with one arm located in the mitochondrial membrane and orientated vertically to 
the plane of the membrane. The other arm is orientated horizontally to the mitochondrial 
matrix. Furthermore, complex I was found to consist of 3 subcomplexes, namely Iλ 
(extrinsic arm), Iα (first part of the membrane arm) and Iβ (second part of the membrane 
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arm). Please refer to table 1 for the subunit composition of subcomplexes Iα, Iλ and Iβ 
[Carrol et al. 2003]. 
 
2.1.5.1.4.2 Complex II 
Regardless of species, complex II of the mitochondrial ETC is the simplest in that it 
contains the least number of subunits.  This complex consists of 4 subunits in animals, 
fungi and bacteria, while the complex consists of 8 subunits in plants [Millar et al. 2004, 
Morales et al. 2009, Gawryluk et al. 2009]. In the amoeba Acanthamoeba castellanii (A. 
castellanii) as well as other eukaryotes, the molecular weight of this complex was found to 
be about 130kDa in its active form [Gawryluk et al. 2012]. Please refer to table II for the 
subunit composition of complex II in A. castellanii. 
 
2.1.5.1.4.3 Complex III 
This complex, regardless of species, has three common subunits which all have active 
redox centers, namely cytochrome b (Cob), cytochrome c1 (CytC1) and the “Rieske” [2Fe-
2S] protein (ISP). The 280kDa eukaryotic complex III is more complex in that it contains 
supplementary subunits, whereas bacterial complex III only contain these three subunits 
[Iwata et al. 1998, Gawryluk et al. 2012]. In bovine heart complex III is composed of 11 
subunits [Pedersen et al. 1999, Leonard et al. 2000]. Refer to table III for the subunit 
composition of complex III in A. castellanii. 
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2.1.5.1.4.4 Complex IV 
This 360kDa complex has been reported to contain more than 10 subunits in A. castellanii 
and about 13 subunits in bovine heart [Pedersen et al. 1999, Leonard et al. 2000, 
Gawryluk et al. 2012]. In addition to the subunits that make up complex IV, there are also 
additional proteins which assist with the assembly of this complex, as seen in table IV 
[Gawryluk et al. 2012]. 
 
2.1.5.1.4.5 Complex V 
In bacteria complex V (ATP synthase) consists of 8 subunits while bovine heart contains 
16 subunits [Müller et al. 2003]. As previously mentioned, this complex consists of two 
major components namely F1 and F0, where each component is composed of 5 subunits in 
A. castellanii. The remainder of the subunits are thought to be associated with the F0 base 
of ATP synthase. Similar to complex IV, there are also additional proteins that play a role 
in the assembly of complex V as listed in table V [Gawryluk et al. 2012].  
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Table I. The subunit composition of subcomplexes Iα, Iλ and Iβ in complex I of bovine 
mitochondrial ETC. Taken from Carroll et al. 2003. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II. The subunit composition of complex II, as well as the assembly proteins which 
assist in the assembly of this complex, in A. castellanii mitochondrial ETC. Taken and 
edited from Gawryluk et al. 2012. 
. 
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Table III. The subunit composition of complex III in A. castellanii mitochondrial ETC. Taken 
and edited from Gawryluk et al. 2012. 
. 
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Table IV. The subunit composition of complex IV, as well as the associated proteins of this 
complex, in A. castellanii mitochondrial ETC. Taken and edited from Gawryluk et al. 2012. 
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Table V. The subunit composition of complex V (ATP synthase), as well as the associated 
proteins of this complex, in A. castellanii mitochondrial ETC. Taken and edited from 
Gawryluk et al. 2012. 
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2.2 Obesity and Insulin signalling 
2.2.1 What is Insulin Resistance? 
A common pathology of obesity is insulin resistance [Reaven 2008] which is classified as 
the inability of normal physiological levels of insulin to prompt a sufficient response in 
target tissues such as skeletal muscle, liver, adipose tissue and of course, the heart 
[Mlinar et al. 2007, Schwenk et al. 2008]. 
 
2.2.2 Changes in substrate utilization by the heart during obesity 
2.2.2.1 Reduced glucose metabolism 
A number of studies have been published regarding myocardial substrate utilization during 
a pathophysiological state such as obesity. Many of these studies involve analyzing 
expression, subcellular localization and functional regulation of GLUT4 and FAT/CD36 as 
these are imperative factors that ascertain the rate of substrate utilization [Coort et al. 
2004]. 
Studies showed that insulin stimulated activity of the PI3K/PKB/Akt pathway was reduced 
in cardiac myocytes isolated from rats that were exposed to a high fat diet and later 
developed T2DM [Ouwens et al. 2005], as well as in cardiac myocytes isolated from 
insulin resistant obese Zucker rats [Coort et al. 2007]. 
Additionally, it was found that insulin-stimulated (physiological concentrations) GLUT4 
translocation and glucose uptake were reduced in cardiomyocytes and cardiac muscle 
isolated from insulin resistant obese rats [Coort et al. 2007]. 
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2.2.2.2 Increased fatty acid β-oxidation 
In insulin resistant obese Zucker rats, it was found that myocardial LCFA uptake was 
increased in the hearts of these animals, which coincided with an elevation in the quantity 
of FAT/CD36 at the sarcolemma and a decrease in the FAT/CD36 intracellular content. 
The total FAT/CD36 content in the heart from the obese animals remained unchanged, 
indicating that there is a permanent relocation of FAT/CD36 from its intracellular 
compartment to the sarcolemma and this is most likely the reason for the increased LCFA 
uptake. Additionally, the rate of cardiac LCFA oxidation was unaffected while the content 
of TAG in myocardium as well as the rate at which LCFAs were converted to TAG, were 
augmented in these obese rats [Coort et al. 2004, Luiken et al. 2002]. 
Most studies conducted on humans are restricted to skeletal muscle. Nevertheless, the 
findings of these studies can be extrapolated to the myocardium, as it too is a muscle and 
regulates its substrate utilization similar to skeletal muscle [Coort et al. 2007]. Analysis of 
skeletal muscle, in obese and T2DM human subjects and compared to lean controls, 
indicated a similar increase in intracellular TAG content and an increase in the amount of 
FAT/CD36 protein at the sarcolemma as in the hearts of obese Zucker rats. Additionally, 
the rate of palmitate (a saturated fatty acid) transport was elevated in these obese and 
T2DM human subjects [Bonen et al. 2002]. 
As these studies have indicated, there is a strong correlation between obesity and cardiac 
insulin resistance and it would seem that the pivotal factor connecting these two conditions 
might be metabolic disturbances, such as increased LCFA and decreased glucose uptake, 
within the myocardium [Coort et al. 2007]. 
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2.2.3 Changes in substrate utilization by the heart during cardiomyopathies 
During myocardial pathophysiological conditions such as ischemia-reperfusion injury, 
hypertrophy, atrophy and advanced heart failure, it has been reported that substrate 
utilization in the heart and its subsequent ATP production, were altered. During these 
cardiomyopathies there is a reduction in fatty acid β-oxidation and elevated glucose 
metabolism, as indicated by a number of studies in humans, canines and rodents [Rosano 
et al. 2008, Hajri et al. 2001, Huss et al. 2005, Stanley et al. 2005]. Several of these 
cardiomyopathies have been shown to lead to heart failure [Taha et al. 2007] and thus, the 
changes in substrate utilization during heart failure will be discussed in further detail. 
There are conflicting studies but the general consensus, recently achieved, is that during 
the initial stages of heart failure, substrate utilization is still relatively normal in that fatty 
acids still serve as the main and glucose as the secondary energy source. It is during the 
late stages of the disease that fatty acid metabolism is blunted and glucose oxidation is 
upregulated [Stanley et al. 2005, Lopuschuk et al. 2010].  
It is thought that the heart perceives these pathologies as stressors and responds to it by 
changing its substrate metabolism, depending on whether or not the “stress” is acute or 
sustained. When the “stress” is acute the changes in substrate utilization manifest itself on 
the cytosolic level and can be considered transient. On the other hand, during chronic 
myocardial stress the initial metabolic changes become permanent as it becomes 
regulated on the nuclear level [Rajabi et al. 2007]. 
 
The precise mechanism is currently not known whereby the substrate switch on the 
cytosolic level leads to the changes seen on the nuclear level. It is speculated that the 
transcriptional level of a number of enzymes and transporters that play significant roles in 
myocardial substrate uptake and metabolism are elevated in the normal adult human 
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heart, in comparison to the foetal heart [Razeghi et al. 2001, Sack et al. 1997, Rajabi et al. 
2007]. While the transcriptional levels of these genes in the adult heart are thought to 
decline to the level found in the foetal heart during heart failure [Razeghi et al. 2001, 
Rajabi et al. 2007].  Please refer to table 1. 
  
Other changes seen during advanced heart failure include a reduction in peroxisome 
proliferator-activated receptor-α (PPAR-α) expression and activity [Barger et al. 2000] as 
well as PPARγ coactivator-1α (PGC-1α) [Heusch et al. 2005, Gottlieb 1999, Downward 
2003, Depre et al. 2005, Lazar 1997], both of which are essential in regulating 
mitochondrial metabolism and biogenesis [Huss et al. 2005, Rajabi et al. 2007]. The 
attenuation in the activity of the electron transport chain activity as well as a reduction in 
the flux of mitochondrial oxidative phosphorylation has also been noted during this stage of 
heart failure [Rajabi et al. 2007]. In addition, a few studies in humans and rodents have 
shown that the activity of several of the ETC complexes were downregulated [Jaretta et al. 
2000, Casademont et al. 2002, Scheubel et al. 2002, Stanley et al. 2005]. 
 
2.2.3.1 Could similar changes in myocardial substrate utilization occur in advanced 
obesity-related cardiomyopathies? 
Transgenic (TG) mice, overexpressing of GLUT1 were used to augment intracellular 
glucose in the heart, while these animals were also fed a high fat diet for 20 weeks to 
elevate fatty acid levels. The wild-type (WT) and TG mice fed high fat diets developed diet-
induced obesity and insulin resistance. The WT mice displayed elevated myocardial fatty 
acid oxidation and reduced glucose in response to the high fat diet. On the other hand, this 
diet did not increase the fatty acid oxidation in the TG mice however they showed 
significantly higher levels of glucose oxidation in the heart. Furthermore, the study found 
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that metabolic gene expression favoured glucose utilization as the elevated glucose levels 
induced decreased PPAR-α and 3-oxoacid CoA transferase expression, while the 
expression of acetyl-CoA carboxylase was enhanced in these mice. Lastly, when TG mice 
were fed a high fat diet they displayed elevated myocardial oxidative stress and contractile 
dysfunction [Yan et al. 2009]. 
This study suggests that despite the presence of elevated fats in the diet, the transgenic 
diet-induced obese mice favour glucose over fatty acid utilization after 20 weeks. The 
decreased myocardial fatty acid and increased glucose oxidation seen in these mice could 
be associated with the decreased PPAR-α and 3-oxoacid CoA transferase and elevated 
acetyl-CoA carboxylase expression.  
 
Belfiore et al. (1998) stated that increased plasma free fatty acids, glucose and insulin 
levels are associated with obesity. Furthermore, the increased free fatty acids induced 
inhibition of pyruvate dehydrogenase (PDH), by increasing acetyl-CoA levels, thereby 
blunting glucose metabolism. Whereas, increased plasma glucose and insulin levels inhibit 
CPT-I, via enhanced malonyl-CoA production, thus inhibiting fatty acid oxidation. These 
mechanisms are thought to occur through the short-term as well as the long term effects of 
obesity. 
On the other hand, as discussed in section 2.2.2 obesity is associated with increased fatty 
acid β-oxidation and decreased glucose oxidation. Perhaps these metabolic substrate 
changes seen are associated with the initial stages of obesity and the start of myocardial 
insulin resistance. Whereas those observed by Yan et al. (2009) could represent the 
changes in substrate utilization during advanced obesity and when insulin resistance is in 
a progressive stage.  
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Currently, little research has been done that compares the substrate utilization during the 
early onset and the advanced stages of obesity, thus it would be difficult to say whether 
the difference in substrate utilization seen by Yan et al. and those discussed in section 
2.2.2 are due to the stage of obesity. 
 
 
 
 
Table VI. Differences in the protein level of enzymes and transporters that play significant 
roles in myocardial substrate uptake and metabolism as well as myocardial structure, in 
the adult, foetal, hypertrophic and atrophied rodent heart. Taken from Rajabi et al. 2007. 
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2.3 Obesity and Cardiac Insulin Resistance 
The precise mechanism by which cardiac insulin resistance is mediated during obesity is 
at present not completely understood and thought to be complicated and attributable to 
multiple factors. Furthermore, research aimed at elucidating the mechanism of insulin 
resistance has mainly focused on skeletal muscle. This has nonetheless provided valuable 
insight into how myocardial insulin resistance could be mediated. One thought is that 
myocardial metabolic anomalies such as excess intracellular lipid accumulation could be 
one of the main culprits in initiating the pathophysiology. The change in myocardial 
substrate preference during obesity, discussed in section 2.2.2, is thus thought to be an 
arbitrator of obesity-related myocardial insulin resistance [Coort et al. 2007, Goodpastor et 
al. 2004, Petersen et al. 2002].  
 
2.3.1 Alluding to the mechanism of obesity-related cardiac insulin resistance 
Obese individuals consume more calories than they burn, in comparison to lean 
counterparts, resulting in a greater availability of metabolic energy that needs to be stored 
in the adipose tissue. This surplus adiposity, particularly intra-abdominal fat accumulation, 
hinders the ability of insulin to suppress hormone-sensitive lipase (HSL) and in turn, 
lipolysis in the adipose tissue. The rest of the proposed mechanism will be explained in 
figure 2.5. 
The elevated lipolysis in the adipocytes (1) subsequently increase plasma free fatty acid 
levels (2) which activate insulin secretion. (3) Thus stimulating permanent FAT/CD36 
translocation to the myocardial sarcolemma during obesity, as mentioned in 2.2.2.2, (4) 
which allows for the uptake of these excess extracellular free fatty acids (LCFAs) into the 
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myocardium. Additionally, there is a greater conversion of LCFAs into TAG which is also 
subsequently oxidised, increasing the intracellular content of TAG metabolites (ceramide, 
diacylglycerol (DAG) and acetyl-CoA). It is thought that by increasing the myocardial 
uptake of excess extracellular LCFAs, the heart has shifted its substrate metabolism to 
increased fatty acid utilization, as discussed in 2.2.2. (5) The intracellular TAG metabolites 
proceeds to activate protein kinase C -θ (PKC-θ), (6) diminishing tyrosine and enhancing 
serine phosphorylation of IRS-1. (7) This reduces the ability of IRS-1 to recruit and activate 
PI3K, which sequentially hinders the activation of protein kinase B (PKB/Akt) [Petersen et 
al. 2002]. When PKB/Akt activation is diminished then (8) GLUT translocation to the 
sarcolemma and glucose uptake is reduced. This reduction in glucose uptake is thought to 
be the second shift in substrate utilization seen during obesity, as discussed in section 
2.2.2. The decrease in glucose uptake is thought to reduce glycogen synthesis and (9) 
elevate blood glucose levels, rendering the cardiomyocyte insulin resistant as the high 
glucose blood levels stimulate the secretion of even more insulin, while the cells’ ability to 
take up the extracellular glucose is severely blunted. 
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Figure 2.5. Metabolic abberations involving the insulin mediated PI3K/PKB/Akt pathway in 
the obese individual, in pathophysiological conditions. Taken and adapted from Coort et al. 
2007. 
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2.3.1.1 How does the excess free fatty acids in the plasma, accumulate in ectopic 
organs during obesity? 
A bone of contention for researchers is the mechanism by which the excess intracellular 
lipids accumulate in ectopic organs such as skeletal muscle, liver, pancreas and the heart 
during obesity, resulting in insulin resistance. There are currently four hypotheses or 
theories available, which attempt to explain this metabolic aberration.  
 
2.3.1.1.1 The portal/visceral hypothesis 
This hypothesis proposes that obese individuals are characterized by elevated adipocyte 
lipolysis and accordingly, there is an increased secretion of fatty acids into the plasma and 
as a result the flux of fatty acids into the liver, via the portal vein, is augmented. 
Additionally, these fatty acids are also able to infiltrate skeletal muscle, the heart and 
pancreas. Hepatic TAG production and assembly into VLDLs are thus enhanced, 
consequently elevating the secretion of VLDLs into the plasma. The high lipid plasma 
levels stimulate the secretion of insulin which in turn activates the translocation of LCFA 
transport proteins to the myocardial sarcolemma. This translocation to the sarcolemma is 
permanent as the plasma lipid levels are chronically elevated in the obese individual. This 
is in contrast to the non-obese individual where the translocation is transient due to normal 
lipid handling by the adipose tissue and liver [Van Gaal et al. 2006, Bergman et al. 2007, 
Kahn et al. 2006].  
This theory then latches onto the Randle cycle by suggesting that insulin resistance in 
these target organs, including the heart, is achieved by increased intracellular 
concentrations of acetyl-CoA, as a result of increased LCFA oxidation. The increased 
acetyl-CoA then augments the concentration of G-6-P and decreases hexokinase activity, 
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ultimately causing a reduction in glucose uptake and oxidation [Bergman et al. 2007, 
Rasvussin et al. 2002, Coort et al. 2007]. 
 
2.3.1.1.2 Ectopic fat storage syndrome hypothesis 
This hypothesis proposes that the adipocyte stem cell precursors, from which the mature 
adipocyte is derived, lack their full proliferative and differentiation ability. Thus, the existing 
peripheral adipocytes undergo hypertrophy when there is excess energy or fat available, 
as is the case in obesity. The subcutaneous fat depots soon become saturated and the 
fatty acids filter into the ectopic organs such as the liver, skeletal muscle and heart, 
causing insulin resistance in the target organ [Ravussin et al. 2002]. 
 
2.3.1.1.3 Impaired fat oxidation hypothesis 
In this hypothesis it is suggested that whole body LCFA oxidation is blighted in the obese 
person, increasing plasma LCFA content and elevating ectopic lipid accretion; culminating 
in insulin resistance of the ectopic organ [Ravussin et al. 2002, Bergman et al. 2007]. 
 
2.3.1.1.4 Endocrine paradigm hypothesis 
This theory puts forward the idea that because adipocytes are also endocrine cells they 
are able to secrete cytokines and hormones [Bergman et al. 2007, Aguilera et al. 2008]. It 
is thought that these hormones or endocrine factors are able to influence the metabolism 
and biology of peripheral tissues such as the liver, muscle and heart and cause insulin 
resistance [Kahn et al. 2006, Ravussin et al. 2002, Bergman et al. 2007]. 
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It would seem that the majority of the literature favours the portal/visceral hypothesis. 
However, it should be noted that there is mounting evidence supporting the other three 
hypotheses. It could then be suggested, that the key to understanding the mechanism 
behind obesity induced ectopic intracellular lipid accumulation, might not lie in only one 
theory but rather a combination of all four theories. 
 
2.4 Obesity and the insulin-mediated PI3K/PKB/Akt pathway 
As seen in the previous sections, the insulin-mediated PI3K/PKB/Akt pathway plays a 
significant role in regulating glucose and fatty acid metabolism in the heart, while any 
aberrations in this pathway can mediate myocardial insulin resistance. The following 
sections will review the role that key components of the PI3K/PKB/Akt pathway plays in 
myocardial glycogen synthesis, during the normal physiological state and during obesity. 
 
2.4.1 The role of the insulin-mediated PI3K/PKB/Akt pathway in glycogen synthesis 
2.4.1.1 The PKB/Akt protein 
PKB/Akt is a 57kDa protein which possesses three isoforms, namely PKBα (Akt1), PKBβ 
(Akt2) and PKBγ (Akt3), and regardless of the isoform, contains an amino-terminal 
pleckstrin homology (PH), a carboxy-terminal regulatory and a kinase domain [Hajduch et 
al. 2001, Lawlor et al. 2001]. 
Growth factors, insulin, and DNA damage all serve as stimuli for the activation of 
cytoplasmic PKB/Akt under normal physiological conditions and once it is activated, 
PKB/Akt can migrate to an array of subcellular compartments [Parcellier et al. 2008]. In 
these subcellular compartments, such as the Golgi apparatus, endoplasmic reticulum, 
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mitochondria and nucleus [Hajduch et al. 2001], PKB/Akt phosphorylates substrates and 
regulates target molecules and genes [Hajduch et al. 2001, Parcellier et al. 2008]. 
Insulin stimulates the activation of tissue specific PKB/Akt isoforms. In the heart all 
isoforms of PKB/Akt are expressed however, that of PKBα/Akt1 and PKBβ/Akt2 was found 
to be the most expansive [Matsui et al. 2001]. 
The main isoform found in skeletal muscle and hepatocytes is PKBα/Akt1, whereas 
PKBβ/Akt2 is mainly expressed in adipocytes. The insulin-mediated activation of 
PKBγ/Akt3 did not occur in these two tissue types but has been detected in other cell lines 
[Walker et al. 1998]. 
Studies indicate that PKBα/Akt1 is most likely plays an important role in growth and 
PKBβ/Akt2 in metabolism whereas, PKBγ/Akt3 is thought to not be essential for either 
growth or metabolism [Chen et al. 2001, Cho et al. 2001]. Instead PKBγ/Akt3 is thought to 
play a role in myocardial hypertrophy and neurological phenotype [Taniyama et al. 2005, 
Sussman et al. 2010]. 
Phosphorylation of PKB/Akt at two specific residues is required for full activation, these 
residues being Thr308 and Ser473 for PKBα/Akt1, Thr309 and Ser474 for PKBβ/Akt2 and Thr305 
and Ser472 for PKBγ/Akt3. These residues are located in the kinase and carboxy-terminal 
regulatory domains, respectively [Delcommenne et al. 1998, Taniyama et al. 2005]. 
PDK-1 was found to be responsible for the phosphorylation of Thr308 while the kinase 
enzyme responsible for Ser473 phosphorylation has not yet been completely characterized, 
it is believed to be PDK-2 (3-phosphoinositide-dependent protein kinase-2) [Hajduch et al. 
2001, Kobayashi et al. 1999, Lawlor et al. 2001]. 
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2.4.1.2 PBK/Akt and glycogen synthesis 
Glycogen synthesis is the body`s mechanism of disposing of excess glucose and when 
this process is impaired in any way, as is the case in obesity, it paves the way for tissue 
specific insulin resistance [Pearce et al. 2004]. PKB/Akt is able to exert its control over this 
metabolic process via the phosphorylation and thus inhibition of the serine/threonine 
protein kinase glycogen synthase kinase-3 (GSK-3) [Rao et al. 2007]. This subsequently 
stimulates the activation of the enzyme glycogen synthase, and glycogen synthesis 
[Parcellier et al. 2008], all of which will be reviewed in the sections that follow.  
 
2.4.1.2.1 Glycogen synthase kinase-3 (GSK-3) protein 
A significant role has been established for GSK-3 in a wide selection of biological 
processes, such as cellular proliferation and differentiation, protein synthesis, embryonic 
development and apoptosis. GSK-3 has been found to regulate these processes by 
phosphorylating a number of proteins, thereby activating a variety of pathways [Frame et 
al. 2001, Xu et al. 2009]. One of the first roles assigned to GSK-3, was in the regulation of 
the glycogen synthesis process [Xu et al. 2009], the mechanism of which is discussed in 
more detail in the sections that follow. 
 
GSK-3 is found in two isoforms namely, GSK-3α and GSK-3β [Pearce et al. 2004], is 
constitutively active when the cells do not receive a stimulus [Hajduch et al. 2001] and is 
expressed in all cells and tissues [Ciaraldi et al. 2006].  
Furthermore, this kinase has an N-terminal residue, Ser21 for GSK-3α and Ser9 for GSK-
3β, that is regulated at all times by PKB/Akt (for the purpose of glucose metabolism), 
determining whether or not the kinase will remain activated or if its activation will be 
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downregulated [Rao et al. 2007, Lawlor et al. 2001, Hajduch et al. 2001]. However upon 
insulin stimulation, activated PKB/Akt phosphorylates these isoforms at their N-terminal 
residues, Ser21 (GSK-3α) and Ser9 (GSK-3β), subsequently leading to GSK-3 inhibition 
[Rao et al. 2007, Lawlor et al. 2001, Hajduch et al. 2001]. 
GSK-3 is also regulated, via phosphorylation, by a number of other substrates, each 
having their own biological significance (which is reviewed elsewhere), such as MAPK-
activated protein kinase-1 (MAPKAP-K1/RSK), epidermal growth factors (EGF) and p70 
ribosomal S6 kinase-1 (S6K1) [Frame et al. 2001, Doble et al. 2003, Xu et al. 2009]. 
 
2.4.1.2.2 GSK-3 during normal physiological conditions 
When insulin sensitive cells are not stimulated by insulin (during periods of rest or fasting 
for example) in a normal, healthy individual, then PKB/Akt activation is inhibited and 
prevents the phosphorylation and inactivation of GSK-3 at their respective serine residues 
[Rao et al. 2007, Lawlor et al. 2001, Hajduch et al. 2001]. This in turn ensures that GSK-3 
remains active and thus, capable of phosphorylating and inhibiting the enzyme glycogen 
synthase and the glycogen synthesis process [Pearce et al. 2004]. 
Active GSK-3 also has the ability to phosphorylate IRS-1 at its serine and threonine 
residues thus mediating a diminished interaction between IRS-1 and the insulin receptor 
by advancing the disintegration of IRS-1 [MacAulay et al. 2007, Boura-Halfon et al. 2009]. 
As a result the insulin signalling cascade is downregulated, reducing the translocation of 
GLUT receptors to the sarcolemma. Glucose uptake as a consequence is downregulated, 
thus maintaining normal blood glucose levels [Pearce et al. 2004]. 
In contrast, when cells are stimulated by insulin (postprandial for example), PKB/Akt is 
able to phosphorylate and inactivate GSK-3. In this subsequent repressed state, GSK-3 
cannot phosphorylate and block glycogen synthase; thus losing its inhibitory control over 
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the glycogen synthesis process. Furthermore, inactive GSK-3 is unable to phosphorylate 
and thereby disintegrate IRS-1, promoting GLUT receptor translocation to the sarcolemma 
and glucose uptake. This not only further promotes glycogen synthesis but also reduces 
the elevated blood glucose levels [Pearce et al. 2004]. 
 
2.4.1.2.3 GSK-3 during obesity 
Section 2.4.1.2.2 emphasizes the significant role that GSK-3 plays in insulin mediated 
glucose and glycogen metabolism as well as the influence the protein has on blood 
glucose levels. More importantly, it highlights the potential role of GSK-3 in mediating 
insulin resistance, a major hallmark of obesity. 
 
Indeed, GSK-3 expression or activity has been found to be significantly augmented in the 
skeletal muscle of animal models of insulin resistance [Ferrannini 1998, Eldar-Finkelman 
et al. 1997] as well as in insulin resistant T2DM patients [Nikoulina et al. 2000]  
Additionally, GSK-3 levels were not only found to be elevated in obese and insulin 
resistant high-fat fed mice [Eldar-Finkelman et al. 1999] and obese Zucker rats [Dokken et 
al. 2005] but in the skeletal muscle of obese humans as well [Henriksen et al. 2006]. 
The actions of activated GSK-3 in the normal, healthy individual give rise to the inhibition 
of glucose uptake and glycogen synthesis when the cells are not stimulated by insulin, as 
seen in section 2.4.1.2.2. Thus, the hypothesis is that glucose uptake and glycogen 
synthesis would be significantly downregulated during periods of rest in the obese 
individual. Furthermore, this is seen as a key contributing factor in mediating obesity-
related insulin resistance. 
A study conducted by Pearce et al. (2004) utilizing genetically engineered mice, which had 
excessively augmented GSK-3 expression specifically in their skeletal muscle, displayed 
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diminished muscle glycogen content despite increased plasma insulin levels at rest [Rao 
et al. 2007]. This study thus supports the role of GSK-3 as a potential mediator of insulin 
resistance. 
GSK-3 is suspected to intensify obesity, by increasing body weight and intra-peritoneal fat 
mass. Eldar-Finkelman et al. (1997) found, when comparing two different strains of 
genetically engineered mice subsequent to being fed a high fat diet for 15 weeks, that the 
obesity and diabetes prone strain (C57BL/6J) had an increased body weight of 30%. The 
A/J strain, which is resistant to diet-induced obesity and diabetes, on the other hand only 
had a fairly small increase in body weight, about 4 grams per animal on average. In 
addition, the GSK-3 activity in the epididymal fat tissue of the C57BL/6J mice displayed a 
two-fold increase in comparison to the control animals, while there was no significant 
difference in the skeletal muscle enzyme activity between the C57BL/6J and control mice. 
These findings thus indicate that GSK-3 might play an important role in mediating 
increased adiposity during the obese state. 
 
2.5 Obesity and Myocardial Cell Death 
2.5.1. Modes of cell death 
Apoptosis is a rigorously controlled biological, energy dependent, process crucial for the 
removal of unwanted or damaged cells [Gupta 2001]. This type of cell death encompasses 
cell shrinkage and the formation of small apoptotic bodies, plasma membrane blebbing, 
chromatin condensation and DNA fragmentation [Bennet 2002, Clerk et al. 2003, 
Dragovich et al. 1998, Strasser et al. 2000]. Apoptosis is also marked by alterations in 
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mitochondrial membrane permeability and the release of proteins from the mitochondrial 
intermembrane space [Krysko et al. 2008]. 
Autophagy was previously thought of as a second type of cell death but has recently been 
defined as a “housekeeping” process as it destroys damaged and dysfunctional organelles 
and protein aggregates in cells by means of degradation, under normal and aberrant 
physiological conditions [Dong et al. 2010]. This strictly regulated process is characterized 
by autophagic vacuoles which is composed of double membranes and is also activated 
when a cell is deprived of essential nutrients or growth factors [Krysko et al. 2008]. 
The third type of cell death, necrosis, or sometimes referred to as oncosis, is associated 
with swift cytoplasmic swelling which causes the intracellular organelles to swell as well, 
furthermore resulting in plasma membrane blebbing (reversible process). Eventually, the 
plasma membrane and organelles rupture, releasing (amongst others) lysosomal enzymes 
which cause inflammation in the adjacent cells and tissue [Dive et al. 1992, Krysko et al. 
2008].  
 
As a result of these features necrosis has long been thought of as an uncontrolled and 
“accidental” process [Krysko et al. 2008]. However, it has recently been shown that the 
necrotic process is regulated via the interaction of several biochemical and molecular 
activities at various cellular levels. 
Necrosis is elicited by stressors such as ATP depletion, ischemia, when a cell is unable to 
maintain ionic homeostasis, heat, high concentrations of reactive oxygen species (ROS) 
such as hydrogen peroxide, osmotic shock as well as mechanical stress; and is often 
characterized by unwanted cell loss in pathophysiological states [Festjens et al. 2006, 
Vanden Berghe et al. 2007]. 
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Apoptotic cell death will be discussed in greater detail in the sections to follow, for the 
purpose of this review, whereas autophagic and necrotic cell death are reviewed 
elsewhere [Dong et al. 2010, Festjens et al. 2006]. 
 
2.5.2 The role of the insulin-mediated PI3K/PKB/Akt pathway in myocardial 
apoptosis. 
The PI3K/PKB/Akt pathway is known to be cardioprotective [Rubio et al. 2009] and 
mediates its protection by activating PKB/Akt which in turn, promotes survival and 
prevents death of the cardiomyocytes [Hill et al. 2002] by moderating the process of 
apoptosis either directly or indirectly [Franke et al. 1997, Hemmings 1997]. Myocardial 
apoptosis is mediated by two pathways; (1) the extrinsic pathway, otherwise known as the 
death receptor pathway, and (2) the intrinsic pathway, also viewed as the mitochondrial 
dependent pathway [Bishopric et al. 2001]. 
 
2.5.2.1 The death receptor apoptotic (extrinsic) pathway 
In terms of the extrinsic pathway, there are actually a number of pathways that fall into this 
category. The receptors of the Fas and tumour necrosis factor receptor-I (TNFR-I) death 
receptor pathways, are active in cardiomyocytes and have been associated with the 
development of cardiovascular disease [Lee et al. 2009a]. These pathways are the most 
well-known of the death receptor apoptotic pathways and as the name suggests, are 
mediated by their respective receptors (Fas and TNF receptors) [Peter et al. 2003, Wang 
et al. 2003]. An overview of the signalling cascade of the Fas and TNFR death receptor 
apoptotic (extrinsic) pathways are given in figure 2.6. 
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Fas and TNFR-I are two of the death receptors which contain death domains that are able 
to undergo trimerization or aggregation once Fas ligands and tumour necrosis factor-α 
(TNF-α) bind to their respective receptors [Gupta 2001, Baines et al. 2005]. This in turn 
allows for the recruitment of adaptor molecules, Fas-associated death domain (FADD) and 
tumour necrosis factor receptor-associated death domain (TRADD) (for Fas and TNFR-I 
receptors, respectively) which are localized in the cytoplasm and contain their own death 
domains [Peter et al. 2003, Wang et al. 2003]. For the TNFR-I death pathway, TRADD first 
has to recruit FADD in order to mediate the activation of apoptosis, whereas FADD is 
directly recruited in the Fas death pathway [Gupta 2001]. Once recruited, FADD is able to 
bind to cytoplasmic procaspase-8 via the interaction of their homologous death effector 
domains (DED). The binding of the death domain (located in the ligand), FADD and 
procaspase-8 forms a complex known as the death-inducing signalling complex (DISC) 
[Gupta 2001, Yang et al. 1998]. While in the complex, procaspase-8 is activated to active 
or mature caspase-8, by means of autoproteolysis, which in turn activates caspase-3 (also 
called “effector” or “executioner” caspase) [Gupta 2001, Baines et al. 2005, Yang et al. 
1998]. Activated caspase-3 subsequently cleaves many “death” substrates (cytoplasmic as 
well as nuclear), leading to DNA fragmentation and the morphological modifications 
coupled to apoptosis [Gupta 2001]. 
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Figure 2.6. The signalling cascade of the Fas and TNFR death receptor apoptotic 
(extrinsic) pathways. Taken and adapted from Tumane et al. 2010. 
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2.5.2.2 PKB/Akt indirectly moderates apoptosis: The role of PKB/Akt in the extrinsic 
apoptotic pathway 
When health prevails the insulin-mediated activation of PKB/Akt is unhampered, as 
reviewed in section 2.1.3. Activated PKB/Akt is known to phosphorylate and activate I-ĸB 
kinase (IKK) at its Thr23 residue [Parcellier et al. 2008]. In turn, activated IKK is responsible 
for the phosphorylation of I-ĸBα on its Ser32 and Ser36 residues, subsequently leading to its 
rapid degradation via an ubiquitin/proteasome system [Kane et al. 1999, Ozes et al.1999]. 
I-ĸBα is a member of the I-κB family, a family of regulatory proteins which are able to 
inhibit nuclear factor-ĸB (NF-ĸB) [Hayden et al. 2004]. I-ĸB inhibits NF-ĸB by forming a 
complex with it and thus sequestering it in the cytoplasm [Huang et al. 2009] NF-ĸB is 
expressed in all cell types and is involved in the cellular response to a variety of stimuli 
such as stress, bacterial or viral antigens, free radicals, , cytokines and ultraviolet 
irradiation [Patel et al. 2009]. Degradation of I-ĸBα liberates NF-ĸB from its hold, thereby 
promoting its activation [Ozes et al. 1999] and migration to the nucleus [Huang et al 2009]. 
This subsequently enables NF-ĸB to activate a wide variety of genes, one group being the 
genes which encode for caspase inhibitors [Barket et al. 1999] while another group 
consists of the anti-apoptotic genes, which includes those that code for B-cell lymphoma-
extra large (Bcl-XL) [Parcellier et al. 2008]. The PKB/Akt-mediated activation of these 
genes, via NF-ĸB, highlights the pro-survival or protective function of PKB/Akt as well as 
NF-ĸB [Ozes et al. 1999]. 
NF-ĸB is increased during obesity [Huang et al. 2009] but it is still undecided whether it is 
the PI3K/PKB/Akt pathway or tumour necrosis factor-α (TNF-α), which is also upregulated 
during obesity, which causes this increase [Ruan et al. 2002]. Two separate studies have 
implicated PKB/Akt in the activation of NF-kB via TNF-α in embryonic kidney cells and 
human cervical carcinoma cells [Ozes et al. 1999] as well as in breast cancer cells [Burow 
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et al. 2000]. In contrast, Bieler et al. (2007) showed that simultaneous activation of 
PKB/Akt and NF-kB was required for the survival of human umbilical vein endothelial cells 
exposed to TNF (the isoform was not stipulated in this study) thereby implicating that these 
pathways were activated separately by TNF. 
There is mounting experimental evidence that supports the possibility of NF-ĸB as a key 
mediator in the genesis of insulin resistance [Patel et al. 2009] when a high fat diet is 
followed and during obesity, as indicated by studies using hepatic IKK-β knockout mice 
[Arkan et al 2005] or transgenic mice which overexpress IKK-β in the liver [Cai et al. 2005]. 
These studies support NF-ĸB as being the main contributor to insulin resistance as 
opposed to IKK, as previously suggested [Arkan et al. 2005].  
TNF-α is thought to induce insulin resistance primarily via the serine phosphorylation of 
IRS-1.  One of the multiple functions of NF-ĸB is to regulate the actions of TNF-α, which in 
turn is also a powerful activator of NF-ĸB (as indicated above); suggesting regulatory 
interplay between these two molecules [Patel et al. 2009].  
 
In addition to IKK, PKB/Akt is also known to phosphorylate forkhead box protein O1 
(FOXO1) on Thr24, Ser256 and Ser319, as well as forkhead box protein O3a (FOXO3a) and 
O4 (FOXO4) on three comparable sites in the nucleus (reviewed in Burgering et al. 2003). 
Forkhead box (FOX) proteins are a family of transcription factors that play a variety of 
significant roles in gene expression regulation, genes which are involved in apoptosis, cell 
growth, proliferation, differentiation, development and metabolism [Tuteja et al. 2007, 
Manning et al. 2007]. PKB/Akt mediated phosphorylation of FOXO allows 14-3-3 proteins 
to bind the transcription factors via their Thr24 and Ser256 residues, dislodging FOXO from 
their target genes and mediating their translocation to the cytoplasm, thus inhibiting the 
transcription factors [Manning et al. 2007].  
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Bcl-2 interacting mediator of cell death (BIM) protein as well as Fas ligand are pro-
apoptotic and are both targets of unphosphorylated (active) FOXO transcription factors, 
thus sequestering FOXO in the cytoplasm (therefore inhibiting it) which promotes cell 
survival [Dijkers et al. 2002, Brunet et al. 1999]. 
Furthermore, PKB/Akt is able to phosphorylate murine double minute 2 (MDM2) (or human 
double minute 2 (HDM2) in humans) on its Ser166 and Ser186 residues, which in turn 
activates MDM2/HDM2 and promotes the translocation of this protein from the cytoplasm 
to the nucleus. MDM2/HDM2 acts like an E3 ubiquitin ligase in that it binds ubiquitin to 
p53, thereby arbitrating ubiquitination on numerous p53 lysine residues. This subsequently 
prepares p53 for proteosomal degradation [Mayo et al. 2001, Iwakuma et al. 2003].  
Puma and Noxa are two pro-apoptotic members of the Bcl-2 family which are 
transcriptional targets of p53-mediated apoptosis. Thus, degradation of p53 would reduce 
Puma and Noxa levels and promote cell survival. Although, the significance of decreased 
Puma and Noxa levels to PKB/Akt mediated cell survival still has to be investigated 
[Villunger et al. 2003]. 
 
As discussed, the PI3K/PKB/Akt pathway plays an important role in promoting cell survival 
via mediators such as NF-ĸB, FOXO and MDM2/HDM2. Furthermore, NF-ĸB is highlighted 
as possibly playing a role in the arbitration of obesity-induced insulin resistance. 
 
2.5.2.3 The mitochondrial-dependent apoptotic (intrinsic) pathway 
The mitochondrial-dependent apoptotic pathway is activated on the receipt of various 
apoptotic stimuli, including ischemia-reperfusion, hypoxia, oxidative stress and loss of 
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growth factors [Regula et al. 2003, Weiss et al. 2003, Gustafsson et al. 2007], all of which 
fuel mitochondrial permeability transition. Augmented permeability of both the inner and 
the outer mitochondrial membranes are hallmark features of mitochondrial permeability 
transition [Weiss et al. 2003, Zamzami et al. 2001, Crompton et al. 2002]. An overview of 
the mitochondrial-dependent apoptotic (intrinsic) pathway signalling cascade is given in 
figure 2.7. 
 
A protein complex that bridges the inner and outer mitochondrial membranes, the 
mitochondrial permeability transition pore (MPTP), have been identified as the determinant 
of mitochondrial permeability [Baines et al. 2005]. It was previously thought that the 
transition pore consisted of the voltage dependent anion channel (VDAC), adenine 
nucleotide translocase (ANT) and cyclophilin-D. These pore constituents were thought to 
be located in the outer membrane, inner membrane and matrix of the mitochondrion 
respectively [Zamzami et al. 2001, Crompton et al. 2002].  
The latest research however, utilizing genetic knockouts, rules out VDAC as one of the 
main structural components of the MPTP. On the other hand, the structural role of 
cyclophilin-D in the pore has been confirmed, while the role of ANT is still controversial 
and thought to possibly play more of a regulatory than a structural function. Furthermore, 
these studies suggest a structural substitute for ANT in the MPTP namely, mitochondrial 
inorganic phosphate carrier (PiC) [Juhaszova et al. 2008, Leung et al. 2008]. 
 
Nevertheless, once the mitochondria are permeabilized, the intermembrane space 
releases a number of different proteins that are mediators of the apoptotic process, 
including cytochrome c, second mitochondria-derived activator of caspases 
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(Smac/DIABLO), endonuclease G (EndoG), and apoptosis-inducing factor (AIF) [Baines et 
al. 2005]. 
 
2.5.2.3.1 Cytochrome c 
Cytochrome c is a component of the mitochondrial ETC [Liu et al. 1996] that is responsible 
for ferrying electrons from complex III to complex IV of the chain [Lee et al. 2009]. When 
cytochrome c is released, upon apoptotic stimuli, it is able to bind to apoptotic protease-
activating factor-1 (Apaf-1) in the cytosol [Lee et al. 2009], increasing its affinity for dATP 
or ATP [Jiang et al. 2000]. The bond between Apaf-1 and dATP or ATP, independent of 
cytochrome c, is rather weak and thus cytochrome c plays a significant role in that it either 
opens up the nucleotide binding site or stabilizes the bound nucleotide to Apaf-1 [Jiang et 
al. 2000]. Once dATP or ATP attaches itself to the Apaf-1/cytochrome c complex, it 
facilitates the oligomerization of the complex, to form a multimeric apoptosome [Zou et al. 
1999, Adrain et al. 2001].  
 
Once complexed in the apoptosome, the caspase recruitment (CARD) domain of Apaf-1 
becomes exposed, enabling it to recruit numerous procaspase-9 molecules to the complex 
and subsequently arbitrate their autoactivation [Wang 2001]. The activated caspase-9 can 
now cleave and activate downstream executioner caspases such as caspase-3 and -7, 
just as caspase-8 cleaves and activates caspase-3 in the death receptor apoptotic 
pathway (section 2.5.2.3) [Rodriguez et al. 1999, Robertson et al. 2000]. The condensation 
of nuclear chromatin, fragmentation of DNA and the disintegration of the nuclear 
membrane as well as the formation of apoptotic bodies, soon occur as a result of the 
cleavage of vital intracellular compounds by the activated executioner caspases [Wang 
2001]. 
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2.5.2.3.2 Smac/DIABLO 
Mature Smac/DIABLO proteins can be found in the mitochondrial intermembrane space in 
healthy cells and is discharged into the cytosol, upon the reception of apoptotic stimuli 
[Wang 2001, Verhagen et al. 2000]. Prior to mature Smac/DIABLO becoming a 
mitochondrial protein, its precursor is produced in the cytosol and then carried to the 
mitochondria. Once there, the precursor undergoes cleavage which serves to expose the 
four amino acid residues Ala-Val-Pro-Ile (AVPI), on the now mature Smac/DIABLO protein. 
Through AVPI, Smac/DIABLO will be able to bind to the baculovirus IAP repeat (BIR) 
domain of inhibitor of apoptosis proteins (IAPs) at a later stage, after it has been triggered 
by apoptotic stimuli. IAPs are bound to pro-apoptotic procaspases-3 and -9 when there is 
a lack of apoptotic stimuli, thus inhibiting apoptosis [Wang 2001]. Once the cell receives 
apoptotic signals, Smac/DIABLO is released into the cytosol [Du et al. 2000, Verhagen et 
al. 2000] and impounds the IAPs, thereby indirectly freeing procaspases-3 and -9 which in 
turn promotes apoptosis [Wang 2001, Verhagen et al. 2002]. 
 
2.5.2.3.3 Endonuclease G (EndoG) 
EndoG, as the name suggests, is a nuclease that is encoded by a nuclear gene and 
translated in the cytosol, and eventually transported to the mitochondria [Côté et al. 1993]. 
It is believed that a significant portion of these nucleases proceed to reside in the 
intermembrane space of the mitochondrion and is released into the cytosol upon apoptotic 
signals, similar to cytochrome c. The ultimate function of EndoG, once it reaches the 
cytosol, is to stimulate nucleosomal DNA fragmentation [Wang 2001]. 
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The activity of EndoG has been identified to be independent of caspase activation [Liu et 
al. 1997, Enari et al. 1998] indicating that it initiates an analogous apoptotic pathway to 
that of the caspase-dependent apoptotic pathway [Wang 2001]. 
 
2.5.2.3.4 Apoptosis inducing factor (AIF) 
AIF is a flavoprotein that is located in the mitochondrial intermembrane space [Susin et 
al.1999] and is essential for the assembly and/or the stabilization of the respiratory 
complex I as well as oxidative phosphorylation [Lee et al. 2009]. This flavoprotein is 
released into the cytosol once apoptosis is induced [Candé et al. 2002]. This flavoprotein, 
just like EndoG, acts independently of caspases [Miramar et al. 2001] and once it reaches 
the cytosol it stimulates the condensation of nuclear chromatin and the fragmentation of 
high-molecular-weight (50kb) DNA [Yu et al. 2002].  
 
2.5.2.4 The Bcl-2 family and its regulation of the intrinsic apoptotic pathway 
The Bcl-2 family regulates the intrinsic pathway of apoptosis and consists of pro-apoptotic 
as well as anti-apoptotic protein members, all of which share at least four conserved 
regions known as Bcl-2 homology (BH) domains [Lee et al. 2009]. The anti-apoptotic 
members, which include B-cell lymphoma-2 (Bcl-2) and Bcl-XL, contain all four subtypes of 
BH domains and obstruct the function of the pro-apoptotic Bcl-2 proteins by promoting cell 
survival [Gustafsson et al. 2007]. The anti-apoptotic Bcl-2 proteins are crucial for cell 
survival and have been shown to defend cells against a wide variety of apoptotic stimuli or 
cellular stressors [Lee et al. 2009]. 
The pro-apoptotic Bcl-2 proteins are divided into two distinctive subfamilies according to 
which domains they contain. The multidomain proteins, which include B-cell lymphoma-
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associated X (Bax) and Bcl-2 homologous antagonist killer (Bak), all share three BH 
domains (BH domains 1 to 3); whereas the BH3-only domain proteins, for instance Bcl-
2/adenovirus E1B 19kDa protein-interacting protein 3 (Bnip3), Bcl-2/adenovirus E1B 
19kDa protein-interacting protein 3-like (Nix/Bnip3L), Bcl-2 associated death (Bad), BH3 
interacting domain (Bid), Noxa, and Puma, only contain one domain (BH domain 3) as the 
name suggests [Danial et al. 2004, Huang et al. 2000]. 
 
The precise mechanism of how the Bcl-2 family proteins moderate apoptosis is at present 
not completely clear. Three different models of apoptotic regulation have been suggested 
by Gustafsson et al. (2007), based on evidence from the literature.  
The first model indicates that pro-apoptotic Bax and Bak directly interact with one or two 
different anti-apoptotic Bcl-2 proteins and are thus retained in an inactive conformation. 
Pro-apoptotic BH3-only proteins are thought to bind and defuse the anti-apoptotic Bcl-2 
proteins and in doing so, release Bax and Bak upon an apoptotic signal. [Gustafsson et al. 
2007] The studies by Willis et al. (2005) and Chen et al. (2005b) provide evidence for this 
model. 
An alternative model suggests that certain pro-apoptotic BH3-only proteins, such as tBid 
and Bim, directly bind to Bax and Bak and thereby initiates apoptosis [Gustafsson et al. 
2007]; as proposed by a number of studies [Cartron et al. 2004, Harada et al. 2004, 
Kuwana et al. 2005, Kuwana et al. 2002, Wang et al. 1996].  
The third model implies that anti-apoptotic Bcl-2 family members prevent the activation of 
pro-apoptotic Bax and Bak by impounding pro-apoptotic BH3-only proteins to the cytosol. 
When the activated BH3-only proteins overcome the anti-apoptotic Bcl-2 proteins (that is, 
upon an apoptotic stimulus), they either directly activate Bax or Bak or they activate an 
unknown factor in the cytosol or mitochondria that is needed for Bax or Bak activation. In 
Stellenbosch University http://scholar.sun.ac.za
 58 
 
doing so, the apoptotic process is triggered [Gustafsson et al. 2007], as suggested by 
several studies [Cheng et al. 2001, Clohessy et al. 2006, Gomez-Bougie at al. 2004, Han 
et al. 2004]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. The signalling cascade of the mitochondrial-dependent apoptotic (intrinsic) 
pathway. Taken and adapted from Crow et al. 2004. 
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2.5.2.5 PKB/Akt directly moderates apoptosis: The role of PKB/Akt in the intrinsic 
apoptotic pathway 
2.5.2.5.1 PKB/Akt and Bad protein 
Under normal physiological conditions, once myocardial PKB/Akt is activated it is able to 
phosphorylate the pro-apoptotic Bad protein in some cell types [Kharas et al. 2005, 
Sussman et al. 2011], at its Ser136 residue [Sale et al. 2008] and in doing so, promotes cell 
survival [Datta et al. 1999]. The phosphorylation of Bad ensures that it is released from its 
complex with anti-apoptotic Bcl-2 or Bcl-XL [Sale et al. 2008], which are located on the 
mitochondrial membrane, and binds to cytosolic 14-3-3 proteins [Parcellier et al. 2008]. 
This sufficiently sequesters Bad in the cytosol, thus blocking its pro-apoptotic function and 
prevents it from initiating mitochondrial-dependent apoptosis [Sale et al. 2008]. In turn, Bcl-
2 and Bcl-XL are free to promote cell survival [Parcellier et al. 2008]. 
The pro-apoptotic protein Bad has been shown to be elevated in the myocardium of obese 
rats [Lee at al. 2008].This protein is known to stimulate apoptosis by forming a heterodimer 
with the anti-apoptotic proteins, Bcl-2 or Bcl-XL, thus blocking their cardioprotective effects 
[Sussman et al. 2011], as previously explained. 
 
2.5.2.5.2 PKB/Akt and Bax protein 
Another member of the Bcl-2 family is the pro-apoptotic protein Bax [Gogvadze et al. 
2006], which is predominantly located in the cytosol of healthy cells. One of the many 
functions of activated PKB/Akt in the myocardium [Sussman et al. 2011] is to 
phosphorylate Bax, at its Ser184 residue [Gardai et al. 2004], thus sequestering it in the 
cytosol and away from mitochondrial membranes and thereby blocking its pro-apoptotic 
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functions [Gardai et al. 2004]. This containment of Bax in the cytosol is achieved by its 
heterodimerization with Bcl-XL or myeloid cell leukemia differentiation protein-1 (Mcl-1) 
[Gardai et al. 2004, Gross et al. 1999, Cory et al. 2003]. 
Another central role of activated PKB/Akt may very well be to suppress conformational 
changes in Bax and inhibit its migration to the mitochondria, thereby averting loss of 
mitochondrial membrane potential and the activation of caspase-3 [Yamaguchi et al. 
2001]. Activated PKB/Akt is thought to mediate the suppression of Bax conformational 
changes by directly impeding the interaction between Bax and Bid or Bax-interacting 
factor-1 (Bif-1), both of which participate in conformational changes in Bax and are pro-
apoptotic members of the Bcl-2 family [Majewski et al. 2004a, Majewski et al. 2004b, 
Sussman et al. 2011].  
A number of studies have highlighted the relationship between PKB/Akt activation, Bcl-2 
family member regulation, and inhibition of cardiomyopathic damage [Johnassen et al. 
2001, Kato et al. 2003, Kuwahara et al. 2000, Negoro et al. 2001, Pastukh et al. 2005, 
Uchiyama et al. 2004]. The inhibition of Bax translocation to the mitochondria, specifically 
via phosphorylation by PKB/Akt, has not been shown in the heart. However, mice which 
are homozygous for the deleted Bax gene have been shown to be protected against 
ischemia-reperfusion injury [Hochhauser et al. 2003]. 
Upon apoptotic stimuli, Bax undergoes a conformational change that exposes its N- and 
C-terminals [Nechushtan et al. 1999], allowing it to insert itself in the outer mitochondrial 
membrane and oligomerize with the membrane [Mattson et al. 2003]. Subsequently, a 
“protein-permanent” pore is formed within the mitochondrial membrane which allows the 
release of cytochrome c into the cytosol, thus initiating apoptosis [Nechushtan et al. 1999].  
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There are a number of other protein members of the Bcl-2 family which are activated by a 
variety of different stimuli, which have been shown to play significant roles in determining 
myocardial cell death or survival. A few of these proteins exerted their pro-apoptotic 
functions and promoted apoptosis in the heart [Gustafsson et al. 2007, Kubli et al. 2008, 
Capano et al. 2006, Hamacher-Brady et al. 2006, Wei et al. 2001, Zong et al. 2001], while 
the anti-apoptotic proteins exerted their cardioprotective functions [Imahashi et al. 2004, 
Brocheriou et al. 2000, Chen et al. 2001, Gustafsson et al. 2007]. However, these will not 
be reviewed here. 
 
2.5.2.6. PKB/Akt directly moderates the intrinsic apoptotic pathway independently of 
the Bcl-2 family 
Hexokinase I (HKI) and hexokinase II (HKII) are two isoforms of the hexokinase protein, 
essential in the first step of glucose metabolism [Robey et al. 2006], which have been 
shown to distinctively bind to the outer mitochondrial membrane (OMM) [Parcellier et al. 
2008]. Several studies have highlighted hexokinases as the downstream effectors of 
growth factor and PKB/Akt arbitrated cell survival [Majewski et al. 2004a, Gottlob et al. 
2001, Robey et al. 2006, Majewski et al. 2004b, Brunet et al. 1999, Robey et al. 2005]. 
PKB/Akt is believed to inhibit the hexokinase disengagement, the detachment being 
initiated by apoptosis, from the mitochondria [Gottlob et al. 2001]. This interrelation 
between PKB/Akt and hexokinase is believed to prevent the release of cytochrome c from 
the mitochondria to preserve their integrity, much like Bcl-2 [Kennedy et al. 1999]. PKB/Akt 
differs from Bcl-2 in that it has been found to be dependent on glucose to exert its 
protective function [Gottlob et al. 2001, Rathmell et al. 2003]. 
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2.5.2.7 PKB/Akt regulation of GSK-3 and its role in apoptosis 
GSK-3, when inhibited, has been found to be cardioprotective [Gomez et al. 2008], where 
inhibition of GSK-3 is achieved by the phosphorylation of Ser21 for GSK-3α and Ser9 for 
GSK-3β via activated PKB/Akt, as discussed in section 2.4.1.2.2 It was shown by Maurer 
et al. (2006) that, activated GSK-3 induces apoptosis, upon the removal of the growth 
factor interleukin-3 (IL-6). Active GSK-3 stimulates the Ser159 phosphorylation of anti-
apoptotic Mcl-1, which in turn encourages ubiquitination and results in Mcl-1 degradation 
by the proteasome. This in turn, provokes the release of cytochrome c from the 
mitochondria thereby initiating apoptosis. These observations emphasize the central role 
of PKB/Akt in the regulation of cell survival, via the inhibition of GSK-3 and in turn, the 
stability of Mcl-1 [Maurer et al. 2006, Parcellier et al. 2008]. 
 
2.6 Apoptosis and Obesity-induced Cardiovascular Disease 
Apoptosis has been linked to cardiac myocyte death, which is characteristic of heart failure 
[Bernecker at al. 2003, Singal et al. 2000, Abbate et al 2006], atherosclerosis [Clarke et al. 
2008], cardiac hypertrophy [Aharinejad et al. 2008], myocardial infarction [Abbate et al. 
2006] and ischemia/reperfusion injury [Gao et al. 2008, Sodha et al. 2008]. This cluster of 
cardiovascular diseases, are examples of cardiomyopathies which are defined as diseases 
of the cardiac muscle which can be implicated in the dysfunction of the heart. A 
cardiomyopathy can be classified either by the dominant physiological feature of the 
pathology or by the disease that is causing the pathology [Davies 2000]. Obesity 
cardiomyopathy is defined as a myocardial disease which occurs during obesity and is 
mediated by the obese state as it cannot be explained by other causes such as diabetes 
mellitus, hypertension, or coronary artery disease [Wong et al. 2007]. Indeed, heart failure 
Stellenbosch University http://scholar.sun.ac.za
 63 
 
[Barouch et al. 2006] and myocardial ischemia/reperfusion injury [Yue et al. 2005, Shibata 
et al. 2005] have been characterized by myocardial apoptosis that has been linked to 
obesity in animal models. 
 
2.6.1 Obesity Cardiomyopathy: Apoptosis and Heart Failure 
Congestive heart failure manifests itself during the late stages of a plethora of 
cardiovascular diseases and is defined by a cardiac output that is ultimately well below the 
threshold required for an organism to function [Neuss et al. 2001]. Characteristic features 
of this cardiomyopathy include changes in the expression pattern of intracellular and 
extracellular matrix proteins, progressive loss of cardiomyocytes, and dilation or 
enlargement of the heart chambers [Narula et al. 2000, Neuss et al. 2001, Wencker et al. 
2003]. 
During the initial stages of heart failure the decline in cardiac output is compensated for by 
myocardial hypertrophy and dilation, ensuring that there is adequate, though not optimal, 
cardiac output [Narula et al. 2000]. However, these compensatory mechanical adaptations 
soon become inadequate to maintain a sufficient cardiac output [Katz 1994], culminating in 
cardiac dysfunction. The mechanism by which cardiac hypertrophy, which is activated by 
heart failure, concludes in myocardial dysfunction is not that apparent. [Narula et al. 2000, 
Wencker et al. 2003]. 
It has been hypothesized that apoptosis might be the key mediator in the progression of 
myocardial hypertrophy to cardiac dysfunction in congestive heart failure [Neuss et al. 
2001, Eichhorn et al. 1996, Beltrami et al. 1995, Narula et al. 1996, Narula et al. 1999, 
Olivetti et al. 1997, Reed et al. 1999]. The basis for this hypothesis is that since adult 
cardiomyocytes are terminally differentiated and cannot divide, growth stimulation (via 
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neurohumoral alterations and cytokine expression) of the cardiomyocytes of the failing 
heart, therefore results in the initiation of apoptosis instead [Narula et al. 2000]. At the 
outset, the stimulation of growth leads to cardiac hypertrophy but as the cardiac output 
declines, the chronic growth stimulation results in apoptosis [Narula et al. 1999]. 
Diverse experimental species and models of heart failure have been used to test the 
hypothesis that apoptosis may be responsible for cardiac dysfunction in heart failure. Much 
controversy still surrounds the role of apoptosis in this regard, despite the considerable 
amount of studies done on this topic. What remains unclear is whether apoptosis is just a 
coincidence, a protective mechanism, or whether it is a key participant in the development 
of the cardiomyopathy [Neuss et al. 2001, Wencker et al. 2003]. 
 
2.6.2 Obesity Cardiomyopathy: Apoptosis and Ischemia/Reperfusion 
While short periods of ischemia allow the heart to recover quite well despite an initial 
degree of impairment, prolonged periods of ischemia are associated with irreversible 
myocardial damage. The aforementioned will prevail provided that reperfusion, defined as 
the reinstatement of normal blood flow, rapidly succeeds the ischemia [Halestrap et al. 
2007]. 
 
2.6.2.1 What is Ischemia/Reperfusion Injury? 
This type of injury is categorized by myocardial damage that occurs during reperfusion that 
aggravates the damage incurred during the ischemic period by having an additive effect 
[Halestrap et al. 2007]. During ischemia/reperfusion injury there is a release of various 
enzymes and cardiomyocyte changes which are associated with necrosis [Halestrap et al. 
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1998, Suleiman et al. 2001, Halestrap et al. 2004], where the necrotic area in the heart is 
defined as the infarct [Halestrap et al. 2007]. Apoptosis has also been implicated in 
ischemia/reperfusion injury as some cardiomyocytes at the borders of the infarct has been 
found to undergo this type of cell death [Fliss et al. 1996, Anversa et al. 1998]. 
 
2.6.2.2 Causes of Ischemia/Reperfusion Injury 
There is an escalating body of evidence that underlines disrupted mitochondrial 
functioning as the determinant of both myocardial necrosis and apoptosis that are 
associated with ischemia/reperfusion injury [Halestrap et al. 1998, Halestrap et al. 2004, 
Shanmuganathan et al. 2005, DiLisa et al. 2006].  
In particular, it is the elevated intracellular concentration of calcium [Ca2+] as well as 
reactive oxygen species (ROS), that commences during ischemia and intensifies during 
reperfusion (due to a second torrent of ROS production and increased intracellular [Ca2+] 
[Kevin et al. 2003]), that is believed to mediate the damaging effects on the mitochondria 
[Halestrap 2006, Solaini et al. 2005]. 
During ischemia, the switch to increased anaerobic glucose metabolism causes lactic acid 
levels to increase and the cell`s pH (pHi) to swiftly decline, which in turn activates the 
Na+/H+ antiporter in an attempt to restore the intracellular pHi. However, glycolysis yields 
fewer ATP molecules than fatty acid β-oxidation which causes the cell`s ATP 
concentrations to rapidly plunge. In turn, this results in Na/K ATPase inhibition and an 
increase in myocellular sodium concentration [Na+], which sequentially blunts pHi 
restoration. Furthermore, the Na+/Ca2+ antiporter, which is responsible for pumping Ca2+ 
out of the cell, is either repressed or reversed which augments intracellular [Ca2+] 
[Halestrap et al. 1998, Halestrap et al. 2004, Solaini et al. 2005]. 
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There is a radical escalation in ROS cellular content [Kevin et al. 2003] that is not only the 
cause of myocardial damage during ischemia but is believed to make the heart more 
susceptible to damage during reperfusion [Halestrap et al. 2007]. Inhibition of repair 
processes, which are dependent on ATP, and loss of cardiomyocyte integrity are two of 
the aberrations that occur as a result of increased intracellular ROS and [Ca2+] as well as 
ATP diminution, during ischemia [Halestrap et al. 1998, Halestrap et al. 2004, Solaini et al. 
2005]. 
. Mitochondria are not only a source of ROS production but have been identified as targets 
of ROS and calcium damage as well, as indicated by the disruption of electron transport 
chain activity in the mitochondria of ischemic hearts [Solaini et al. 2005, Chen et al. 2006]. 
On the whole, the rise in intracellular ROS and [Ca2+] content has been shown to be the 
trigger for the opening of the mitochondrial permeability transition pore (MPTP) during 
ischemia/reperfusion injury [Halestrap et al. 1998, Halestrap et al. 2004, DiLisa et al. 2006, 
Solaini et al. 2005, Garcia Dorado et al. 2006]. 
 
2.7 The role of the PI3K/PKB/Akt pathway in heart failure and ischemia/reperfusion 
injury 
When the PI3K/PKB/Akt pathway mediator GSK-3 is inhibited, it has been found to reduce 
ischemia/reperfusion injury in the heart [Das et al. 2008, Gomez et al. 2008] and to be 
cardioprotective during heart failure [Hirotani et al. 2007]. GSK-3-mediated myocardial 
protection is mediated via the mitochondria but the precise mechanism is not entirely 
known [Das et al. 2008].  
GSK-3 has been proposed to play a major role in the cardioprotection associated with 
ischemic preconditioning [Tong et al. 2002, Murphy et al. 2005]. Ischemic preconditioning 
entails the exposure of the heart to two or three cycles of short periods of ischemia, 
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interspersed by brief periods of reperfusion [Edwards et al. 2000]. If this preconditioning 
takes place within 1-3 hours of a prolonged period of ischemia then the heart has been 
found to be protected against ischemia/reperfusion injury in both humans and 
experimental animals [Edwards et al. 2000, Yellon et al. 2003, Kloner et al. 2006]. 
During ischemic preconditioning, adenosine, bradykinin endogenous opioids and 
catecholemines are released and interact with their respective G-protein coupled receptors 
[Juhasova et al. 2004, Downey et al. 2007]. Consequently, PI3K is activated and in turn 
phosphorylates and activates PKB/Akt [Hausenloy et al. 2006, Hausenloy et al. 2005], 
amongst other kinase enzymes (discussed in Tong et al. 2004, Hausenloy et al. 2007, 
Liem et al. 2007).  
PKB/Akt is known to phosphorylate and inhibit GSK-3, as mentioned in section 2.4.1.2, 
and in doing so, its pro-apoptotic properties are blocked and cell survival is promoted 
[Jope et al. 2004]. The exact cardioprotective effect of GSK-3 on the mitochondria is not 
completely understood but it is thought that GSK-3 inhibition allows its migration to the 
mitochondria [Juhaszova et al. 2004]. It is at present undecided whether the 
phosphorylation of VDAC by GSK-3 (either directly or indirectly), could play a role in 
sensitizing the cell to MPTP opening as VDAC has recently been ruled out as an essential 
constituent of the MPTP (as discussed in section 2.5.2.3) [Juhaszova et al. 2004, 
Pastorino et al. 2005, Das et al. 2008]. 
 
In addition to GSK-3, PKB/Akt (once activated by PI3K) has also been found to 
phosphorylate Bad and Bax during ischemia/reperfusion injury, inhibiting their pro-
apoptotic effects by preventing them from migrating to the mitochondria, as discussed in 
sections 2.5.2.5.1 and 2.5.2.5.2 [Rácz et al. 2008]. 
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2.8 A Closer Look at the of Mitochondrial Permeability Transition Pore (MPTP) 
during Apoptosis  
Only a few essential metabolites and ions can gain access to the mitochondria through its 
inner membrane under normal physiological conditions, ensuring that the cell`s membrane 
potential and pH gradient is maintained and oxidative phosphorylation is able to proceed 
[Halestrap et al. 2007].  
In contrast, during unhealthy conditions where there are high intracellular calcium levels, 
oxidative stress, elevated phosphate and low adenine nucleotide concentrations, the 
MPTP opens (a non-specific pore). In the open state, the MPTP allows just about any 
molecule smaller than 1.5kDa into the mitochondria and in doing so, disintegrates the 
“permeability barrier” of the inner membrane [Halestrap et al. 2007].  
One consequence of MPTP opening is the unobstructed movement of protons over the 
inner mitochondrial membrane, which results in uncoupling of oxidative phosphorylation. 
ATP synthesis is not only inhibited but the ATPase pump shunts the existing ATP back 
into the cell and in doing this, hydrolyses the ATP [Halestrap et al. 2007].  This brisk 
deterioration in ATP leads to not only the activation of phospholipases, proteases and 
nucleases, all degradative enzymes, but an impairment of cellular homeostasis (ionic and 
metabolic) [Halestrap et al. 2004, Halestrap et al. 2006, Solaini et al. 2005]. 
A second outcome of MPTP opening is the depolarization of the mitochondrial membrane 
which results in additional pore opening in that particular mitochondrion [Scorrano et al. 
1997] and once the mitochondrion is completely open it begins to expand at length 
[Bernardi et al. 1999]. Ultimately, the outer membrane ruptures and cytochrome c and 
other vital pro-apoptotic factors are discharged from the mitochondria, allowing them to 
mediate cell death [Doran et al. 2000, Halestrap et al. 2007]. 
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2.9 Motivation for objectives and hypothesis of our study 
2.9.1 Motivation 
A review of the literature has shown that obesity-related cardiomyopathies are complex 
and mediated by multiple factors. What has come to light is that cardiac insulin resistance 
is implicated as one of the main causes of obesity-related CVD. A few studies have 
implicated perturbations in the insulin-mediated PI3K/PKB/Akt pathway in mediating this 
insulin resistance. Moreover, the PI3K/PKB/Akt pathway has been shown to regulate 
myocardial apoptosis, indicating that this pathway not only regulates metabolism but also 
plays a significant role in determining cell fate. 
Despite the large number of studies conducted, the mechanism of obesity-related 
cardiovascular diseases has not been completely elucidated. Of great interest, but for 
which few studies can be found, is the role of the PI3K/PKB/Akt and apoptotic pathway in 
the early versus advanced stages of obesity. 
 
2.9.2 Objectives 
The first objective of the study was to compare the early and advanced stages of obesity in 
terms of cardiac: 
(i) Cytosolic PI3K/PKB/Akt signalling 
(ii) Cytosolic apoptotic signalling 
(iii) Mitochondrial integrity 
 
The second objective was to assess the following in the myocardium during the advanced 
stages of obesity: 
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(i) Mitochondrial PI3K/PKB/Akt signalling  
(ii) Mitochondrial apoptotic signalling 
(iii) Mitochondrial function 
(iv) Mitochondrial integrity 
 
2.9.3 Hypothesis 
We hypothesize that obesity will have different effects on the myocardium during the initial 
and advanced stages of obesity. We propose that elevated PI3K/PKB/Akt and attenuated 
intrinsic apoptotic signalling will take place in the cytosol during the initial stages of obesity. 
During the advanced stages of obesity we hypothesize that signalling via the 
PI3K/PKB/Akt pathway will be downregulated in the cytosol, while that of apoptotic 
signalling will be augmented. Furthermore, we theorize that the signalling via these two 
pathways will be associated with increased cardioprotection during the initial stages, while 
this protection will be lost during the advanced stages of obesity. 
It terms of mitochondrial PI3K/PKB/Akt and apoptotic signalling, we hypothesize this will 
be downregulated and upregulated in the heart, respectively, in the advanced stages of 
obesity. Additionally, we anticipate that mitochondrial integrity and function will be 
negatively affected. 
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Chapter 3: Materials and Methods 
 
3.1 Materials 
The reagents utilized in this study, for the various experiments, were purchased at a 
number of different companies such as: 
Bayer-Bayer  
Eutha-naze (sodium pentobarbital).  
BDH Laboratory 
Na2S2O4, trichloroacetic acid (TCA) and perchloric acid (PCA). 
Cell Signalling technology  
Antibodies against total and phosphorylated: PI3K (p85 subunit), PKB/Akt Ser473, GSK-
3α/β Ser9 and Bad. 
Antibodies against total: Bax, Bcl-2 and β-Tubulin. 
Clover S.A. (Pty) Ltd. 
Elite fat free instant milk powder. 
Eli Lilly (S.A.) (Pty) Ltd. 
Humulin R (regular biosynthetic human insulin). 
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GE Healthcare (formerly known as Amersham Biosciences) 
ECLTM anti-rabbit Ig, horseradish peroxidase linked whole secondary antibody (from 
donkey), ECLTM anti-mouse Ig, horseradish peroxidase linked species-specific whole 
secondary antibody (from sheep). 
Merck NT laboratory supplies (Pty. Ltd)  
NaCl, KCl, CaCl2, KH2PO4, NaHCO3, MgSO4, NaSO4, NaK-Tartrate, CuSO4, Na2CO3, HCl, 
H3PO4, Na2HPO4, NaOH, Na
+ pyrophosphate, Folin Ciocalteus (Folin C) reagent, sodium 
dodecyl sulphate (SDS), tris (hydroxylmethyl) aminomethane, acrylamide, D-glucose, 
glutamate, malate, sucrose, glycine, Tween-20. 
MitoSciences 
MitoProfile® Total OXPHOS Rodent Western Blot Antibody (Catalogue # MS604). 
Roche Diagnostics  
Bovine serum albumin (BSA). 
Sigma-Aldrich Life Science  
Na2VO3, ammonium persulfate (APS), mecarpto-ethanol, N,N,N,N,-
tetramethylethylenediamine (TEMED), Ponceau S (reversible) staining solution, 
phenylmethylsulphonyl fluoride (PMSF), EGTA, EDTA, β-glycerophosphate, triton-X-100, 
aprotonin, leupeptin), 99% pure methanol, palmitoyl-L-carnitine, succinate,rotenone, 
oligomycin, carbonyl cyanide m-chlorophenylhydrazone (CCCP), ATP, AMP, ADP, CrP, 
12.% (v/v) HPLC graded methanol, tetrabuthylammonium perchlorate (TBAP). 
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3.1.1 Animals  
Ethical approval for this study was obtained from the Ethics Committee of Stellenbosch 
University, Faculty of Medicine and Health Sciences (Ethics number: 08/11/013). To 
maintain ethical standards, the revised South African National Standard for the care and 
use of laboratory animals for scientific purposes (South African Bureau of Standards 
(SABS), SANS 10386, 2008) was consulted throughout the study. 
For the purpose of this study, age and weight matched male Wistar rats, which had been 
weaned at 4 weeks of age, were utilized. The rats were housed in the University of 
Stellenbosch Central Research Facility and were given free access to food and water. 
They were subjected to a 12-hour artificial day/night cycle where a constant temperature of 
22°C and humidity of 40% were maintained.  
 
3.2 Methods 
3.2.1 Study design 
Rats weighing ± 200g were randomly assigned to either a control or a diet-induced obesity 
(DIO) group. Control rats were fed a standard rat chow diet which supplied an average of 
380kJ of energy per day. The DIO group were fed an obesity inducing diet that is, a high 
caloric diet which consisted of standard rat chow (33%), sucrose (7%), sweetened full 
cream condensed milk (Clover®) (33%) and distilled water (27%), which provided an 
average of 575kJ energy per day (refer to table 3.1). This method of diet-induced obesity 
and the average daily kilojoules intake was previously described by Du Toit et al. (2008).  
In reference to figure 3.1, the control and DIO groups were further subdivided into two 
groups according to the time period they were placed on their respective diets, that is the 8 
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and 20 weeks groups. The 8 weeks group represented the early stages of diet-induced 
obesity, while the 20 weeks group exemplified the advanced stages thereof. A further 
subdivision occurred in the 8 weeks group that is, groups 8A and 8B. Likewise, the 20 
weeks group was subdivided into groups 20A, 20B, 20C and 20D.  
Following their specific diet period, all of the animals in the 8 weeks group and the 20 
weeks group were fasted overnight, anaesthetized and then subjected to an intra-
peritoneal glucose tolerance test (IPGTT) to evaluate blood glucose homeostasis (refer to 
part (i) of figure 3.1). All the animals were allowed to recover for at least 1 week before any 
further experiments were conducted. 
Additionally, once the animals were anaesthetized, blood was collected from the jagular 
vein, prior to glucose administration, and allowed to clot on ice and thereafter centrifuged 
for 10 minutes at 11 500rpm and 4ºC. The resultant serum was collected and stored at -
80ºC for serum insulin level determination at a later stage in order to assess whole-body 
insulin sensitivity. 
Throughout all of the experiments, the animals were anaesthetized and weighed, to 
determine their total body weight as a measure of obesity, prior to being sacrificed. Once 
the hearts had been removed, the intra-peritoneal fat was collected (surrounding the 
kidneys and testes) and weighed to gauge intra-peritoneal adipocity.  
Groups 8A and 20A were sacrificed and their hearts immediately freeze-clamped in liquid 
nitrogen and stored at -80oC. These myocardial tissue were later subjected to western blot 
analysis to determine the early and advanced effects of diet-induced obesity with regard to 
protein markers of the PI3K/PKB/Akt and apoptotic signalling pathway (listed in figure 
3.1(i)), in the cytosolic fraction of the heart. Groups 8B and 20B were sacrificed and their 
hearts freeze-clamped in liquid nitrogen and stored at -80oC which were later used to 
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prepare mitochondrial lysates. These were then subjected to western blot analysis of 
various protein subunits (listed in figure 3.1(i)) located in the mitochondrial electron 
transport chain (ETC) in order to assess mitochondrial integrity. 
The animals in group 20C were further subdivided into groups 20C(i) to 20C(iii), sacrificed and 
their fresh hearts used for mitochondrial isolation upon which various respiration analyses 
were subsequently done (refer to figure 3.1(ii)), in order to moderate mitochondrial function 
during the advanced stages of obesity.  
The control animals in group 20D were subdivided into an untreated, insulin and ischemia 
group and administered their various treatments as stipulated in section 3.5.1. This 
protocol was repeated with the DIO animals in group 20D. Post sacrifice, the fresh hearts 
of all the animals in group 20D were utilized to produce mitochondrial lysates which were 
stored at -80oC. These were later used to assess the effects of advanced diet-induced 
obesity on the translocation of protein markers of the PI3K/PKB/Akt and apoptotic 
signalling pathway (refer to figure 3.1(ii)) from the cytosol to the mitochondria, via western 
blot analysis. 
 
Table 3.1:  Macronutrient composition of control versus DIO diets 
 
 
 
 
  
 
Control group DIO group Difference 
Carbohydrates 60% 65% 5% 
Protein 30% 19% 11% 
Fat 10% 16% 6% 
KJ/day ± 380KJ/day ± 575KJ/day ± 195KJ/day 
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Figure 3.1: (i) and (ii) Study design for the respective groups after 8 and 20 weeks of diet. 
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3.3 Experimental procedures 
3.3.1. Intra-peritoneal glucose tolerance test (IPGTT) 
Prior to this specific experiment, the animals were deprived of food for a period of 18 hours 
but given free access to water. The rats were anaesthetized with sodium pentobarbital 
(55mg/kg body weight) by intra-peritoneal injection and blood samples were subsequently 
collected by means of a pin-prick in the tail. These drops of blood were placed on the 
absorbent film of a disposable test strip (Gluco PlusTM, distributed by CIPLA DIBCARE, 
Bellville, South Africa) which was then inserted into a glucometer (Gluco PlusTM, 
distributed by CIPLA DIBCARE, Bellville, South Africa) to determine the baseline blood 
glucose level. The animals then received an intra-peritoneal injection of a 50% D-glucose 
solution, 1g/kg body weight, and the fasting blood glucose level subsequently determined 
at various time intervals (refer to figure 3.2). 
 
 
 
 
 
 
 
 
 
Figure 3.2: Experimental protocol for the intra-peritoneal glucose tolerance test (IPGTT). 
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3.3.2 Whole heart excision 
After the IPGTT’s, the animals were allowed to recover for a period of 1 week. Animals 
were then anaesthetized with sodium pentobarbital (160mg/kg) until a foot-pinch showed a 
lack of consciousness. Their hearts were removed and washed in ice cold Krebs-Henseleit 
buffer (pH 7.4) containing 119mM NaCl, 24.9mM NaHCO3, 4.74mM KCl, 1.19mM KH2PO4, 
0.6mM MgSO4, 0.5mM Na2SO4, 1.25mM CaCl2 and 11 mMD-glucose. The hearts were 
then freeze clamped in liquid nitrogen and stored at -80oC for western blot analysis. 
 
3.3.3 Fasting serum insulin level determination 
The serum from the fasted blood which had been collected from the experimental animals, 
as stipulated in section 3.2.1, were defrosted at room temperature. The purchased Coat-A-
Count® Insulin assay (Diagnostics Products Corporation, LA, USA), used for the 
quantitative measurement of serum insulin levels, provided all the necessary solutions and 
materials, all of which were brought to room temperature.  
Uncoated polypropylene tubes were labelled for total counts (T1 – T2) as well as non-
specific binding (N1 – N2), while fourteen of the insulin antibody-coated tubes were labelled 
as such: number 1 = MaxB (representing maximum insulin binding) and numbers 2-14 = 
Std1-14 (representing the rest of the standards). Furthermore, the rest of the insulin 
antibody-coated tubes were allocated for the controls (Cn+1,2,3...) and the samples 
(Sn+1,2,3...). 200μl of the zero calibrator A was subsequently pipetted into the non-specific 
binding and maximum binding tubes. Thereafter, 200μl of each remaining calibrator, 
control and sample was pipetted into their respective prepared tubes. 1.0ml of 125I insulin 
was then added to each tube, vortexed and then incubated for 18-24 hours at room 
temperature. Post incubation, all tubes (except the total count tubes) were placed in a 
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foam decanting rack and inverted on paper towels, for about 3 minutes,  to allow the 
effluent to drain. Any excess moisture surrounding the top half of the tube was removed 
with a cotton bud. The radioactivity was then measured in each tube using a gamma 
scintillation counter (Cobra II Auto Gamma, A.D.P, South Africa).  
 
3.4 Whole heart analysis 
3.4.3 Western blot analysis of cytosolic PI3K/PKB/Akt and apoptotic pathway 
signaling proteins 
(i) Lysate preparation 
Heart tissue (250mg) from groups 8A and 20A, which had been stored at -80
oC, were 
homogenized on ice in 700μl ice-cold lysis buffer with a polytron PT-10 homogenizer (PCU 
Kinematica, Luzern, Switzerland) for 2 x 4 seconds at setting 4. The lysis buffer, which 
was used throughout all of the experiments, contained 20mM Tris-HCl (pH 7.5), 1mM 
EGTA, 1mM EDTA, 150mM NaCl, 1mM Na2VO3, 1mM β-glycerophosphate, 2.5mM 
sodium-pyrophosphate, 0.3mM PMSF, 1% (v/v) Triton X-100, 10μg/ml leupeptin, 10μg/ml 
aprotonin and 50µg/ml PMSF. The homogenates were then incubated on ice for 15 
minutes and thereafter centrifuged (Eppendorf Centrifuge 5413, Hamburg, Germany) at 
4oC and 11 500rpm for 10 minutes. The resultant supernatants were then subjected to a 
Bradford protein determination. 
 
(ii) Bradford protein determination [Bradford 1976] 
A series of protein standards were prepared, in duplicate, from a diluted bovine serum 
albumin (BSA) solution (diluted 1:5 with dH2O) in order to obtain a standard curve. 
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Throughout all of the experiments, a BSA stock solution with a known protein 
concentration of 1.22μg/μl was used. The diluted BSA solution was aliquoted into protein 
determination tubes such that the protein concentration increased linearly. That is, each 
tube had the following amount of protein (in µg) in the tube 2.42, 4.83, 9.66, 14.50 and 
19.33. The volume pipetted into each tube was (in μl): 10, 20, 40, 60 and 80, thereafter 
dH2O was added to each tube to give a final volume of 100μl. The supernatants from the 
experimental samples, refer to 3.4.3 (i), were diluted 1:10 with dH2O and 5μl of each of 
these samples were further diluted with 95μl of dH2O, in duplicate, with a final volume of 
100μl. Subsequently, 900μl of diluted Bradford reagent (1:5 with dH2O) was added and the 
samples vortexed and incubated at room temperature for 15-30 minutes. The Bradford 
reagent stock solution consisted of 0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) 
ethanol, and 8.5% (v/v) phosphoric acid. The absorbance values were read at 595nm 
using a spectrophotometer (Spectronic® 20 GenesysTM, Spectronic Instruments, USA). 
The generated standard curve and optical density (OD) values were subsequently used to 
determine the protein concentration of the experimental samples in milligrams per millilitre 
(mg/ml). 
From the standard curve, the volume of experimental sample, lysis buffer and 3x Laemmli 
sample buffer, needed to prepare an aliquot of each experimental sample (with a final 
volume of 180µl), was calculated. The 3x Laemmli sample buffer contained 63mM Tris-HCl 
(pH 6.8), 10% Glycerol, 2% SDS, 0.002% Bromophenol Blue and 5% 2-mercaptoethanol. 
Addition of the lysis buffer ensured that all the samples were diluted to an equal protein 
concentration. Lastly, the samples were boiled for 5 minutes and stored at -80ºC for use 
during gel electrophoresis. 
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(iii) Sample loading and gel electrophoresis  
 
The experimental samples, refer to 3.4.3 (ii), were defrosted by boiling it for 5 minutes. The 
samples were then centrifuged at room temperature and 15 000rpm (Sigma® 101M 
Centrifuge, distributed by Lasec SA, Cape Town, South Africa) for 5 minutes and the 
proteins therein separated by means of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using the standard Bio-Rad Mini-Protein III system (Bio-Rad, 
CA, USA). Throughout the study, a 4% stacking gel was utilized whereas the percentage 
resolving gel used depended on the molecular weight of the protein in question (refer to 
table 3.2). The experimental samples and a prestained protein ladder were loaded into the 
gel and the running buffer, containing 250mM Tris, 192mM glycine and 1% sodium 
dodecyl sulphate (SDS), subsequently poured into the system. Electrophoresis of the gels 
followed at 100 volts (V) and 200 milliampere (mA) for 10 minutes initially and thereafter 
for 65 minutes at 200V and 200mA.  
 
 
Table 3.2:  Acrylamide gel constituents for SDS-PAGE 
 
 
 
 
 
 
 
 
Resolving Gel Stacking Gel 
 
7.5% Gel 10% Gel 12% Gel    4% Gel 
dH2O  4.65ml 3.85ml 3.35ml 2.7ml 
1.5 M Tris-HCl (pH 8.8) 2.50ml 2.50ml 2.50ml ------- 
0.5 M Tris-HCl (pH 8.8) ------- ------- ------- 1.25ml 
10% SDS  90µl 90µl 90µl 50µl 
40% Acrylamide  1.7ml 2.25ml 2.7ml 450µl 
10% APS   50µl 50µl 50µl 50µl 
99% TEMED  20µl 20µl 20µl 10µl 
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(iv) Electroblotting and blockage of non-specific binding 
Following separation, the proteins were transferred to a polyvinylidene flouride (PVDF) 
membrane (Immobilon PTM, Millipore, MA, USA) using an electrotransfer system (BioRad 
Mini Transblot System, BioRad, CA, USA) at 200V and 200mA, while submerged in a 
transfer buffer containing 25mM Tris-HCl, 192mM glycine and 20% v/v methanol for 1 
hour. Post transfer, the PVDF membranes were soaked in 99% pure methanol for 30 
seconds and then left to air-dry for 15 minutes. Ponceau S (reversible red) staining 
solution (0.1% Ponceau S (w/v) and 5.0% acetic acid (w/v)) was subsequently used to 
ascertain the presence of the proteins and to confirm if the transfer process was 
successful. To remove the Ponceau red stain from the membranes, it was washed with 
washing buffer (TBS-Tween) composed of 10% of a 10x Tris-buffered saline (TBS) 
solution (50mM Tris, 150mM NaCl and 90% dH20), 90% dH2O and 0.1% Tween-20. The 
washing occurred for 3 x 5 minutes at room temperature on a rotator (LAB Rotator: Model 
DSR 2800V, Digisystem Laboratory Instruments Inc., Taiwan). This washing protocol was 
followed throughout all of the experiments, unless stipulated otherwise. 
The membranes were then blocked, from non-specific protein binding, by incubating them 
in membrane blocking buffer composed of TBS-Tween and 5% fat free milk powder, for 
1.5 to 2 hours. Post incubation, the membranes were washed and incubated in the primary 
(1°) antibody, all of which were diluted according to the manufacturers’ instructions (refer 
to table 3.3), that specifically recognizes the protein of interest. The incubation took place 
overnight at 4oC on the LAB Rotator. 
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Table 3.3:  Protein characteristics for western blot analysis 
 
 
 
 
 
 
 
(v) Secondary (2o) antibody incubation and protein detection  
The following day, the PVDF membranes were thoroughly washed and thereafter the 
membranes were incubated at room temperature on the LAB Rotator in anti-rabbit 
horseradish peroxidise-labelled secondary antibody. The secondary antibody was diluted 
according to manufacturers’ instructions for each specific protein of interest (refer to table 
3.3), for 1 hour at room temperature. After secondary antibody incubation, the membranes 
were thoroughly washed.  
In terms of protein detection, PVDF membranes were coated with enhanced 
chemiluminescence (ECL) detection reagents for 40 seconds in a dark room. 
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Subsequently, the membranes were exposed to an autoradiography film (Amersham 
Hyperfilm ECL (# RPN 2103), GE Healthcare UK Limited, Buckinghamshire, UK) to detect 
light emission from the protein of interest. The interval of exposure differed for each protein 
of interest.  
 
(vi) Densitometry  
Once the proteins were detected by chemiluminescence, the autoradiography films were 
scanned (Epson Perfection V700 Photo Scanner, Digital ICE Technologies, Indonesia) 
and analysed with densitometry (UN-SCAN-IT, Silk Scientific Inc., Orema, Utah, USA). 
This technique detects the density of each protein band, which is an indication of the 
amount of protein present, and relays that density in terms of total pixel values or arbitrary 
densitometry units. 
 
x) Equal loading determination 
To verify that unequal loading was not a factor, the PVDF membranes were stripped of all 
antibodies as well as the ECL detection reagents by washing them with distilled water 
(dH2O) for 2 x 5 minutes at room temperature on the LAB Rotator. The membranes were 
then incubated for 5 minutes in 0.2M NaOH on the belly dancer at room temperature and 
then again washed with dH2O, as previously mentioned. Thereafter, steps (iv) to (vi) of the 
protocol were followed. The β-Tubulin primary antibody was diluted, according to 
manufacturer`s instructions, 1:1000 (5μl 1º antibody in 5ml TBS-Tween), while the anti-
rabbit horseradish peroxidise-labelled secondary antibody was diluted 1:4000 (5μl 2º 
antibody in 20ml TBS-Tween). Equal protein loading was confirmed, if all of the protein 
bands on the β-tubulin autoradiography films had an equal density as seen in figure 3.3. 
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Figure 3.3: The (1) pPKB/Akt and (2) β-Tubulin autoradiography films, as an example 
confirmed equal loading. 
 
xi) P/T ratio 
The P/T ratio is that of the phosphorylated over the unphosphorylated (total) form of a 
particular protein and was obtained by dividing the arbitrary densitometry units, as 
described in section 3.4.3 (vi), of the phosphorylated by that of the unphosphorylated 
protein. 
 
xii) Sample number (n-value) 
All the n-values displayed on the graphs in Chapter 4 indicate the number of individual 
samples (hearts) per group. The images accompanying the graphs in figures 4.4-4.6, 4.11-
4.14 and 4.19-4.32 represent the autoradiography films developed during protein 
exposure, as explained in section 3.4.3 (v). The western blot experiment was duplicated 
with a different set of samples (i.e. more than one electroblot was run per protein of 
interest) for the previously mentioned graphs. 
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3.5 Cardiac mitochondrial analyses 
3.5.1 Western blot analysis of mitochondrial PI3K/PKB/Akt and apoptotic pathway 
signaling proteins 
(i) Mitochondrial isolation 
Prior to mitochondrial isolation, the control and DIO animals in group 20D were subdivided 
into a control, insulin and ischemia group. (1) Control: after anaesthesia of the rats, hearts 
were excised and arrested in a sorval tube with ice cold KE isolation medium (pH 7.4), 
which contained 0.18M KCl (13.42g/L) and 0.01M EDTA (3.72g/L), for 1-3 minutes. (2) 
The insulin group: Animals were injected intra-peritoneally with 20 units of a 100IU/ml 
insulin solution and given a 10 minute waiting period. Thereafter, they were anaesthetized 
and their hearts excised as explained in section 3.3.2. (3) Ischemia: the hearts from these 
animals were arrested in room temperature KE isolation medium and left for 25 minutes at 
room temperature.  
Subsequently, all of the fresh hearts were snipped into small pieces with scissors and the 
majority of the blood removed by repetitive washing with the ice cold isolation medium. All 
further procedures were performed on ice. The tissue was homogenized while submerged 
in the ice cold isolation medium, on ice with the Polytron PT10 homogenizer for 2 x 4 
seconds (setting 4). Next the sorval tube was filled to the top with the ice cold isolation 
medium and the homogenate was centrifuged for 10 min at 2 500rpm (755 x g) and 4°C in 
a Sorval® RC6 Plus, Thermo Electron Corporation, Osterode, Germany (SS34 rotor)). The 
resultant supernatants were decanted into a clean sorval tube and centrifuged at 12 
500rpm (18 800 x g) to obtain a mitochondrial pellet which was subsequently resuspended 
in 1ml ice cold lysis buffer, refer to 3.4.3 (i), and homogenized using a glass Teflon Potter 
Elvehjem homogenizer. The lysates were further homogenized with a polytron (Virsonic 
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Digital 550, The VirTis Co., USA) for 2 x 3 seconds at setting 3. The lysates were left to 
undergo additional digestion on ice for 15 minutes and thereafter it was centrifuged for 10 
minutes at 11 500rpm at 4ºC. The resultant supernatant was collected and the protein 
concentration determined by the method of Bradford, as explained in step (ii) of section 
3.4.3. Thereafter, the mitochondrial lysates were subjected to western blot analysis, as laid 
out in steps (iii) to (x) of section 3.4.3.  
 
3.5.2 Western blot analysis of mitochondrial ETC complex protein subunits 
(i) Mitochondrial isolation 
For the purpose of this experiment, frozen (at -80ºC) myocardial tissue, from groups 8B 
and 20B, were subjected to the same protocol as indicated in section 3.5.1 (i).  
 
(ii) Sample loading and gel electrophoresis  
10µg of each mitochondrial lysate sample, and 5µl of the molecular weight marker, were 
loaded into a commercially available pre-cast acrylamide gradient gel (Mini-Protean® 
TGXTM, BioRad, CA, USA).  Electrophoresis then proceeded in the previously mentioned 
Bio-Rad Mini-Protein III system, which was filled to the top with electrophoresis running 
buffer containing 25mM Tris, 192mM glycine and 0.1% SDS. The proteins were separated 
at 150V and 150mA for 2 hours or until the bromophenol blue dye of the Laemmli sample 
buffer had run out of the bottom of the gel. Thereafter, the gel was soaked in 
electroblotting transfer buffer, which contained 25mM Tris, 192mM glycine, 10% methanol 
and 0.1% SDS, for 30 minutes. 
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(iii) Electroblotting and blockage of non-specific binding 
Subsequent to soaking the gel, it was assembled in a standard transfer sandwich, using a 
PVDF membrane, which was placed in the Bio-Rad Mini Transblot system and fully 
submerged in electroblotting transfer buffer. Electroblotting was carried out at 150mA and 
150V for 2 hours. Post transfer, the proteins were fixed by immersing the PVDF 
membranes in methanol and the protein transfer confirmed with Ponceau red reversible 
dye, as explained in section 3.4.3 (iv). Throughout the experiment, the membranes were 
washed with membrane washing buffer, containing phosphate buffered saline solution 
(PBS) (1.4mM KH2PO4, 8mM Na2HPO4, 140mM NaCl and 2.7mM KCl, pH 7.3) and 0.05 
% Tween-20, for 3 x 5 minutes.  
The membranes were blocked overnight, at 4ºC on the LAB Rotator, in membrane 
blocking buffer containing PBS and 5% fat free milk powder. Post blocking, the 
membranes were incubated in a MitoProfile® Total OXPHOS Rodent Western Blot 
Antibody Cocktail, dilution factor 1:1000 (5µl primary antibody in 5ml 1 % fat free milk 
powder/PBS), at room temperature for 2 hours on the belly dancer. 
 
(iv) Secondary (2o) antibody incubation and protein detection  
The membranes were incubated in anti-mouse horseradish peroxidase (HRP) conjugated 
secondary antibody, dilution factor 1:4000 (5µl primary antibody in 20ml 1% fat free milk 
powder/PBS), at room temperature for 2 hours on the LAB Rotator. 
 
(v) Densitometry  
The same protocol was followed as in section 3.4.3 (vi). 
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(vi) Equal loading determination 
The same protocol was followed as in section 3.4.3 (x). 
 
3.5.3 Mitochondrial respiration analyses 
Mitochondria were prepared from fresh hearts (from all of the animals in group 20C) as 
described in section 3.5.1 The mitochondrial pellet was resuspended in 500µl KE isolation 
medium and homogenized with the glass Teflon Potter Elvehjem homogenizer. 50μl of 
each mitochondrial sample was precipitated in 1ml of 10% trichloroacetic acid (TCA) 
overnight at 4ºC for subsequent Lowry protein determination. Furthermore, 50μl of the 
resuspension was stored at -80ºC for citrate synthase assay analysis at a later stage.  
 
(ii) Lowry protein determination [Lowry et al. 1951] 
The precipitated samples were centrifuged for 15 minutes at 2 500rpm (755 x g) (Heraeus 
Megafuge 16R Centrifuge, Thermo Fisher Scientific Inc. (NYSE: TMO), USA). Thereafter, 
the supernatant was discarded while 500μl 1N NaOH was added to the pellet and 
vortexed. The proteins in the samples were then dissolved by heating it in a water bath at 
70°C for 10 minutes or until the solution was lucid. Subsequently, 500μl dH20 was added 
to each sample and then vortexed rendering a 0.5N NaOH solution.  
Three different albumin stock solutions, of which the protein concentration was known, 
were pipetted into lucham tubes and used to produce a standard curve. 0.5N NaOH was 
used as a blank. In duplicate, 50μl of the mitochondrial samples was added to lucham-
tubes. Thereafter, 1ml NaK-Tartrate-CuSO4 solution, consisting of 2% NaK-Tartrate, 1% 
CuSO4.5H2O and 2% Na2CO3, was added to each tube within a 10-30 second time 
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interval. The tubes were vortexed after each addition and after 10 minutes, 100μl diluted 
Folin Ciocalteu’s solution (diluted 1:3) was added at the same time interval. The tubes 
were again vortexed after each addition and subsequently left for 30 minutes to incubate at 
room temperature. The optical density was read at visible light (750nm). The generated 
standard curve and OD values were then used to determine the protein concentration of 
the mitochondrial samples in mg/ml. 
 
(iii) Oxygraph calibration 
Respiration of isolated mitochondria was measured at 25°C using an oxygraph containing 
a Clarke-type electrode disc (Hansatech Oxygraph, distributed by Scientific Associates cc 
(Tokai, RSA), whereby the O2 consumption was measured in nmolO2/ml/min. 
One of two incubation media was used to calibrate the oxygraph prior to the actual 
experiment, depending on its objective of that experiment. To assess respiration when 
glutamate served as a metabolic substrate, the glutamate  incubation medium (pH 7.4) 
was used, which consisted of 250mM sucrose, 10mM Tris-HCl (pH 7.4), 8.5mM 
K2HPO4.2H2O, 5mM glutamate and 20mM malate. In contrast, 5mM palmitoyl-L-carnitine 
replaced the 5mM glutamate in the glutamate incubation medium (i.e. palmitoyl-L-carnitine 
incubation medium) in order to establish respiration in the presence of fatty acids 
(metabolic substrate). 
An aliquot (the volume was dependent on the end reaction volume) of the incubation 
media was pipetted into the chamber of the oxygraph, subsequently an imprecise but 
small amount of sodium dithionite (Na2S2O4) was added to the chamber to scavenge all 
oxygen and render the medium anoxic. The chamber was sealed and the oxygraph 
calibrated to a 0 and 100% oxygen level. After the calibration the chamber was repetitively 
rinsed with dH2O to remove all remnants of the Na2S2O4.  
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(iv) Baseline mitochondrial respiration analysis 
Referring to figure 3.4, (1) 650µl of the incubation medium was added to the oxygraph 
chamber and allowed to become saturated with air for about 90 seconds. The first set of 
experiments used the glutamate medium whereas a separate set of experiments used the 
palmitoyl-L-carnitine incubation medium. (2) Thereafter, 50μl of the mitochondrial 
suspension (cardiac mitochondria isolated from group 20C(i)) was added and its 
equilibration in the chamber recorded for 90-120 seconds. (3) Hereafter 50μl ADP was 
added and the stopper rapidly closed, effectively sealing the chamber. (4) The active 
mitochondrial state 3 respiration was recorded that is, the mitochondria were allowed to 
use all the ADP to produce ATP. (5) Once the all the ADP was depleted, (6) state 4 
respiration was allowed to ensue (the mitochondria were allowed to respire in the absence 
of a high energy phosphate) (7) until all the oxygen in the chamber was depleted. O2 
consumption was measured in nmolO2/ml/min at 25ºC. The concentration of the ADP 
(stock solution diluted 250x) was determined spectrophotometrically by reading the 
absorbance in a quartz cuvette at a UV wavelength of 259nm. The molar extinction 
coefficient of ADP is 15.4 x 106.  
 
State 3 and 4 respiration was computed as the natoms oxygen consumed (during their 
respective respiration states) per milligram mitochondrial protein per minute (natoms 
O2/mg mitochondrial protein/min). 
The respiratory control index (RCI) was calculated as the ratio of state 3 to state 4 
respiration, whereas the ADP/O ratio was established as the amount of ADP 
phosphorylated (to ATP) over the amount of oxygen consumed during state 3 respiration. 
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The oxidative phosphorylation rate was calculated as the state 3 respiration rate multiplied 
by the ADP/O ratio. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: A standard respiration graph produced by an oxygraph 
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(v) Anoxia/Reperfusion analysis 
During this analysis 600µl incubation medium was added to the chamber and after 90 
seconds 100μl of the mitochondrial suspension added. Following a 90 seconds 
equilibration period, 50μl ADP was added and the chamber sealed. The mitochondria were 
allowed to reach state 3 and state 4 respiration and thereafter 100μl of a 17.7mM ADP 
solution was added and the chamber rapidly sealed again, allowing for maximum 
stimulated respiration. Consequently, the oxygen levels within the chamber became 
completely depleted, making the chamber anoxic. This was allowed to proceed for 20 
minutes after which the mitochondria were re-oxygenated by removing the stopper and 
bubbling air through the reaction mixture with a plastic Pasteur pipette. The mitochondria 
were then allowed to regain state 3 respiration for 2 minutes. A recording of mitochondrial 
oxygen consumption was taken throughout the experiment. This protocol was followed for 
two separate sets of experiments, the first using glutamate and the second using 
palmitoyl-L-carnitine incubation medium. 
Subsequent to the anoxia/reperfusion analysis, the state 3 percentage recovery was 
computed as indicated below: 
 
 
 
 
                     (
                                      
                                      
)      
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(vi) Mitochondrial electron transport chain complex analysis [Lanza et al. 2009] 
Prior to the experiment, the oxygraph was a calibrated (as explained in 3.5.3 (iii)) and a 
baseline mitochondrial respiration analysis was conducted to measure respiration without 
substrates (as explained in 3.5.3 (iv)). For this experiment, 680µl incubation medium was 
pipetted into the oxygraph chamber and after 90 seconds, 20μl of the mitochondrial 
suspension was added. After another 90 seconds had passed, 50μl ADP was added and 
the chamber sealed with the stopper. A different pharmaceutical substance, each one 
inhibiting or uncoupling a specific complex within the ETC, was then injected through the 
capillary tube in the chamber stopper. After each addition the reaction was allowed to 
progress for at least 120 seconds with continuous recording. The order of addition was as 
follows: (1) 45μl of a 80Mm succinate stock solution, (2) 8μl of a 50μM rotenone stock 
solution, (3) 5μl of a 5mg/1ml oligomycin stock solution and (4) 8μl of a 5mM carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) stock solution. This protocol was followed for 
two separate sets of experiments, the first using 5mM glutamate (glutamate incubation 
medium) and the other using 5mM palmitoyl-L-carnitine (palmitoyl-L-carnitine incubation 
medium) as substrate. 
 
The protocol used by Lanza et al., indicate the purpose of the various ETC inhibitors and 
uncouplers, which will briefly be discussed below: 
 
(1) Succinate: Succinate can stimulate respiration above the glutamate and malate 
stimulated state 3 thresholds by providing additional electron flow through complex 
II.  
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(2) Rotenone: Rotenone, in addition to succinate, is used to assess the function of 
complex II as it also selectively stimulates the flow of electrons through complex II 
in the presence of succinate. This is achieved by inducing a redox shift that 
effectively inhibits all of the NADH-linked dehydrogenases in the TCA cycle. 
 
(3) Oligomycin: Induces state 4 respiration by inhibiting the Fo unit of the ATP synthase 
enzyme, thus blocking the proton channel and effectively eliminating ATP synthesis. 
Due to the lack of ADP phosphorylation, there is a leakage of protons across the 
inner mitochondrial membrane and thus, oligomycin is used to indicate the degree 
of uncoupled respiration or proton leak. 
 
(4) CCCP: This uncoupler dissipates the proton gradient across the inner mitochondrial 
membrane and thus, uncouples oxidative phosphorylation. 
 
3.5.4 High performance liquid chromatography (HPLC)  
Prior to the HPLC analysis, the final reaction mixtures (from the experiments laid out in 
3.5.3 (iv), (v) and (vi)) were removed from the oxygraph chamber and added to 1ml of 6% 
PCA (perchloric acid). This allowed for protein precipitation which took place on ice for a 
maximum of 30 minutes. Thereafter, the mixture was centrifuged at 4000rpm at 4°C for 10 
minutes and 1 ml of the supernatant removed and added to 5μl universal pH indicator, 
transforming the supernatant from colourless to purple. A neutralization mixture (40% 
saturated KOH-KCl and 0.2M Tris-HCl in a 2:3 ratio) was progressively (± 5μl at a time) 
added to the supernatant until it turned green in colour, indicating a neutral pH (pH 7.0 - 
pH 7). Subsequently, the mixture was centrifuged at 4000rpm at 4°C for 3 minutes. The 
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resultant supernatants were then filtered through a 0.45μm nitrocellulose filter (Millipore, 
MA, USA) into Eppendorf tubes and stored at -80°C for subsequent HPLC analysis. 
For our experiments, we performed reverse-phase HPLC using a Spectra Physics 
(SP8440 XR) on-line UV detector (CA, USA) with a wavelength of 210nm. The mobile 
phase consisted of a buffer containing 257mM KH2PO4, 1.18mM 
tetrabutylammoniumphosphate (TBAP), 12.5 % (v/v) HPLC graded methanol, pH 4.0 with 
H3PO4. The column (distributed by Phenomenex
®, UK), which was 250mm in length and 
had an internal diameter of 4.6mm, was packed with LUNA C18 (2) with a particle size of 
5μm and was filtered and de-gassed with helium. 
The amount of ATP, ADP, AMP and CrP were all quantified (in μmol/g mitochondrial 
protein) subsequent to the HPLC analysis, from the peak area ratio which was based on 
the calibration or standard curve generated from each individual standard. All of the 
standards used had known concentrations:  ATP = 0.4535nmol/10μl, ADP = 
0.5853nmol/10μl, AMP = 0.7200nmol/10μl and CrP = 0.7640nmol/10μl. 
 
3.5.6 Citrate synthase assay 
Prior to the assay, CellLytic M Cell lysis reagent (Catalogue # C2978, Sigma, St. Louis, 
USA) (about 200μl per g of mitochondrial tissue) was added to 50μl of each the 
mitochondrial samples (which had been stored at -80ºC in KE isolation medium). A citrate 
synthase assay kit (Catalogue # CS0720, Sigma, St. Louis, USA) was then used to 
determine the level of citrate synthase activity in each mitochondrial sample. The kit 
consisted of  1x Assay buffer solution,  30mM Acetyl-CoA, 10mM 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB), 10mM oxaloacetate (OAA) solution and a diluted citrate 
synthase solution which served as the positive control. Subsequently, two reaction 
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mixtures were prepared (1 and 2) both containing 10μl Acetyl-CoA and 10μl DTNB 
solution. In addition, reaction mixture 1 also contained 920μl of the assay buffer, whereas 
mixture 2 contained 90μl of this buffer. 10μl of the diluted citrate synthase solution was 
added to reaction mixture 2 which served as the enzyme standard (positive control) from 
which a standard curve was later generated. Furthermore, 10μl of the mitochondrial 
samples were added to reaction mixture 1, which was later used to determine the citrate 
synthase activity these samples.Thereafter, the positive control and mitochondrial samples 
were heated to 25ºC and transferred to a 1ml absorbance reading cuvette and the OD 
measurements taken at a wavelength of 412nm every 20 seconds for a total of 1.5 
minutes to measure any baseline reaction. 50μl of the oxaloacetate solution was then 
added to all of the samples, the samples gently mixed and the OD measurements taken 
again every 20 seconds for a total of 1.5 minutes to measure the total citrate synthase 
activity. The generated standard curve and OD values were then used to calculate the 
level of citrate synthase activity in µmol/mg protein/minute. 
 
3.5.6 Statistical analyses 
For the purpose of this study, results were statistically compared using Microsoft 
GraphPad Prism, version 5.0. The unpaired Student t-test was used to compare one 
variable between two groups while the one-way analysis of variance (1-way ANOVA) test, 
followed by a Bonferroni post hoc test, was used to compare a single variable amongst 
more than two groups . On the other hand, a two-way analysis of variance (2-way ANOVA) 
test was used to compare multiple variables amongst more than two groups. All of the 
values were expressed as the mean ± standard error of the mean (SEM) and a p-value of 
less than 0.05 (p<0.05) was considered statistically significant. 
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Chapter 4: Results 
 
4.1 Physiological parameters  
4.1.1 8 weeks 
Consequent to following their respective diets, there was no significant difference between 
the control and DIO group with respect to their total body weight. In contrast, the DIO 
animals presented with significant increases in their intra-peritoneal fat mass (p<0.05), 
fasting blood glucose levels (p<0.05) and serum insulin levels (p<0.05) when compared to 
their controls. Please refer to table 4.1. 
 
4.1.2 20 weeks 
In comparison to the control animals, the DIO animals showed a significant elevation in 
both their total body weight (p<0.0001) and intra-peritoneal fat mass (p<0.0001). 
Additionally, these animals displayed significantly augmented fasting blood glucose levels 
(p<0.001) as well as serum insulin levels (p<0.0001). Please refer to table.4.1. 
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Table 4.1: The various physiological parameters of the DIO versus control animals 
subsequent to 8 and 20 weeks on their respective diets. 
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4.2 Intra-peritoneal glucose tolerance test (IPGTT) data 
4.2.1 8 weeks 
Subsequent to following their respective diets for a period of 8 weeks, the DIO animals 
displayed a significantly bigger area under the curve (AUC) (749.7mg/ml/min, p=0.0034), 
in comparison to the control animals (604.8mg/ml/min), during a 2 hour IPGTT (figure 4.1). 
Additionally, the baseline fasting blood glucose levels was significantly elevated in the DIO 
group (4.55mmol/L ± 0.24,   p<0.01), in contrast to their controls (3.91mmol/L ± 0.17). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The fasting blood glucose levels of control versus DIO animals, following an 8 
weeks high caloric diet, during a 2 hour IPGTT. 
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4.2.2 20 weeks  
The DIO animals displayed a significantly greater AUC (568.0mg/ml/min, p=0.0043) in 
comparison to the control animals (466.8mg/ml/min) during a 2 hour IPGTT, following 20 
weeks of diet (figure 4.2). As seen in figure 4.3, the DIO animals showed significantly 
higher fasting blood glucose levels at the zero (a) (5.28mmol/L ± 0.15, p<0.01) and 2 hour 
(b) time points (4.15 mmol/L ± 0.15, p<0.01), in comparison to the control animals (4.32 
mmol/L ± 0.21 and 3.38 mmol/L ± 0.18, respectively). 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.2: The fasting blood glucose levels of control versus DIO animals, following a 20 
weeks high caloric diet, during a 2 hour IPGTT. 
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Figure 4.3: The fasting blood glucose levels of control versus DIO animals (n=10 per 
group), following a 20 weeks high caloric diet, during a 2 hour IPGTT at the zero (a) and 2 
hour (b) time points. 
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4.3 Effects of 8 weeks high caloric diet on myocardial protein signalling 
4.3.1 Western blot data (cytosolic PI3K/PKB/Akt and apoptotic signalling analysis) 
 
4.3.1.1 p85 subunit of phosphatidylinositol-3 kinase (p85 PI3K) 
Subsequent to following their respective diets for 8 weeks, the total p85 (tp85) as well as 
the phosphorylated p85 (pp85) subunit levels (of the PI3K protein) were significantly higher 
in the DIO animals when normalized to their controls, figure 4.4 (a) and (b) respectively. 
Additionally, the P/T ratio was also found to be significantly elevated in the DIO animals 
when compared to the control animals (figure 4.4 (c)). 
 
4.3.1.2 Protein kinase B (PKB) 
After following their respective diets for a period of 8 weeks, The DIO animals showed no 
significant differences, in comparison to their controls, when the protein level of total 
PKB/Akt (tPKB/Akt) was analysed in whole heart lysates (figure 4.5 (a)).  
The protein level of phosphorylated PKB/Akt (pPKB/Akt) (figure 4.5 (b)) as well as the P/T 
ratio (figure 4.5 (c)) were significantly higher in the DIO animals, when matched against 
their controls. 
 
4.3.1.3 Glycogen synthase kinase-3 α/β (GSK-3 α/β) 
Subsequent to following their respective diets for a period of 8 weeks, the DIO animals 
showed no significant differences, in comparison to their controls, when the protein level of 
total GSK-3 α/β, (tGSK-3 α/β) was analysed in whole heart lysates (figure 4.6 (a)). When 
Stellenbosch University http://scholar.sun.ac.za
 104 
 
evaluated, the DIO group had both a significantly higher level of phosphorylated GSK-3 
α/β, (pGSK-3 α/β) and P/T ratio in comparison to their controls (figure 4.6 (b) and (c)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: The myocardial tp85 (a) and pp85 (b) levels as well as the P/T ratio (c) in 
control versus DIO animals (n=8 per group), following 8 weeks of their respective diets. 
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Figure 4.5: The myocardial tPKB/Akt (a) and pPKB/Akt (b) levels as well as the P/T ratio 
(c) in control versus DIO animals (n=11 per group), following 8 weeks of their respective 
diets. 
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Figure 4.6: The myocardial tGSK-3 α/β (n=15 per group) (a) and pGSK-3 α/β (b) levels as 
well as the P/T ratio (n=8 per group) (c) in control versus DIO animals, following 8 weeks 
of their respective diets. 
*p<0.05 
   n=11 
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4.3.1.4 Bcl-2 associated death promoter (Bad) protein   
The myocardial level of total Bad (tBad) was not significantly different between the control 
and DIO groups, following 8 weeks of their respective diets (figure 4.7 (a)). 
The phosphorylated Bad (pBad) protein level as well as the P/T ratio was significantly 
higher in the DIO animals, as seen in figure 4.7 (b) and (c). 
 
4.3.1.5 Bcl-2 associated X (Bax) protein 
The DIO group exhibited significantly higher levels of myocardial Bax protein (figure 4.8 
(a)) and Bcl-2 protein (figure 4.8 (b)), when compared to their control groups, upon the 
completion of 8 weeks of their respective diets. 
 
4.3.1.6 Bax/Bcl-2 protein ratio 
There was no significant difference between the control and DIO animals in terms of their 
Bax/Bcl-2 protein ratio, after 8 weeks of their respective diets (figure 4.8 (c)).  
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Figure 4.7: The myocardial tBad (a) and pBad (b) levels as well as the P/T ratio (c) in 
control versus DIO animals (n=6 per group), following 8 weeks of their respective diets. 
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Figure 4.8: The myocardial Bax (a) and Bcl-2 (b) levels as well as the Bax/Bcl-2 ratio (c) in 
control versus DIO animals (n=6 per group), following 8 weeks of their respective diets. 
 
n=6 
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4.4 Effects of 8 weeks high caloric diet on cardiac mitochondrial integrity 
4.4.1 Western blot data (myocardial mitochondrial ETC complex analysis) 
 
4.4.1.1 NADH-ubiquinone oxidoreductase ASHI (NADH ASHI) subunit (of the ETC 
Complex I) 
The DIO group showed no significant difference in their level of NADH ASHI subunit when 
compared to the control group, subsequent to 8 weeks of their respective diets (figure 4.9 
(a)). 
4.4.1.2 Succinate dehydrogenase [ubiquinone] iron-sulfur (SDH) subunit (of the ETC 
Complex II) 
No significant difference was found in the level of SDH subunit, in the DIO group when 
compared to the control group, following 8 weeks of their respective diets (figure 4.9 (b)). 
4.4.1.3 Core protein 2 (UQCR2/QCR2) subunit (of the ETC Complex III) 
No significant difference was found in the level of Core protein-2 subunit, in the DIO group 
when compared to the control group, following 8 weeks of their respective diets (figure 4.9 
(c)). 
4.4.1.4 Subunit I (of the ETC Complex IV) 
No protein bands were revealed upon exposure. 
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4.4.1.5 α-subunit (of the ETC Complex V/ATP synthase) 
No significant difference was found in the level of α-subunit, in the DIO group when 
compared to the control group, following 8 weeks of their respective diets (figure 4.9 (d)). 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4.9: The mitochondrial complex NADH ASHI (a), SDH (b), (c) Core protein-2 and 
(d) α- subunit levels in control (n=5 per group) versus DIO animals (n=6 per group), 
following 8 weeks of their respective diets. 
  n=5-6 
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4.5 Effects of 20 weeks high caloric diet on myocardial protein signalling  
4.5.1 Western blot data (Cytosolic PI3K/PKB/Akt and apoptotic signalling analysis) 
 
4.5.1.1 p85 subunit of phosphatidylinositol-3 kinase (p85 PI3K) 
The myocardial tp85 subunit level was not significantly different between the DIO and 
control group, subsequent to following their respective diets for 20 weeks (figure 4.10 (a)). 
The level of pp85 subunit as well as the P/T ratio was significantly lower in the DIO 
animals when assessed against their controls, as seen in figure 4.10 (b) and (c) 
respectively. 
4.5.1.2 Protein kinase B (PKB) 
Subsequent to 20 weeks of their respective diets, the DIO animals presented with 
significantly lower levels of myocardial tPKB/Akt as well as pPKB/Akt, when compared to 
their control animals (figure 4.11 (a) and (b), respectively). However, no significant 
difference was found between the DIO and control groups with respect to their P/T ratios, 
as seen in figure 4.11 (c). 
4.5.1.3 Glycogen synthase kinase-3 α/β (GSK-3 α/β) 
In comparison to the control group, the DIO group showed no significant difference in their 
tGSK-3 α/β protein level subsequent to following their respective diets for 20 weeks, as 
seen in figure 4.12 (a). 
The pGSK-3 α/β level and P/T ratio was significantly lower in the DIO group, when 
matched against their controls. Figure 4.12 (b) and (c) respectively. 
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Figure 4.10: The myocardial tp85 (a) and pp85 (b) levels as well as the P/T ratio (c) in 
control versus DIO animals (n=6 per group), following 20 weeks of their respective diets. 
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Figure 4.11: The myocardial tPKB/Akt (n=12 per group) (a) and pPKB/Akt (b) levels as 
well as the P/T ratio (n=11 per group) (c) in control versus DIO animals, following 20 
weeks of their respective diets. 
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Figure 4.12: The myocardial tGSK-3 α/β (n=11 per group) (a) and pGSK-3 α/β (b) levels 
as well as the P/T ratio (n=8 per group) (c) in control versus DIO animals, after following 
their respective diets for a 20 week period. 
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4.5.1.4 Bcl-2-associated death promoter (Bad) protein 
The tBad protein level was significantly elevated in the DIO animals, in comparison to the 
control animals, following 20 weeks of their respective diets (figure 4.13 (a)).  
There was no significant difference between the control and DIO animals in terms of their 
myocardial pBad protein level (figure 4.13 (b)), while the P/T ratio was significantly 
decreased in the DIO animals (figure 4.13 (c)). 
4.5.1.5. Bcl-2-associated X (Bax) and B-cell lymphoma/leukemia2 (Bcl-2) protein 
The Bax as well as the Bcl-2 protein level was not significantly different between the DIO 
and control groups following 20 weeks of their respective diets, as seen in figure 4.14 (a) 
and (b) respectively. 
4.5.1.6 Bax/Bcl-2 protein ratio 
There was no significant difference between the control and DIO animals in terms of their 
Bax/Bcl-2 protein ratio, after 20 weeks of their respective diets (figure 4.14 (c)).  
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Figure 4.13: The myocardial tBad (a) and pBad (b) levels as well as the P/T ratio (c) in 
control (n=4 per group) versus DIO animals (n=5 per group), after following their 
respective diets for a 20 week period. 
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Figure 4.14: The myocardial Bax (n=11 per group) (a) and Bcl-2 (b) levels as well as the 
Bax/Bcl-2 ratio (n=8 per group) (c) in control versus DIO animals, after following their 
respective diets for a 20 week period. 
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4.6 Effects of 20 weeks high caloric diet on cardiac mitochondrial integrity 
4.6.1 Western Blot data (Myocardial mitochondrial ETC complex analysis) 
 
4.6.1.1 NADH-ubiquinone oxidoreductase ASHI (NADH ASHI) subunit (of ETC 
Complex I) 
The NADH ASHI subunit level was significantly lower in the DIO animals than in the 
control animals subsequent to 20 weeks of their respective diets, as depicted in figure 4.15 
(a). 
4.6.1.2 Succinate dehydrogenase [ubiquinone] iron-sulfur (SDH) subunit 
The DIO animals had a significantly lower level of the SDH subunit, when compared to the 
control animals, after having followed their respective diets for a period of 20 weeks (figure 
4.15 (b)).  
4.6.1.3 Core protein-2 (UQCR2/QCR2) subunit (of the ETC Complex III) 
The DIO animals had a significantly higher level of the Core protein 2 subunit, when 
compared to the control animals, after having followed their respective diets for a period of 
20 weeks (figure 4.15 (c)). 
4.6.1.4 Subunit I (of the ETC Complex IV) 
No protein bands were revealed upon exposure. 
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4.6.1.5 α-subunit (of the ETC Complex V/ATP synthase) 
A significantly higher level of the α-subunit was found in the DIO animals, in comparison to 
the control animals, after having followed their respective diets for a period of 20 weeks 
(figure 4.15 (d)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: The mitochondrial complex NADH ASHI (a), SDH (b), Core protein-2 (c) and 
α- (d) subunit levels in control (n=5 per group) versus DIO animals (n=6 per group), 
following 20 weeks of their respective diets. 
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4.7 Effects of 20 weeks high caloric diet on cardiac mitochondrial function 
4.7.1 Cardiac mitochondrial function and anoxia/reperfusion data 
 
 
Table 4.2 The ADP/O ratio, State 3, State 4, oxidative phosphorylation (OXPHOS) rate, 
RCI as well as the percentage recovery of the control and DIO groups, using glutamate as 
a substrate, following 20 weeks of their respective diets. 
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Table 4.3 The ADP/O ratio, State 3, State 4, oxidative phosphorylation (OXPHOS) rate, 
RCI as well as the percentage recovery of the control and DIO groups, using palmitoyl-L-
carnitine as a substrate, following 20 weeks of their respective diets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
After following a high caloric diet for a period of 20 weeks, the DIO group showed no 
significant differences, in comparison to the control group, in terms of the mitochondrial 
State 4, OXPHOS rate and percentage recovery when glutamate was used as a substrate. 
However, a significant difference was observed in the DIO animals when the ADP/O ratio, 
State 3 and RCI were analysed (table 4.2). 
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When palmitoyl-L-carnitine was used as a substrate, the DIO group displayed significant 
differences in their ADP/O ratio and percentage recovery, while analyses of their State 3 
and 4, RCI and OXPHOS rate yielded no significant differences (table 4.3). 
 
4.7.2 Cardiac mitochondrial complex inhibition data 
 
 
Table 4.4 The State 3 respiration, in control versus DIO animals following 20 weeks of 
their respective diets, subsequent to the addition of succinate or the mitochondrial complex 
inhibitors rotenone, oligomycin and CCCP, using glutamate as a substrate. 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 124 
 
Table 4.5 The State 3 respiration, in control versus DIO animals following 20 weeks of 
their respective diets, subsequent to the addition of succinate or the mitochondrial complex 
inhibitors rotenone, oligomycin and CCCP, using palmitoyl-L-carnitine as a substrate.  
 
 
 
 
 
 
 
 
When glutamate was used as a substrate, the DIO group, when compared to the controls, 
showed no significant difference in terms of their state 3 respiration following the addition 
of succinate, rotenone and oligomycin. However, the DIO did display a significant 
difference in the state 3 respiration after the addition of CCCP (refer to table 4.4). 
The DIO group showed no significant difference in their state 3 respiration when any of the 
above mentioned mitochondrial complex inhibitors were utilised and palmitoyl-L-carnitine 
was used as a substrate, as depicted in table 4.5. 
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4.7.3 Cardiac mitochondrial citrate synthase activity data 
There was a significantly decreased level of citrate synthase activity in the DIO animals, in 
comparison to the control animals, after following their respective diets for 20 weeks. Refer 
to figure 4.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: The citrate synthase activity level (μmol/mg mitochondrial protein/minute) in 
control (n=13 per group) versus DIO animals (n=11 per group), subsequent to 20 weeks of 
diet. 
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4.7.3 High pressure liquid chromatography (HPLC) analysis data 
4.7.3.1 ATP produced 
The amount of ATP produced was not significantly different between the DIO and control 
animals, following 20 weeks of their respective diets, when either glutamate or palimotyl-L-
carnitine was used as a substrate as seen in figure 4.17 (a) and (b), respectively. 
 
  
 
 
 
 
 
 
 
  
 
 
Figure 4.17: The amount of ATP produced in control (n=2 per group) versus DIO animals 
(n=3 per group), subsequent to a 20 week period of their respective diets, using glutamate 
(a) and palmitoyl-L-carnitine (b) as a substrate.  
 
n=2-3 
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4.7.3.2 ATP/O ratio 
The ATP/O was significantly decreased in the DIO in comparison to the control animals, 
following 20 weeks of their respective diets, when glutamate as well as palimotyl-L-
carnitine was used as a substrate as seen in figure 4.18 (a) and (b), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: The ATP/O ratio in control (n=2 per group) versus DIO animals (n=3 per 
group), subsequent to a 20 week period of their respective diets, using glutamate (a) and 
palmitoyl-L-carnitine (b) as a substrate.  
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4.8 Effects of 20 weeks high caloric diet on cardiac mitochondrial protein signalling 
4.8.1 Western blot data (Mitochondrial PI3K/PKB/Akt and apoptotic signalling 
analysis) 
 
4.8.1.1 p85 subunit of phosphatidylinositol-3 kinase (p85 PI3K) 
Control: There were no significant differences between the untreated, insulin treated and 
ischemia subjected control groups in terms of the tp85 protein subunit levels found at the 
mitochondria isolated from the hearts of these groups (figure 4.19 (a)). The pp85 level and 
the P/T ratio were significantly higher in the cardiac mitochondria for both the insulin and 
ischemia groups, in comparison to the untreated controls. However, no significant 
difference was found between the insulin and ischemia groups in terms of pp85 level and 
P/T ratio. Refer to figure 4.19 (b) and (c), respectively. 
 
DIO: The tp85 (a) and pp85 levels (b) were significantly higher in the insulin and the 
ischemia groups when compared to the untreated group (figure 4.20). Additionally, the 
pp85 subunit level was significantly higher in the ischemia group in comparison to the 
insulin group (figure 4.20 (b)). 
In comparison to the untreated DIOs, the P/T ratio was significantly higher in the ischemia 
group but not the insulin group. Furthermore, the P/T ratio was significantly elevated in the 
ischemia DIO group in comparison to the insulin DIO group. Refer to figure 4.20 (c). 
Control versus DIO: When the DIOs were compared to the controls, the pp85 level (b) 
and the P/T ratio (c) was significantly elevated in the untreated, insulin and ischemia DIO 
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groups (figure 4.21). There was no significant difference between these groups in terms of 
tp85 subunit level at their cardiac mitochondria (figure 4.21 (a)). 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4.19: The mitochondrial tp85 (a) and pp85 (b) levels as well as the P/T ratio (c) in 
untreated versus insulin versus ischemia control animals (n=6 per group), following 20 
weeks of their respective diets. 
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Figure 4.20: The mitochondrial tp85 (a) and pp85 (b) levels as well as the P/T ratio (c) in 
untreated versus insulin versus ischemia DIO animals (n=6 per group), following 20 weeks 
of their respective diets. 
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Figure 4.21: The mitochondrial tp85 (a) and pp85 (b) levels as well as the P/T ratio (c) in 
untreated, insulin and ischemia control versus DIO animals (n=6 per group), following 20 
weeks of their respective diets. 
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4.8.1.2 Protein kinase B (PKB) 
Control: The mitochondrial tPKB/Akt subunit level was significantly higher in the insulin 
group, in comparison to the untreated group, as well the ischemia group when compared 
to the insulin group. No significant difference was found between the untreated and 
ischemia groups. Refer to figure 4.22 (a). 
The insulin and ischemia groups were significantly higher than the untreated group when 
the mitochondrial pPKB/Akt level was determined. No significant difference was found 
when comparing the insulin and ischemia groups with each other. Refer to figure 4.22 (b). 
The P/T ratio was significantly higher in the ischemia group when compared to the 
untreated group, while no significant difference was found between the insulin and 
untreated group. The P/T ratio was found to be significantly higher in the ischemia group 
when compared to the insulin group. Refer to figure 4.22 (c). 
 
DIO: No significant differences were found between any of the groups in terms of tPKB/Akt 
subunit levels. Refer to figure 4.23 (a). 
The pPKB/Akt level (a) as well as the P/T ratio (b) were significantly lower in the ischemia 
group in comparison to the untreated group. Furthermore, the pPKB/Akt level (a) and the 
P/T ratio (b) were significantly lower in the ischemia group when compared to the insulin 
group. Refer to figures 4.23 (b) and (c). 
 
Control versus DIO: When comparing the tPKB/Akt subunit level between all possible 
groups, no significant differences were found (a). The pPKB/Akt level (b) and the P/T ratio 
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(c) were significantly lower in the untreated, insulin and ischemia DIO groups in 
comparison to their controls. Refer to figure 4.24. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 4.22: The mitochondrial tPKB/Akt (a) and pPKB/Akt (b) levels as well as the P/T 
ratio (c) in untreated versus insulin versus ischemia control animals (n=6 per group), 
following 20 weeks of their respective diets. 
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Figure 4.23: The mitochondrial tPKB/Akt (a) and pPKB/Akt (b) levels as well as the P/T 
ratio (c) in untreated versus insulin versus ischemia DIO animals (n=6 per group), following 
20 weeks of their respective diets. 
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Figure 4.24: The mitochondrial tPKB/Akt (a) and pPKB/Akt (b) levels as well as the P/T 
ratio (c) in untreated, insulin and ischemia control versus DIO animals (n=6 per group), 
following 20 weeks of their respective diets. 
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4.8.1.3 Glycogen synthase kinase-3 α/β (GSK-3 α/β) 
Control: The tGSK-3 α/β subunit level was found to be significantly lower in the insulin 
and ischemia groups when compared to the untreated group. No significant difference was 
found between the insulin and ischemia groups. Refer to figure 4.25 (a). 
The ischemia group had a significantly higher level of pGSK-3 α/β and P/T ratio in 
comparison to the untreated group (figure 4.25 (b) and (c), respectively). No significant 
differences were found between the insulin and untreated groups, as well as the insulin 
and ischemia groups, in terms of the protein level of pGSK-3 α/β (figure 4.25 (b)). The P/T 
ratio was found to be significantly elevated in the insulin and ischemia groups in 
comparison to the untreated group, while no significant difference was found between the 
insulin and ischemia group (figure 4.25 (c)). 
 
DIO: The tGSK-3 α/β protein level was significantly lower in both the insulin and ischemia 
groups in comparison to the untreated group. No significant difference was found between 
the insulin and ischemia groups in terms of tGSK-3 α/β protein level. Refer to figure 4.26 
(a). 
The level of pGSK-3 α/β and the P/T ratio was significantly elevated in both the insulin and 
ischemia groups when compared to the untreated group. Additionally, the ischemia group 
had a significantly higher level of pGSK-3 α/β, as well as a significantly elevated P/T ratio, 
in comparison to the insulin group. Refer to figures 4.26 (b) and (c), respectively. 
Control versus DIO: No significant differences were found between any of the groups in 
terms of the myocardial tGSK-3 α/β protein level at the mitochondria (figure 4.27 (a)). The 
pGSK-3 α/β protein level as well as the P/T ratio was found to be significantly elevated in 
Stellenbosch University http://scholar.sun.ac.za
 137 
 
the untreated, insulin and ischemia DIO groups when compared to their controls. Refer to 
figures 4.27 (b) and (c), respectively. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4.25: The mitochondrial tGSK-3 α/β (a) and pGSK-3 α/β (b) levels as well as the 
P/T ratio (c) in untreated versus insulin versus ischemia control animals (n=6 per group), 
following 20 weeks of their respective diets. 
Stellenbosch University http://scholar.sun.ac.za
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: The mitochondrial tGSK-3 α/β (a) and pGSK-3 α/β (b) levels as well as the 
P/T ratio (c) in untreated versus insulin versus ischemia DIO animals (n=6 per group), 
following 20 weeks of their respective diets. 
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Figure 4.27: The mitochondrial tGSK-3 α/β (a) and pGSK-3 α/β (b) levels as well as the 
P/T ratio (c) in untreated, insulin and ischemia control versus DIO animals (n=6 per group), 
following 20 weeks of their respective diets. 
 
*p<0.05 
    n=6 
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4.8.1.4. Bcl-2-associated death promoter (Bad) protein 
Control: No significant differences were found amongst any of the groups in terms of 
myocardial tBad and pBad protein levels, as well as P/T ratio, present at the mitochondria. 
Refer to figures 4.28 (a), (b) and (c), respectively. 
 
DIO: The tBad and pBad levels were significantly higher in the ischemia group in 
comparison to the untreated group. In terms of the tBad and pBad levels, no significant 
differences were found between the untreated and ischemia groups as well as between 
the insulin and ischemia groups. Refer to figures 4.29 (a) and (b). 
No significant differences were found amongst any of the groups when the P/T ratio was 
assessed (figure 4.29 (c)). 
 
Control versus DIO: The tBad protein level was significantly higher in the untreated, 
insulin and ischemia DIO groups in comparison to their controls (figure 4.30 (a)).  
When matched with their controls, the pBad protein level was significantly elevated in the 
ischemia DIO group; while no significant differences were found between the insulin and 
untreated DIO groups, and their controls (figure 4.30 (b)).  
The P/T ratio was significantly lower in the untreated, insulin and ischemia DIO groups in 
comparison to their controls (figure 4.30 (c)). 
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Figure 4.28: The mitochondrial tBad (a) and pBad (b) levels and the P/T ratio (c) in 
untreated versus insulin versus ischemia control animals (n=6 per group), following 20 
weeks of their respective diets. 
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Figure 4.29: The mitochondrial tBad (a) and pBad (b) levels and the P/T ratio (c) in 
untreated versus insulin versus ischemia DIO animals (n=6 per group), following 20 weeks 
of their respective diets. 
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Figure 4.30: The mitochondrial tBad (a) and pBad (b) levels as well as the P/T ratio (c) in 
untreated, insulin and ischemia control versus DIO animals (n=6 per group), following 20 
weeks of their respective diets. 
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4.8.1.5. Bcl-2 associated X (Bax) protein 
Control: No significant differences were found amongst any of the groups when the Bax 
protein level at the myocardial mitochondria was determined (figure 4.31 (a)). 
 
DIO: The insulin and the ischemia groups were significantly higher than the untreated 
group in terms of the Bax protein level. Additionally, the ischemia group displayed 
significantly elevated levels of Bax in comparison to the insulin group. Refer to figure 4.31 
(b). 
 
Control versus DIO: The untreated, insulin and ischemia DIO groups all had significantly 
higher levels of Bax protein than their controls (figure 4.31 (c)). 
 
4.8.1.6. B-cell lymphoma/leukemia2 (Bcl-2) protein 
Control: In terms of the cardiac Bcl-2 protein level at the mitochondria, no significant 
differences were found amongst any of the groups (figure 4.32 (a)). 
 
DIO: The Bcl-2 protein level was significantly lower in the insulin and ischemia groups in 
comparison to the untreated group, while no significance was found between the insulin 
and ischemia groups (figure 4.32 (b)). 
 
Control versus DIO: The untreated, insulin and ischemia DIO groups all had significantly 
higher levels of Bcl-2 protein than their controls (figure 4.32 (c)). 
Stellenbosch University http://scholar.sun.ac.za
 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.31: The mitochondrial Bax protein level in untreated, insulin and ischemia control 
hearts (a) as well as DIO hearts (b). The P/T ratio in untreated, insulin and ischemia 
control versus DIO hearts (c), following 20 weeks of their respective diets. n=6 per group. 
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Figure 4.32: The mitochondrial Bcl-2 protein level in untreated, insulin and ischemia 
control hearts (a) as well as DIO hearts (b). The P/T ratio in untreated, insulin and 
ischemia control versus DIO hearts (c), following 20 weeks of their respective diets. n=6 
per group. 
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Chapter 5: Discussion 
 
5.1 Overview of the study 
The correlation between obesity, insulin resistance and myocardial disease is well known 
today, however this association is a convoluted one and not straightforward as one would 
think [Bergman et al. 2007, Reaven 2008]. What adds to the complexity of this relationship 
between these diseases is that it has not been completely elucidated on a molecular level.  
A study conducted by Park et al., published in 2005, reported the development of 
myocardial insulin resistance in C57BL/6 mice after just one and a half weeks of high-fat 
feeding. Associated with the insulin resistance was a decline in PKB/Akt activity, GLUT 4 
protein levels and glucose uptake [Park et al. 2005], indicating that a high caloric diet, as 
often followed by obese individuals, can negatively affect myocardial insulin-mediated 
PI3K/PKB/Akt signalling. 
Lu et al. (2007) observed in their study that genetically obese rats had decreased 
myocardial anti-apoptotic Bcl-2 levels while the pro-apoptotic BNIP3 and Bad protein 
levels were elevated, in comparison to their lean counterparts. Furthermore, other studies 
involving a variety of animal models of obesity have showed that a number of 
cardiovascular diseases or aberrations involve the highly controlled process of apoptosis 
[Yue et al. 2005, Shibata et al. 2005].   
 
It is now common knowledge that insulin regulates the process of apoptosis via the 
PI3K/PKB/Akt pathway, as reviewed elsewhere [Duronio 2008, Iliadis et al. 2011]. 
However, what has received less attention thus far is the role of insulin in the context of 
apoptosis, specifically in the myocardium during obesity.  
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The focus of the present study was thus to elucidate if the insulin-mediated PI3K/PKB/Akt 
pathway played a role in the regulation of the mitochondrial-dependent pathway of 
apoptosis in the myocardium during obesity. This was achieved by utilizing a rat model of 
diet induced obesity and determining if any changes occurred in the proteins associated 
with PI3K/PKB/Akt pathway signalling in the cytosol, specifically PI3K, PKB/Akt and GSK-
3α/β, of these animals. In addition, their hearts were probed for any changes in the 
apoptotic markers Bad, Bax and Bcl-2. These proteins were characterized 8 as well as 20 
weeks after the completion of the obesity-inducing diet.  
After 20 weeks, the presence of these apoptotic markers and PI3K/PKB/Akt pathway 
proteins were also probed for specifically in the mitochondria to further elucidate the 
interplay between the two pathways during obesity. 
The study further aimed to establish if obesity resulted in cardiac mitochondrial dysfunction 
by analyzing mitochondrial respiration function during both anoxia/reperfusion and ETC 
complex inhibition after 20 weeks. Moreover, the protein profile of the various ETC 
complexes was analyzed for any changes after 8 as well as 20 weeks of diet to determine 
if structural changes had occurred in the mitochondria. 
The aim of the various experiments conducted after the 8 week time point was to assess 
the early effects of obesity on the myocardium, while the 20 week time point was used to 
evaluate the advanced effects. 
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5.2 Physiological and biometric data 
The obesity-inducing high caloric diet used in this study was causal in elevating total body 
weight gain when followed for a period of 20 weeks. Then again, when followed for a 
period of 8 weeks this diet did not cause a significant increase in total body weight gain 
(table 4.1). Nevertheless, regardless of the time period the DIO animals were on their diet, 
both of the experimental groups showed an elevation in intra-peritoneal fat accumulation 
(table 4.1). This augmented intra-peritoneal adipose deposition was associated with 
increased fasting blood glucose levels and serum insulin levels in both groups of obese 
animals. This indicates that an increase in intra-peritoneal fat accumulation has a positive 
correlation, more so than an increase in total body weight, with elevated blood glucose and 
serum insulin levels during obesity. Our data coincides with a number of other studies in 
which visceral obesity exhibited a greater correlation with various metabolic aberrations 
than overall or peripheral obesity [Fujioka et al. 1987, Poirier et al. 2005, Bergman et al. 
2007].  
Impaired glucose handling is often a consequence of obesity [Attallah et al. 2006, Fall et 
al. 2008], reviewed in Chapter 2, and would thus explain the presence of high serum 
insulin levels in both groups of DIO animals. Furthermore, this would be an indication that 
our obese animals were whole-body insulin resistant and that the excess insulin secretion 
is a compensatory mechanism, required by these animals to maintain their blood glucose 
levels. Although the DIO animals had significantly higher fasting blood glucose levels, after 
8 as well as 20 weeks high caloric diet, they were not characterized by T2DM. The fasting 
blood glucose levels of both groups were below 6.1mmol /L, which are considered within 
the normal range [Kahn et al. 1997]. 
In addition to these metabolic parameters, our 8 as well as 20 weeks DIO animals also 
had a lower glucose tolerance during their 2 hour IPGTT (figure 4.1; figure 4.2), in 
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comparison to their non-obese controls, as illustrated by their greater IPGTT AUC. This 
substantiates that both obese groups had systemic insulin resistance and corresponds 
with previous data found in our laboratory, where the obese animals were whole body 
insulin resistant and had higher fasting blood glucose and insulin levels after 8 weeks of 
following a high caloric diet [Huisamen et al. 2012]. Additionally, Liao et al. (2011) found 
that both high fat diet sedentary and high fat diet exercise groups (consisting of male 
Sprague-Dawley rats) had larger IPGTT areas under the curve after 6 weeks of protocol, 
once again illustrating that a high fat diet correlates with impaired glucose tolerance. 
 
5.3 Signalling proteins associated with the cytosol after 8 weeks 
5.3.1 Western blot analysis after 8 weeks  
Analysis of these hearts revealed that the obesity-inducing diet, had up-regulated the 
cytosolic PI3K/PKB/Akt and blunted the apoptotic signalling in these animals after 8 
weeks, when compared with their control counterparts. This was revealed by the increased 
levels of total (a) and phosphorylated (b) p85 subunit of the pro-survival [Duronio 2008] 
kinase PI3K, as well as an elevated p85 subunit P/T ratio (c) in the DIO animals (figure 
4.4). 
Furthermore, the phosphorylated PKB/Akt (figures 4.5 (b)) and GSK-3α/β levels (figure 4.6 
(b)), as well as their P/T ratios (figures 4.5 (c) and 4.6 (c), respectively), were elevated in 
these hearts. The total PKB/Akt and GSK-3α/β levels remained unchanged as seen in 
figures 4.5 (a) and 4.6 (a), respectively. 
The DIO animals concurrently displayed heightened pBad (b) and an increased Bad P/T 
ratio (c), while the tBad protein level in these animals did not differ from the controls (a) 
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(figure 4.7). It has been established that phosphorylation of pro-apoptotic Bad by various 
kinases, including PKB/Akt, allows the scavenging of this protein by the 14-3-3 scaffold 
proteins, conferring a pro-survival status [Danial 2009, Sussman et al. 2011]. 
Our results also revealed that the obese animals had increased myocardial levels of the 
anti-apoptotic protein Bcl-2 after 8 weeks of diet (figure 4.8 (b)), while concurrently having 
increased pro-apoptotic Bax levels as seen in figure 4.8 (a). Since these data contradicted 
each other, we calculated at the Bax/Bcl-2 ratio which can be used as an indicator of a 
cell`s apoptotic status (death versus survival) [Anarkooli et al. 2008]. It was found that the 
ratio did not differ between the obese and control animals. However, activation of PKB/Akt, 
as well as GSK-3α/β, and the increased pBad level and Bad P/T ratio in the DIO animals 
indicate that the pro-apoptotic signalling was decreased and that cell survival was 
favoured. 
Insulin has been shown to be cardioprotective in patients undergoing cardiac surgery 
[Carvalho et al. 2011, Ng et al. 2012] and of course, in the popular studies involving 
ischemic post-conditioning in rodent models [Jonassen et al. 2001, Zhu et al. 2006, Yin et 
al. 2009]. These reviews and studies have also indicated that insulin signalling and 
insulin–mediated cardiac protection are complex and occur via a number of different 
pathways. However, the 2009 experimental findings by Yin et al. and the 2012 review 
published by Ng et al., suggest that insulin is able to mediate these cardioprotective effects 
mainly via the PI3K/PKB/Akt pathway.  
In fact, the 2006 study conducted by Zhu et al. found that myocardial ischemic post-
conditioning elevated the protein levels, as well as its activity of PKB/Akt and GSK-3β in 
both healthy and “remodelled” hearts. This was in comparison to healthy and remodelled 
hearts which had undergone ischemia without post-conditioning. Moreover, the post-
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conditioning was associated with smaller infarct sizes and increased functional recovery in 
the “remodelled” hearts. 
Interestingly, when the enzyme activity of extracellular signal-regulated kinases 1 and 2 
(ERK1/2) was analyzed, it did not differ significantly between the healthy and “remodelled” 
hearts during post-conditioning. This suggests that the PI3K/PKB/Akt pathway is better 
associated with the cardioprotection of ischemic post-conditioning than the ERK1/2/MAPK 
pathway. [Zhu et al. 2006]  
In the present study, we therefore propose that the hyperinsulinemia during the initial 
stages of obesity-related insulin resistance is an adaptive mechanism not only to reduce 
plasma glucose levels but to elicit cardioprotection, after 8 weeks of a high caloric diet. A 
previous study conducted in our laboratory could substantiate this proposition as it found 
that DIO animals developed smaller myocardial infarct sizes in comparison to controls. 
This was after both groups followed an 8 weeks high caloric diet, and their hearts exposed 
to 25 minutes regional ischemia and subsequent reperfusion [Huisamen et al. 2012]. 
We propose that insulin mediates this protection via the PI3K/PKB/Akt signalling pathway, 
in a manner similar to the above mentioned studies. This would substantiate why we found 
increased PI3K/PKB/Akt and downregulated apoptotic signalling in the hearts of our obese 
animals. 
5.3.2 Mitochondrial ETC complex western blot analysis after 8 weeks  
NADH ASHII, SDH, α- and core protein-2 subunits are key protein components of the ETC 
complexes I, II, III and IV respectively, in that they are essential to the assembly and thus 
function of these complexes. With regard to these subunit levels, we found no significant 
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differences between the DIO and control animals (figure 4.9 (a)-(d)) indicating that an 8 
week obesity-inducing diet had no effect on ETC complex assembly. 
It would seem that the cardioprotective effects on the cytosolic level, provided by the 
elevated PI3K/PKB/Akt signalling (discussed in 5.3.1), were also exerted on the 
mitochondrial level after an 8 weeks high-caloric diet. That is, the augmented insulin-
mediated PI3K/PKB/Akt signalling prevented obesity-induced alterations in complex 
subunit assembly, allowing the mitochondria to maintain its ETC integrity.  
On the whole, it would thus seem that after 8 weeks the high caloric diet improved the 
hearts response to systemic insulin resistance and could be cardioprotective. Evidence of 
this would be that the mitochondrial integrity appears unchanged after 8 weeks of the diet. 
5.4 Signalling proteins associated with the cytosol after 20 weeks 
5.4.1 Western blot analysis after 20 weeks  
Whole heart tissue analysis from our obese animals revealed that the high energy diet, 
when followed for 20 weeks, was associated with reduced cytosolic PI3K/PKB/Akt and 
enhanced apoptotic signalling in these animals.  
Our results showed decreased levels of myocardial phosphorylated p85 PI3K subunit 
(figure 4.10 (b)), PKB/Akt (figure 4.11 (b)) and GSK-3α/β (figure 4.12 (b)) in the obese 
animals after 20 weeks of diet. Furthermore, the tPKB/Akt protein level (figure 4.11 (a)) as 
well as the p85 PI3K subunit and GSK-3α/β P/T ratios (figures 4.10 (c) and 4.12 (c) 
respectively) and were reduced in these animals.  
Similar tendencies were observed in other animal models of high caloric diet. Lee et al. 
(2010) researched whether whole-body and myocardial insulin resistance developed 
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together, by comparing the insulin signalling in skeletal and cardiac muscle in micropigs 
after 7 months of either a control (low fat) or high caloric diet. The results showed that the 
obese pigs had decreased phosphorylation and activation of PI3K and PKB/Akt in both 
myocardial and skeletal muscle tissue [Lee et al. 2010]. 
When transgenic mice, for the cardiac myocyte overexpression of IGF-1, were subjected 
to a high-fat diet for 5 months, the diet was associated with cardiac damage and 
dysfunction. The diet also correlated with decreased cardiac IRS (tyrosine), PKB/Akt and 
GSK-3β phosphorylation, and this is thought to most likely underlie the myocardial 
aberrations [Zhang et al. 2012]. 
The present study corroborates the findings in these two studies in that it indicates that 
obesity, induced after 20 weeks of a high caloric diet, is associated with attenuated 
myocardial PI3K/PKB/Akt signalling.  
Concurrent to the PI3K/PKB/Akt pathway protein aberrations, the apoptotic pathway was 
up-regulated in the obese animals after 20 weeks as revealed by the elevated tBad protein 
level and decreased Bad P/T ratio (figure 4.13 (a) and (c)). The Bax as well as the Bcl-2 
protein levels in the DIO rats did not differ significantly, in comparison to the controls 
(figure 4.14 (a) and (b)). This prompted us to once again look at the Bax/Bcl-2 ratio to 
obtain a clearer indication of what was happening in the cell in terms of cell death versus 
survival. The ratio was not significantly different between the control and DIO animals. 
Nevertheless, the increase in tBad and the reduction in its P/T ratio suggest that these 
hearts were more susceptible to apoptosis after following an obesity-inducing diet for 20 
weeks. 
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In terms of the Bad protein levels in the 20 weeks DIO animals, our findings are similar to 
that of Lu et al. 2007 in that the obese Zucker rats had increased cardiac levels of pro-
apoptotic Bad at 5 to 6 months of age.  
In addition to the impaired cardiac insulin signalling (discussed above), Zhang et al. (2012) 
also found that the cardiomyocytes of high fat fed transgenic mice had significantly 
attenuated levels of anti-apoptotic Bcl-2. However, this study also reported significantly 
elevated levels of phosphorylated Bax and Bad in these cardiomyocytes. Phosphorylation 
of these two molecules has been shown to promote cell survival as it inhibits their pro-
apoptotic activities [Gardai et al. 2004, Wente et al. 2006]. It is most likely that the Bax/Bcl-
2 ratio in these cardiomyocytes would have given a more appropriate indication of the 
apoptotic status of these cells.  
Nevertheless, it has been shown that a small amount of apoptosis is detrimental to the 
heart [Masri et al. 2008]. This would, in conjunction with the above studies, support our 
hypothesis that the obese animal hearts will be more susceptible to apoptosis and damage 
as a result of their decreased PI3K/PKB/Akt and increased apoptotic signalling. 
Experimental findings in previous studies conducted in our laboratory can substantiate the 
susceptibility of the 20 weeks DIO animals to myocardial damage in the current study. du 
Toit et al. (2008) and Nduhirabandi et al. (2011) both found that animals given a high 
caloric diet for 16 weeks developed hyperphagia-induced obesity. Furthermore, these 
obese animals in both studies had significantly larger myocardial infarct sizes after ex-vivo 
exposure to ischemia/reperfusion, indicating they were more susceptible to 
ischemia/reperfusion injury and had reduced cardioprotection. 
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5.4.2 Mitochondrial ETC complex western blot analysis after 20 weeks  
In contrast to the findings obtained after 8 weeks of diet, analysis after 20 weeks revealed 
that the integrity of complexes I and II had been compromised in the DIO rats, indicated by 
the reduction of NADH ASHII and SDH subunit levels in these animals. In contrast, α- and 
core protein-2 subunit levels were increased, demonstrating that complex III and V 
assembly and integrity were enhanced in the obese animals. 
The loss of complexes I and II integrity in these animals can be substantiated by the 
decreased PI3K/PKB/Akt signalling, and possible reduction in cardioprotection, as seen on 
the cytosolic level (discussed in 5.4.1). Contrasting levels of subunit expression are not 
foreign findings, as similar results were observed in other studies, for example, Liesa et al. 
2008. In their study, PGC-1β knockout mice were fed a high fat diet for 6 months and their 
liver assessed for mitochondrial ETC complex protein subunit expression. These mice 
displayed elevated subunit expression for two of the ETC complexes, while no significant 
differences were found in the subunit levels for the other complexes. The mitochondrial 
ETC complexes changes seen in their study were associated with attenuated Mitofusin 2 
expression, a protein essential for mitochondrial fusion [Chen et al. 2005]. 
The western blot ETC complex analysis data in the current study, suggests that 
mitochondria from the obese animals had disrupted integrity. In contrast, the integrity had 
remained intact in mitochondria from the obese animals, after following a high fat diet for 8 
weeks. 
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5.5 Cardiac mitochondrial function after 20 weeks 
In obesity, and diabetes, there is attenuated myocardial function which is associated with 
elevated fatty acid and reduced glucose metabolism, as well as increased cardiac oxygen 
consumption. Mitochondrial uncoupling proteins have been implicated in these cardiac 
aberrations, however little concrete evidence exists for this [Boudina et al. 2005]. 
Our study thus aimed to assess if different substrates could alter mitochondrial function in 
obese animals by evaluating oxidative phosphorylation capacity and performing 
anoxia/reperfusion analysis. Furthermore, we conducted mitochondrial ETC complex 
inhibition analysis to determine if complex inhibition or uncoupled respiration could 
mediate these cardiac dysfunctions. 
 
 
5.5.1 Oxidative phosphorylation capacity and anoxia/reperfusion analysis after 20 
weeks 
When both glutamate (table 4.2) and palmitoyl-L-carnitine chloride (table 4.3) were used 
as substrates the ADP/O ratio was lower in the DIO animals, indicating that these animals 
consumed more natoms oxygen than the control animals for the same amount of nmoles 
ADP utilized.  
Moreover, we found that the mitochondrial state 3 respiration rate was higher in the obese 
rats (table 4.2) with glutamate as substrate; an increase (not significant) was also 
observed when palmitoyl-L-carnitine was used as substrate, indicating that these animals 
were consuming significantly more oxygen during ATP production. With both substrates, 
the state 4 respiration rates showed that it was also higher (not significant) in the obese 
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animals causing a reduction in RCI, which is an indication of uncoupled mitochondrial 
respiration.  
This implies that the obese rats had poor respiratory control and that the coupling between 
mitochondrial respiration and phosphorylation was weaker than that of their lean 
counterparts. Taken overall, the above parameters indicate that the mitochondrial function 
in the obese hearts have been negatively affected when either glucose or fatty acids were 
used as their main source of energy. 
It would therefore appear that the elevated plasma free fatty acid level observed in the DIO 
animals had an in vivo effect on their mitochondrial oxidative phosphorylation capacity, 
which persisted in vitro when mitochondria were isolated and incubated under optimal 
conditions. This demonstrates the uncoupling effect of fatty acids on mitochondrial function 
[Stanley et al. 2005] and illustrates that the obesity-inducing diet indeed altered 
mitochondrial function. 
Interestingly, when palmitoyl-L-carnitine was used as substrate, the percentage 
mitochondrial functional recovery (as indicated by state 3 respiration) after a period of 
anoxia was greater in the obese animals, despite having a reduced ADP/O ratio. The 
percentage recovery, with glutamate as a substrate, did not differ between the obese and 
control groups, suggesting that mitochondria isolated from obese animals fare better with 
respect to their mitochondrial function when incubated in the presence of a fatty acid 
substrate such as palmitoyl-L-carnitine.  
Our findings indeed indicate that there is a shift in cardiac substrate utilization from 
glucose to fatty acids during obesity. Despite their improved recovery after exposure to 
anoxia, mitochondria isolated from hearts of obese animals have a significantly impaired 
oxidative phosphorylation.  In the long-term this may have a profound effect on myocardial 
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contractile function as shown by du Toit et al. (2008). In their study, du Toit et al. found 
that the DIO animals had a significantly reduced aortic output at reperfusion (and prior to 
ischemia) in comparison to the controls. Additionally, these obese animals were marked by 
attenuated percentage recovery post-ischemia. 
 
5.5.2 ETC complex inhibition analysis after 20 weeks 
In order to assess if mitochondrial electron transport chain complexes plays a role in diet-
induced obesity myocardial dysfunction we inhibited and uncoupled the complexes with 
various complex specific inhibitors and uncouplers. Thereafter, we determined the state 3 
respiration rate as a measure of mitochondrial function in the control and obese animals. 
Neither the addition of succinate nor the complex inhibition with rotenone or oligomycin, 
using either glutamate or palmitoyl-L-carnitine as substrate, yielded any differences 
between the DIO and control animals with respect to their state 3 respiration rates. 
However, OXPHOS uncoupling with CCCP [Benard et al. 2007] produced a higher 
respiration rate in the obese animals with glutamate as substrate but not when palmitoyl-L-
carnitine was used. This further substantiates the uncoupled state of the mitochondria in 
the DIO animals, especially when glutamate served as substrate. 
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5.6 Mitochondrial integrity after 20 weeks 
5.6.1 Citrate synthase assay 
Citrate synthase is the primary enzyme that mediates the binding of acetyl coenzyme A 
acetyl CoA and oxaloacetate to form citrate in the TCA cycle. Furthermore, this enzyme is 
located in the mitochondrial matrix and is used as a well-established marker to determine 
the amount of undamaged mitochondria present in a sample, and is achieved by 
measuring the activity of the enzyme [Raffaella et al. 2012]. Our study revealed that the 
citrate synthase activity was lower in the obese rats (figure 4.16), indicating that these 
animals had a lower number of intact cardiac mitochondria per mg isolated protein. This 
suggests that either there were fewer intact mitochondria initially present in the tissue or 
that the mitochondria were easily damaged upon isolation.  
These findings correlate to other studies in which the CS activity was lower and 
mitochondrial damage elevated, in animals fed high fat diets [Raffaella et al. 2012].  
The decreased number of intact mitochondria, taken together with the reduced 
mitochondrial ETC complex integrity (section 5.4.2); indicate that the obese animals had 
attenuated mitochondrial integrity after 20 weeks of diet. 
 
5.6.2 HPLC analysis after 20 weeks 
As described on in Chapter 3, the total amount of ATP formed during state 3 respiration 
was determined by HPLC analysis. No significant differences were found amongst the 
control and DIO animals with respect to the ATP yield, when either (a) glutamate or (b) 
palmitoyl-L-carnitine were used as substrates (figure 4.17). However, when we calculated 
the ATP/O ratio, from the ATP values obtained and the amount of oxygen taken up during 
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state 3 respiration, we saw that this was significantly reduced in the obese animals (figure 
4.18). This denotes that for both of these substrates, the obese animals produced less 
ATP than the controls but utilized more oxygen in order to do so, according to their lower 
ADP/O ratio. This confirms that the obese animals indeed had elevated cardiac oxygen 
consumption and were wasting it during ATP synthesis as discussed in 5.5.1. 
Overall, our data from the anoxia/reperfusion (section 5.5.1), ETC complex inhibition 
(section 5.5.2) and HPLC analyses indicate that there was a reduction in mitochondrial 
function in the heart after 20 weeks of diet-induced obesity. This especially seemed to be 
the case when glutamate acted as substrate. When palmitoyl-L-carnitine was used, the 
obese animals had a better recovery during anoxia/reperfusion analysis. We suspect that 
this is as a result of a metabolic substrate switch and increased use of fatty acids in these 
animals. 
Furthermore, the elevated complexes III and V integrity, could explain the increased 
percentage recovery after anoxia within the mitochondria from the DIO group, when 
utilizing palmitoyl-L-carnitine as a substrate.  
 
5.7 Signalling proteins associated with the mitochondria after 20 weeks 
Obesity associated cardiovascular diseases often stem from structural and functional 
aberrations as a result of irregularities in both cardiac cytosolic and mitochondrial 
signalling [Kim et al. 2008].  
Thus, our study further compared PI3K/PKB/Akt and apoptotic signalling in cardiac 
mitochondria isolated from control and obese rats under basal conditions (i.e. untreated) 
as well as after insulin treatment or exposure to ischemia. Firstly, we did the comparison in 
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control animals, 20 weeks after their standard diet, and secondly in the obese high caloric 
diet group. The purpose of this was to establish how exogenous insulin and ischemia 
would affect signalling in these two pathways, as both insulin [Duronio 2008, Ilidias et al. 
2011] and ischemia [Yong et al. 2008, Yin et al. 2009] have been shown to activate the 
PI3K/PKB/Akt pathway as a cardioprotective mechanism. Lastly, we compared myocardial 
markers of the PI3K/PKB/Akt and apoptotic signalling pathways, amongst control and DIO 
groups, at basal and when the hearts were treated with insulin and when exposed to 
ischemia. 
 
5.7.1 Western blot analysis after 20 weeks 
5.7.1.1 Mitochondrial signalling post insulin administration 
(i) Control animals 
Intra-peritoneal administration of insulin served to augment the PI3K/PKB/Akt signalling at 
the mitochondria in the control animals, while concurrently preventing an increase in 
apoptotic signalling. 
This can be seen by the increased phosphorylation of the p85 PI3K subunit, despite a lack 
of increased tp85 PI3K subunit translocation. Furthermore, the P/T ratio was higher in the 
insulin treated controls in comparison to the untreated controls, indicating that a larger 
portion of the p85 subunit was phosphorylated than dephosphorylated (figure 4.19 (a), (b) 
and (c)). 
In addition, not only was there an increase in tPKB/Akt translocation to the mitochondria in 
the insulin treated controls, there was also an increase in the phosphorylation of these 
PKB/Akt molecules (figure 4.22 (a) and (b)). Furthermore, we saw that the tGSK-3α/β 
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translocation level was lower (a) but that the phosphorylation of this molecule (b), as well 
as the P/T ratio (c), were elevated in these animals (figure 4.25). 
In terms of apoptotic pathway signalling, the mitochondrial translocation of tBad (figure 
4.87 (a)) and Bax (figure 4.31 (a)) in the insulin treated controls did not differ significantly 
from the untreated controls. The phosphorylation level of tBad in the insulin treated 
controls also did not differ significantly from that in the untreated controls, as seen in figure 
4.28 (b). Furthermore, there were no increases in the anti-apoptotic Bcl-2 level at the 
mitochondria (figure 4.32 (a)).  
The lack of increased apoptotic protein levels and translocation, to the mitochondria, and 
elevated PI3K/PKB/Akt pathway signalling indicates that the insulin treated control animals 
were afforded cardiac protection. 
 
(ii) DIO animals 
With regard to the insulin treated DIO animals, we found these animals displayed elevated 
mitochondrial insulin-mediated PI3K/PKB/Akt pathway protein translocation, and 
decreased apoptotic pathway protein translocation.  
We found that the tp85 and pp85 translocation to the mitochondria increased upon insulin 
administration in the obese animals (figure 4.20 (a) and (b)). The translocation of tPKB/Akt 
however, and the phosphorylation of this protein, remained unchanged (figure 4.23 (a) and 
(b), respectively). At the same time, there was decreased translocation of downstream 
tGSK3α/β but the phosphorylation of this protein, as well as the P/T ratio, was elevated in 
the insulin treated DIO animals (figure 4.26 (a), (b) and (c)).  
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In terms of the apoptotic signalling, we saw no decreased levels of tBad translocation, and 
parallel to that the phosphorylation of tBad and its P/T ratio did not increase in the insulin 
treated DIO animals (figure 4.29 (a), (b) and (c)). Conversely, pro-apoptotic Bax 
translocation increased while anti-apoptotic Bcl-2 levels decreased, indicating an increase 
in apoptotic signalling at the mitochondria. 
The above results would then indicate that at the mitochondrial level, the enhanced 
PI3K/PKB/Akt signalling was unable to provide protection against myocardial apoptosis in 
the obese insulin treated animals. 
On the whole, these findings denotes that exogenous insulin administration is able to elicit 
elevated PI3K/PKB/Akt signalling, in the mitochondria in the hearts of control as well as 
diet-induced obese animals after 20 weeks. However, it would seem that this pathway was 
only able to prevent increased intrinsic apoptotic signalling in the control but not the DIO 
animals. Thus, cardioprotection was lost at the mitochondrial level in the obese animals 
making these hearts more susceptible to apoptosis, while the control animal hearts were 
protected. 
Yang et al. (2009) conducted a study, in which they compared the insulin-mediated 
PI3K/PKB/Akt pathway in control and type-1 (T1DM), as well as type-2 (T2DM), diabetic 
rats. The T1DM mice were obtained by injecting normal rats with a once-off dose of 
streptozotocin, while the T2DM mice were obtained by feeding the animals a high fat diet 
for 6 weeks. After all the groups were fasted overnight and administered insulin acutely via 
the inferior vena cava, western blot analysis revealed that the translocation of tPKB/Akt 
and pPKB/Akt to the mitochondria was significantly higher in the T1DM animals, in 
comparison to the controls. Furthermore, the PKB/Akt P/T ratio in the mitochondria was 
higher in these mice. In contrast, the translocation of tPKB/Akt and pPKB/Akt to the 
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mitochondria, as well as the P/T ratio in the mitochondria, were attenuated upon acute 
insulin administration. Yang et al. concluded that the insulin-mediated PI3K/PKB/Akt 
signalling in the mitochondria was elevated in the T1DM model due to the insulin 
deficiency, which is characteristic of this type of diabetes. This deficiency has been shown, 
by other studies, to increase the number of insulin receptors as well as the receptor 
signalling to PI3K in the heart [Wang et al. 1999].  
On the contrary, Yang et al. (2009) further concluded that the attenuated PI3K/PKB/Akt 
signalling observed in the mitochondria of the T2DM animals were due to them being 
insulin resistant as other studies had shown that insulin receptor signalling is decreased in 
these animals [Bonnard et al. 2008, Milne et al. 2007]. 
 
The above conclusions could authenticate why the obese animals experienced a reduction 
in mitochondrial integrity and function, despite elevated PI3K/PKB/Akt signalling in the 
mitochondria. It is possible that as a result of our obese animals being insulin resistant, 
there was only a minimal amount of insulin receptor signalling to PI3K in the mitochondria. 
The signalling could have been sufficient to elevate tp85 PI3K subunit translocation and to 
enhance p85 phosphorylation in these animals. However, the insulin resistance most likely 
affected PI3K activation and phosphorylation of downstream PKB/Akt as Bax levels 
increased and pBad levels were unchanged in the mitochondria. Active PKB/Akt is known 
to phosphorylate Bad and Bax and thus inhibit their pro-apoptotic abilities [Wente et al. 
2006, Gardai et al. 2004]. 
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5.7.1.2 Mitochondrial signalling during cardiac ischemia 
(i) Control animals 
Similar to the insulin treated controls, mitochondria isolated from control hearts exposed to 
ischemia showed increased PI3K/PKB/Akt signalling, while the apoptotic signalling 
neglected to increase. 
In our study, the level of translocation of tp85 PI3K subunit and tPKB/Akt to the 
mitochondria in the ischemia controls was not significantly different from that of the 
untreated controls, as seen in figures 4.19 (a) and 4.22 (a). However, the phosphorylation 
of p85 (figure 4.19 (b)) and PKB/Akt (figure 4.22 (b)), as well as both of their P/T ratios 
(figures 4.19 (c) and 4.22 (c)), were greater in the ischemia groups. We found that 
although the level of tGSK3α/β translocation decreased in the ischemia controls, the 
phosphorylation of the mitochondrial protein was amplified (figure 4.25 (a) and (b)). 
Additionally, the P/T ratio increased in these animals as seen in figure 4.25 (c). 
In parallel, we found there were no significant changes in the translocation of apoptotic 
pathway proteins to the mitochondria in the ischemia controls, in comparison to the 
untreated controls: pro-apoptotic tBad did not translocate, nor did the phosphorylation 
thereof increase (figure 4.28 (a) and (b). Additionally, the Bad P/T ratio did not significantly 
increase in the ischemia controls as seen in figure 4.28 (c). We also failed to see an 
elevation in pro-apoptotic Bax levels nor an increased level of anti-apoptotic Bcl-2 
mitochondrial translocation in the ischemia controls. 
The elevated translocation of the insulin-mediated PI3K/PKB/Akt pathway proteins to the 
mitochondria during ischemia, as well as the lack of translocation of pro-apoptotic or anti-
apoptotic protein, indicate that these control hearts were protected. 
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(ii) DIO animals  
The DIO hearts in our study, which were subjected to ischemia, displayed both increased 
mitochondrial PI3K/PKB/Akt and decreased apoptotic signalling which indicates that these 
hearts were protected against ischemia. 
We found that the translocation of tp85 PI3K subunit to the mitochondria, as well as the 
phosphorylation thereof, was higher in the ischemia treated DIO hearts (figure 4.20 (a) and 
(b)). Additionally, the P/T ratio was elevated in these animals as seen in figure 4.20 (c). 
tPKB/Akt translocation in the ischemia DIO group did not alter significantly from that in the 
untreated DIO group (figure 4.23 (a)) whilst the phosphorylation of PKB/Akt and the P/T 
ratio was lower (figure 4.23 (b) and (c)).  
This finding produces a contrast as the changes regarding upstream PI3K p85 subunit 
indicate an increase in insulin-mediated PI3K/PKB/Akt signalling in the mitochondria, 
whilst those changes concerning downstream PKB/Akt signify a reduction in the signalling. 
To obtain a better understanding of the mitochondrial insulin signalling in the ischemia DIO 
animals, we analyzed the modifications regarding GSK3α/β. We found that less tGSK3α/β 
mitochondrial translocation occurred in these animals during ischemia (figure 4.26 (a)) 
however, the phosphorylation of this protein, as well as its P/T ratio, increased significantly 
(figure 4.26 (b) and (c)). On the whole, this indicates that the PI3K/PKB/Akt signalling 
pathway was upregulated in these animals. 
When we analyzed the apoptotic signalling protein profile in the ischemia DIO group, our 
results yielded that the tBad translocation was higher in this group than the untreated DIO 
animals (figure 4.29 (a)) and, the phosphorylation of this protein had increased 
simultaneously (figure 4.29 (b). This explained why we saw no significant difference 
between the untreated and ischemia DIO animals in terms of their Bad P/T ratio, as seen 
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in figure 4.29 (c). Nonetheless, we found that the Bax translocation had increased (figure 
4.31 (b)) while the Bcl-2 translocation had decreased collectively (figure 4.32 (b)), 
indicating that apoptotic signalling was elevated in these animals. 
The overall mitochondrial protein profile, during ischemia of the DIO animals, reveals 
increased myocardial apoptosis and loss of cardiac protection despite augmented 
PI3K/PKB/Akt signalling.  
It would thus seem that ischemia was able to instigate elevated PI3K/PKB/Akt signalling at 
the mitochondria in control as well as obese animals, after 20 weeks of their respective 
diets. However, this pathway was only able to prevent elevated apoptotic signalling in the 
control animals while it was unable to do so in mitochondria isolated from DIO ischemic 
hearts. 
Increased mitochondrial PI3K/PKB/Akt signalling in ischemia was also observed by others. 
Ahmad et al. (2006) found that when the mitochondrial KATP (mitoKATP) channels were 
activated in a mouse model of I/R injury, the level of cardiomyocyte apoptosis decreased 
as a result of elevated PKB/Akt phosphorylation in the mitochondria. It was concluded that 
the PI3K/PKB/Akt pathway is essential for cardioprotection against this type of injury when 
mediated through activated mitoKATP channels. Interestingly, they found that if 
phosphorylation of PKB/Akt only took place in the cytosol, it would not suffice in protecting 
the heart from ischemia. The results of this study indicated that pPKB/Akt needed to 
translocate from the cytosol to the mitochondria, to put forth its protective effects. [Ahmad 
et al. 2006] 
In the current study, the increased PI3K/PKB/Akt signalling is only associated with 
myocardial protection in the control animals whereas the obese animals showed elevated 
levels of cardiac apoptotic signalling. The fact that pPKB/Akt needed to translocate from 
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the cytosol to the mitochondria to protect the heart from ischemia, in the above study, 
indicates that PI3K/PKB/Akt signalling needs to be augmented in both the cytosol and 
mitochondria simultaneously for the cardioprotection to be exerted. The attenuated 
cytosolic PI3K/PKB/Akt signalling (section 5.4.1) could thus substantiate why our study 
found a reduction in cardiac mitochondrial function (sections 5.5.1, 5.5.2 and 5.6.2) and 
integrity (section 5.4.2. and 5.6.1) after 20 weeks. The augmented PI3K/PKB/Akt signalling 
in the mitochondria was thus not sufficient to protect the obese heart from mitochondrial 
damage and dysfunction. 
 
 
5.7.1.3 Mitochondrial signalling in control versus obese animals 
Comparisons amongst the untreated (basal), insulin and ischemia groups, in control 
versus DIO animals, indicated that PI3K/PKB/Akt as well as apoptotic signalling in the 
mitochondria was enhanced in the obese animals.  
This is substantiated by the lack of a difference in the translocation level of tp85 PI3K 
subunit, tPKB and tGSK-3α/β subunit to the mitochondria in all three control groups. 
However, the DIO animals in all three groups had elevated pp85 and pGSK-3α/β levels, as 
well as increased p85 PI3K subunit and GSK-3α/β P/T ratios at the mitochondrial level. 
This was also reflected in the lack of elevated Bad P/T ratio. Despite this, the well-known 
cardioprotective GSK-3α/β presented at mitochondrial elevated phosphorylated levels. In 
contrast, the obese animals in all three groups had decreased levels of pPKB/Akt and 
PKB/Akt P/T ratios in the mitochondria. 
In terms of apoptotic signalling, the tBad, Bax and Bcl-2 translocation to the mitochondria 
was augmented in all three of the obese groups. There was no difference in the pBad 
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levels in the mitochondria of the untreated and insulin DIO animals, in comparison to their 
controls. The DIO animals in the ischemia group on the other hand, displayed an 
increased level of pBad in the mitochondria when matched against its control. However, 
the Bad P/T ratios in all three groups of obese animals were blunted, indicating on the 
whole that Bad signalling was enhanced; while both Bax and Bcl-2 signalling was 
increased. 
Therefore, it would seem that PI3K/PKB/Akt as well as the apoptotic pathway was 
enhanced in the mitochondria of the obese animals in the untreated, insulin and ischemia 
groups. This indicates that myocardial protection was blunted during diet-induced obesity, 
despite an upregulation in the cardioprotective PI3K/PKB/Akt signalling pathway.  
The studies by Yang et al. (2009) and Ahmad et al. (2006), discussed in 5.7.1.1 and 
5.7.1.2 respectively, can provide assistance in clarifying why there was a contrast in terms 
of increased PI3K/PKB/Akt signalling but loss of cardioprotection in the DIO animals. It 
might be that the insulin resistance in filtered down to the insulin receptor signaling in the 
mitochondria and blunted receptor signalling to PKB/Akt, thus explaining why we saw a 
reduction in phosphorylation of PKB/Akt in these animals. The receptor signalling was 
clearly sufficient to elevate p85 PI3K subunit phosphorylation to a certain extent although, 
we suspect that the signalling was not operating at optimal level as we failed to see 
increased recruitment of tp85 subunit to the mitochondria. [Yang et al. 2009] What is more, 
the obese animals only had increased PI3K/PKB/Akt signalling in the mitochondria, 
whereas in the cytosol this pathway`s signalling was downregulated. We have seen from 
the study conducted by Ahmad et al. (2006) that upregulation of PI3K/PKB/Akt signalling in 
both the cytosol and the mitochondrion is essential for myocardial protection, and that 
increased mitochondrial signalling alone will not be adequate. 
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In summation, comparison of p85, PKB/Akt and GSK-3α/β in the cytosol and mitochondria 
of control and obese hearts show a translocation of p85 and GSK-3α/β from the cytosol to 
the mitochondria, while PKB/Akt is reduced in both fractions. Loss of cardioprotection 
occurs despite a 5 fold increase in mitochondrial pGSK-3α/β. 
GSK-3α/β can also be phosphorylated by other kinases but it seems as if the loss of 
PKB/Akt activation plays a significant role in the loss of mitochondrial function and 
cardioprotection, during obesity. 
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Chapter 6: Conclusions 
 
6.1 Conclusions 
We hypothesized initially that obesity would have different effects on the myocardium 
during the initial and advanced stages of the disease. We proposed cardiac protection 
would take place during the initial stages of obesity, whereas this protection would be lost 
during the advanced stages thus negatively affecting the heart. Furthermore, we consider 
these differences in myocardial protection to be mediated through the PI3K/PKB/Akt and 
intrinsic apoptotic pathways, at both the cytosolic and mitochondrial level of the 
cardiomyocyte. 
Indeed we saw during the initial stages of obesity (8 weeks of diet-induced obesity), that 
the DIO animals had accumulated a significantly elevated amount of intra-peritoneal fat 
mass and were positive for systemic insulin resistance. These animals presented with 
augmented myocardial PI3K/PKB/Akt and blunted intrinsic apoptotic signalling at the 
cytosolic level, after 8 weeks. These changes correlated with a lack of change in 
mitochondrial ETC complex integrity during the initial stages of the disease, which could 
be associated with cardioprotection. 
The 20 weeks diet-induced obese animals, representing the advanced stages of obesity, 
had increased intra-peritoneal fat mass and whole body insulin resistance, similar to the 8 
weeks DIO animals. In contrast, the advanced stages were characterized by decreased 
PI3K/PKB/Akt and increased intrinsic apoptotic signalling at the cytosolic level. An 
unexpected finding was that these animals had elevated mitochondrial PI3K/PKB/Akt as 
well as apoptotic pathway signalling on the mitochondrial level. This was the case when 
the two pathways were compared in the control and obese animals, at basal level and 
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when insulin was administered as well as when the hearts were exposed to ischemia. We 
argue that this contrast seen, results from a resistance in the insulin receptor-mediated 
signalling to PKB/Akt, and because cardioprotection can only be mediated if PI3K/PKB/Akt 
signalling is upregulated in both the mitochondria and cytosol. Thus, these animals might 
be more susceptible to myocardial damage. 
This is further substantiated by the reduction in citrate synthase activity and the 
downregulation in the expression of ETC complexes I and II, thus revealing aberrations in 
the mitochondrial integrity. Furthermore, on the whole mitochondrial oxidative 
phosphorylation function is also negatively affected during the advanced stages of obesity, 
regardless of the substrate used. We observed that the obese animals using glutamate as 
a substrate present with a reduced RCI ratio, a sign of uncoupled respiration.  
In contrast, the mitochondrial function initially seems to be upregulated in the advanced 
obese animals as we see an increased percentage recovery after anoxia/reperfusion, 
when palmitoyl-L-carnitine serves as substrate. We do not see this elevated recovery 
when glutamate is used, indicating that the obese animals might have undergone a 
metabolic shift by increasing their fatty acid utilization.  
In summation (figure 6.1), we find that the initial stage of obesity is associated with 
augmented myocardial protection due to increased PI3K/PKB/Akt and attenuated 
apoptotic signalling. Conversely, the advanced stage of the disease is marked by loss of 
cardioprotection and increased susceptibility to apoptosis, as a result of decreased 
cytosolic PI3K/PKB/Akt and enhanced apoptotic signalling.  
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Figure 6.1: Summary of the present study`s experimental findings, regarding the 
myocardial changes at the cytosolic and mitochondrial level during the initial and advanced 
stages of diet-induced obesity. 
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6.2 Limitations of the study 
The current study did not assess cardiac mitochondrial function as well as mitochondrial 
PI3K/PKB/Akt and apoptotic signalling in the heart after 8 weeks of diet-induced obesity.  
Additionally, the study did not look at the effects of insulin administration and myocardial 
ischemia exposure on cytosolic PI3K/PKB/Akt and apoptotic signalling subsequent to 8 
weeks of diet-induced obesity. 
 
6.3 Future perspectives 
In our study, we were able to demonstrate the role of the PI3K/PKB/Akt pathway in 
cardioprotection. It is likely that this pathway does not act alone and thus it would be of 
great therapeutic value to ascertain the roles of other pathways (ERK and SAFE 
pathways), and the influence these might have on PI3K/PKB/Akt signalling, in myocardial 
protection.  
Furthermore, we showed that PI3K/PKB/Akt-mediated regulation of certain apoptotic 
markers, Bad, Bax and Bcl-2, was essential in determining the cells’ apoptotic fate. In 
future studies, it would be beneficial to look at other markers of apoptosis such as, cleaved 
caspase-3 and-9, cleaved PARP as well as FOXO1 to establish an even bigger picture of 
the apoptotic signalling during the initial and advanced stages of obesity. 
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